

10/19/99
Jc377 U.S. PRO

A

Patent
246/285

To: Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Jc588 U.S. PRO
09/421506
10/20/99

NEW APPLICATION TRANSMITTAL
CLAIMING PRIORITY ON NONPROVISIONAL APPLICATION

Sir:

Transmitted herewith for filing is a **utility** patent application:

Inventor(s): Salvatore Albani

Title: Method for Isolation, Quantification, Characterization and Modulation of
Antigen-Specific T Cells

I. PAPERS ENCLOSED HERewith FOR FILING UNDER 37 CFR § 1.53(b):

107 Page(s) of Written Description

45 Page(s) Claims

1 Page(s) Abstract

24 Sheets of Drawings Informal x Formal

II. ADDITIONAL PAPERS ENCLOSED IN CONNECTION WITH THIS FILING:

☒ Declaration

☒ Power of Attorney: ☐ Separate or ☒ Combined with Declaration

☐ Assignment to and assignment cover sheet

☒ Verified Statement establishing "**Small Entity**" under 37 CFR §§ 1.9 and 1.27

SD-133609.1

CERTIFICATE OF MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

EL 088595219 US
Express Mail Label No.

October 19, 1999
Date of Deposit

Irene Grimes Betke

Name of Person Mailing Paper

Signature of Person Mailing Paper

- ☐ Priority Document No(s): _____
- ☒ Information Disclosure Statement w/PTO 1449 ☒ Copy of Citations
- ☒ Sequence Listing and diskette and verification statement
- ☐ Preliminary Amendment
- ☒ Return Postcard

III. THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

BASIC FILING FEE:							\$760.00
Total Claims	219	-	20	=	199	x \$18.00	\$3582.00
Independent Claims	20	-	3	=	17	x \$78.00	\$1326.00
Multiple Dependent Claims	\$260	(if applicable)				<input type="checkbox"/>	\$0.00
TOTAL OF ABOVE CALCULATIONS							\$5668.00
Reduction by ½ for Filing by Small Entity. Note 37 CFR §§ 1.9, 1.27, 1.28. If applicable, Verified Statement must be attached.							<input checked="" type="checkbox"/> \$2834.00
Misc. Filing Fees (Recordation of Assignment -- \$40) Petition for color drawing							\$130.00
TOTAL FEES SUBMITTED HERewith							\$2964.00

IV. METHOD OF PAYMENT OF FEES

- ☐ A check in the amount of _____.
- ☒ Charge Lyon & Lyon's Deposit Account No. **12-2475** in the amount of \$2,964.00.
- ☐ This application is being filed without fee or Declaration under 37 CFR § 1.53.

V. AUTHORIZATION to CHARGE FEES

The Commissioner is authorized to charge Lyon & Lyon's Deposit Account No. **12-2475** for the following:

- ☒ 37 CFR § 1.16(a), (f) or (g) – **(Filing fees)**
- ☒ 37 CFR § 1.16(b), (c) and (d) – **(Presentation of Extra Claims)**
- ☒ 37 CFR § 1.16(e) – **(Surcharge for filing the basic filing fee and/or Declaration on a date later than the filing date of the application)**
- ☒ 37 CFR § 1.17 – **(Any Application processing fees)**

☒ Credit Lyon & Lyon's Deposit Account No. **12-2475** for overpayment of fees.

Respectfully submitted,

LYON & LYON LLP

Dated: October 15, 1999

By: 

Reg. No. 37,549

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(213) 489-1600

Applicant : Salvatore Albani

Serial or Patent No. : To be assigned

Filed or Issued: Filed Herewith

For: Methods for Isolation, Quantification, Characterization and Modulation of Antigen-Specific T cells.

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) AND 1.27(b)) – INDEPENDENT INVENTOR**

As a below-named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark office with regard to the above-entitled invention described in

- ☒ the specification filed herewith
- ☐ the application serial no. _____, filed _____.
- ☐ patent no. _____, issued _____.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed or licensed or am under an obligation under contract or law to assign, grant, convey or license any rights in the invention is listed below.

- ☒ no such person, concern or organization.
- ☐ persons, concerns or organizations listed below:

FULL NAME _____

ADDRESS _____

***NOTE:** Separate verified statement are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statement and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Salvatore Albani

TITLE OF PERSON SIGNING: Inventor

ADDRESS OF PERSON SIGNING: c/o Cevis; 4186-M Sorrento Valley Blvd., San Diego, CA 92121

Signature of Inventor _____ Date: _____

METHODS FOR ISOLATION, QUANTIFICATION, CHARACTERIZATION AND
MODULATION OF ANTIGEN-SPECIFIC T CELLS

GOVERNMENT SUPPORT

5 This invention was made with government support under NIH Grant Nos.
AR40770, AI37232, and AR41897. The government has certain rights in this invention.

RELATED APPLICATIONS

10 This application claims priority to provisional application number 60/105,018, filed
October 20, 1998.

FIELD

15 The field of this invention is immunology, specifically, methods of preparing
artificial antigen presenting cells and their application to methods of isolating antigen-
specific T cells, methods of modulating the T cell response and methods of treating
conditions which would benefit from the modulation of the T cell response, for example,
transplantation therapy, autoimmune disorders, allergies, cancers and viral and bacterial
infections.

20 BACKGROUND

The following description provides a summary of information relevant to the
present invention. It is not an admission that any of the information provided herein is
prior art to the presently claimed invention, nor that any of the publications specifically or
implicitly referenced are prior art to the invention.

25 The immunologic arts have advanced markedly over the past ten years. The
complexity of the science explaining aspects of the field is immense. We set forth below
in this section a discussion concerning known aspects of various elements involved in
immunogenic responses and concepts in the art that are related to the invention disclosed
herein.

30

T Cells

T lymphocytes (i.e., T cells) are part of the immune system, which defends the body against bacterial, viral and protozoal infection, as well as aberrant molecules that contain epitopes recognized as non-self. The recognition of non-self molecules as well as
5 the destruction of infectious agents carrying non-self antigens is a function of T cells. These cells provide for the cell-mediated immune responses of adaptive immunity.

Infecting pathogens are generally accessible to extracellular antibodies found in the blood and the extracellular spaces. However, some infecting agents, and all viruses, replicate inside cells where they are not exposed to, and cannot be detected by,
10 extracellular antibodies. In order for these foreign agents to be accessible to the cell-mediated immune response, the cells harboring such pathogens must either “express” antigenic motifs of the infecting agents on the surface of the cells or the antigenic motifs must be shed from the cells, e.g. by cell death, to be accessible to and subsequently expressed on the cell membrane of phagocytic antigen presenting cells (“APCs”) that
15 participate in the immune process.

Antigens derived from replicating virus for example, are displayed on the surface of infected cells where they may be recognized by “cytotoxic” T cells which may then control the infection by recognizing the viral antigen and killing the cell. The actions of such cytotoxic T cells depends upon direct interaction between the antigenic motif of the
20 infecting agent expressed on the surface of the infected cells and the T cell’s receptors having a specificity for the motif.

Although T cells are important in the control of intracellular infections, some foreign agents evade such control because they replicate only in the vesicles of macrophages; an important example is *Mycobacterium tuberculosis*, the pathogen that
25 causes tuberculosis. Whereas bacteria entering macrophages are usually destroyed in the lysosomes, which contain a variety of enzymes and bactericidal substances, infectious agents such as *M. tuberculosis*, survive because the vesicles they occupy cannot fuse with the lysosomes. The immune system provides for fighting such agents by a second type of T cell, known as a T helper cell, which helps to activate macrophages and induce the fusion
30 of lysosomes with the vesicles containing the infecting agents. The helper cells also bring

about the stimulation of other immune mechanisms of the phagocyte. T helper cells may further be involved in initiating and/or sustaining the immune system's release of soluble factors that attract macrophages and other professional APCs to the site of infection.

Additionally, specialized "helper" T cells play a central part in the destruction of
5 extracellular pathogens by interacting with B cells. Depending on the type of infection being controlled, participating T helper cells may have an inflammatory or Th1-like phenotype, or a suppressive Th2-like phenotype.

T Cell Receptors

10 T cell receptors (TCRs) are closely related to antibody molecules in structure and are involved in antigen binding. Variability in the antigen binding site of the TCR is created in a fashion similar to antibodies in that a large capacity for diversity is available. The diversity is found in the CDR3 loops of TCR variable regions which are found in the center of the antigen-binding site of the TCR. The diversity that is obtainable by TCRs for
15 specific antigens is also directly related to an MHC molecule on the APC's surface to which the antigenic motif is bound and presented to the TCR.

One type of MHC that is involved in presenting processed antigen is class II MHC. The antigen or peptide binding site for a peptide on a class II MHC molecule lies in a cleft between the alpha and beta chain helices of the MHC molecule. In another type of MHC,
20 the class I MHC, the binding site for a peptide lies in a cleft between the two alpha helices of the alpha chain. From the arrangement of highly variable antigens complexing with MHC molecule alleles, it is understandable that the mechanism of TCR recognition involves a combined distribution of variability in the TCR which must correlate with a distribution of variability in the ligand (i.e., antigen/MHC molecule complex). (Garboczi,
25 et al., *Nature* Vol. 384; 134-41; Ward and Quadri, *Curr Op Immunol*. Vol. 9:97-106; Garcia, et al., *Science*, Vol. 279:1166-72).

MHC Molecules

In general, T cell responses to non-self motifs depend on the interactions of the T
30 cells with other cells containing proteins recognized as non-self. In the case of cytotoxic T

cells and Th1 cells, non-self proteins (*i.e.* antigens) are recognized on the surface of the target cell (such as an infected cell). Th2 cells, on the other hand, recognize and interact with antigen presented by professional antigen presenting cells such as dendritic cells, and B cells. Dendritic cells non-specifically internalize antigen while B cells bind and

5 internalize foreign antigens via their surface immunoglobulin. In any case, T cells recognize their targets by detecting non-self antigenic motifs (*e.g.*, peptide fragments derived from for example, a bacterium or virus) that are expressed either on infected cells or other immune cells, *e.g.* phagocytic APC. The molecules that associate with these peptide or antigen fragments and present them to T cells are membrane glycoproteins
10 encoded by a cluster of genes bearing the cumbersome name “major histocompatibility complex” (MHC). These glycoproteins were first identified in mice in studies examining the effects on the immune response to transplanted tissues. In humans, the MHC equivalent has been termed HLA for “human leukocyte antigen”. In general, the term MHC is used to describe generally the molecules in the mammalian immune system
15 involved in the presentation of antigenic motifs to T cells. As used specifically in this Letters Patent, MHC means any major histocompatibility complex molecule, either class I or class II, from any mammalian organism including a human, such molecule comprising full-length MHC molecules or sub-units thereof further comprising MHC encoded antigen-presenting glycoproteins having the capacity to bind a peptide representing a fragment of
20 an autoantigen or other non-antigenic or antigenic sequence (*e.g.*, a peptide), said MHC further having an amino acid sequence that is expressed and purified from natural sources, or by any artificial means in prokaryotic or eukaryotic systems having different glycosilations, or of either natural or synthetic origin that contains or comprises a modification of a natural MHC sequence.

25 The actions of T cells depend on their ability to recognize antigenic motifs on cells (such as cells harboring pathogens or that have internalized pathogen-derived products). T cells recognize peptide fragments (*e.g.*, pathogen-derived proteins) in the form of complexes between such peptides and MHC molecules that are expressed on the surface of “antigen presenting cells”.

The two types of MHC molecules, i.e., MHC class I and MHC class II, deliver peptides from different sources (class I being intracellular, and class II being extracellular) to the surface of the infected cell. The two classes of MHC molecules vary with respect to the length of peptides that they are able to present. The binding pocket of the MHC class I molecules is blocked at either end, thereby imposing severe restrictions on the size of peptides it can accommodate (8-10 residues). The binding groove of the MHC class II molecules on the other hand allows peptides to protrude from the ends, and consequently much longer peptides (8-30 residues) can bind. (Rudensky, et al. *Nature*, Vol. 353:622-27; Miyazaki, et al., *Cell*, Vol. 84:531-41; Zhong, et al., *J. Exp. Med.*, Vol. 284:2061-66).

Antigen Processing

Peptides bound to MHC class I molecules are recognized by CD8+ T cells (cytotoxic T cells), and those bound to MHC class II molecules are recognized by CD4+ T cells (helper T cells). Two functional subsets of T cells are thereby activated to initiate the destruction of antigenic motifs, and thereby the source (e.g. a pathogen) which may reside in different cellular compartments. CD4+ T cells may also help to activate B cells that have internalized specific antigen, and in turn give rise to the stimulation of antibody production against the antigenic motifs of the extracellular pathogens.

Infectious or antigenic agents can reside in either of two distinct intracellular compartments. Viruses and certain bacteria replicate in the cytosol or in the contiguous nuclear compartment, while many pathogenic bacteria and some eukaryotic parasites replicate in the endosomes and lysosomes that form part of the vesicular system. The immune system has different strategies for eliminating such agents from these two sites. Cells containing viruses or bacteria located in the cytosol are eliminated by cytotoxic T cells which express the cell-surface molecule CD8. The function of CD8 T cells is to kill infected cells.

Immunogenic agents located in the vesicular compartments of cells (which may or may not have been involved in the internalization of extracellular matter) are detected by a different class of T cell, distinguished by surface expression of the molecule CD4. CD4 T cells are specialized to activate/modulate other cells and fall into two functional classes:

Th1 cells which activate various immune competent cells to have the intravesicular non-self antigenic agents they harbor destroyed, and Th2 cells which help to activate B cells to, among other things, make antibody against such foreign agents.

To produce an appropriate response to infectious microorganisms, T cells need to
5 be able to distinguish between self and foreign or non-self material coming from the different processing pathways. This is achieved through delivery of peptides to the cell surface from each of these intracellular compartments by the different classes of MHC molecules. As noted above, MHC class I molecules deliver peptides originating in the cytosol to the cell surface, where the antigen (*i.e.*, non-self recognized peptide) is expressed
10 in association with the MHC molecules (antigen:MHC complex) and is recognized by CD8 T cells. Likewise, MHC class II molecules deliver the non-self peptides originating from extracellular sources to the cell surface, where they are recognized by CD4 T cells.

Antigen Presenting Cells

15 When naïve T cells encounter for the first time a specific antigen on the surface of an antigen-presenting cell (APC), they are activated to proliferate and differentiate into cells capable of contributing to the removal of the antigen and its source (*e.g.* an infecting pathogen). The APCs are specialized in that they express surface molecules that synergize with a specific antigen in the activation of naïve T cells. APCs become concentrated in the
20 peripheral lymphoid organs, to which they migrate after trapping antigen while circulating in the periphery. APCs present peptide fragments or antigenic motifs to recirculating naïve T cells. Arguably, the most important APCs are dendritic cells whose known function includes the presentation of antigen to Macrophages and are important in phagocytosis of cells that provide a first line of defense against infecting agents. APCs are also known to
25 be activated by armed effector T cells. B cells also serve as APCs under some circumstances.

One of the features of APCs is the expression of co-stimulatory molecules including B7-1 and B7-2 molecules. Naïve T cells will respond to an antigenic motif only when the same APC presents to the T cell both the specific motif recognized by the TCR
30 and a B7 molecule which is recognized by CD28 or CTLA-4, the receptors for B7 existing

on the T cell surface. (Anderson, et al., *J. Immunol.*, Vol. 159:4:1669-75). The activation of T cells by APCs leads to proliferation of the activated T cells and to the differentiation of their progeny into armed effector T cells. The proliferation and differentiation of T cells depends on the production of cytokines (such as the T cell growth factor, IL-2) and their
5 binding to high-affinity receptors on the activated T cell. T cells whose TCRs are bound to antigens in the absence of co-stimulatory molecules fail to make cytokines and instead become anergic. This dual requirement for both receptor/antigenic interaction and co-stimulation helps to further mediate naïve T cell response.

Proliferating T cells develop into armed effector T cells, the critical event in most
10 adaptive immune response. Once an expanded clone of T cells achieves effector function, the T cell clone progeny can act on any target cell that displays or expresses a specific antigen on its surface. Effector T cells can mediate a variety of functions. The killing of infected cells by CD8 cytotoxic T cells and the activation of professional APC by Th1 cells together make up cell-mediated immunity. The activation of B cells by both Th2 and Th1
15 cells help to produce different types of antibodies, thus driving the humoral immune response. (Kirberg, et al., *J. Exp. Med.*, Vol. 186:8:1269-75).

T Cell Activation

T cells generally become sensitized to antigens by becoming trapped in lymphoid
20 organs as the T cells drain into lymph nodes through which they circulate. Antigens introduced directly into the bloodstream, or that reach the bloodstream from an infected lymph node, are picked up by APCs in the spleen for example where lymphoid cell sensitization occurs in the splenic white pulp. The trapping of antigen by APCs that migrate to these lymphoid tissues combined with the continuous recirculation of T cells
25 through the tissues ensures that rare antigen-specific T cells will encounter their specific antigen being presented by an APC.

The recirculation of naïve T cells through the lymphoid organs is orchestrated by adhesive interactions between lymphocytes and endothelial cells. Naïve T cells enter the lymphoid organs through a process which is thought to occur in a number of steps. The
30 first step in this process is mediated by selectins expressed on the T cell. For example, L-

selectin on naïve T cells binds to sulfated carbohydrates on the vascular addressins GlyCAM-1 and CD34. CD34 is expressed on endothelial cells in many tissues but is properly glycosylated for L-selectin binding only on the high endothelial venule cells of lymph nodes. L-selectin binding promotes a rolling interaction, which is critical to the selectivity of naïve lymphocyte homing. Although this interaction is too weak to promote extravasation, it is essential for the initiation of the stronger interactions that then follow between the T cell and the high endothelium, which are mediated by molecules with a relatively broad tissue distribution. (Finger, et al., *Nature*, Vol. 379:266-9).

Stimulation by locally bound chemokines activates the adhesion molecule LFA-1 on the T cell, increasing its affinity for ICAM-2, which is expressed constitutively on all endothelial cells, and ICAM-1, which, in the absence of inflammation, is expressed only on the high endothelial venule cells of peripheral lymphoid tissues. The binding of LFA-1 to its ligands, ICAM-1 and ICAM-2 plays a major role in T cell adhesion to and migration through the wall of the blood vessel into the lymph nodes. Bachmann et al., *Immunity*, Vol. 7:549-57).

The high endothelial venules are located in the lymph nodes. This area is inhabited by dendritic cells, which have recently migrated from the periphery. The migrating T cells scan the surface of these APCs for specific antigen:MHC complexes. If they do not recognize antigen presented by these cells, they eventually leave the node via an efferent lymphatic vessel, which returns them to the blood so that they can recirculate through other lymph nodes. Rarely, a naïve T cell recognizes its specific antigen:MHC complex on the surface of an APC, which then signals the activation of LFA-1, causing the T cell to adhere strongly to the APC. Binding to the antigen:MHC complex also activates the cell to proliferate and differentiate, resulting in the production of armed, antigen-specific T cells. The number of T cells that interact with each APC in lymph nodes is very high, as can be seen by the rapid trapping of antigen-specific T cells in a single lymph node containing antigen.

Identification and Isolation of Antigen-Specific T Cells

As noted above, T cells represent a major component of the body's immune defenses against bacterial, viral and protozoal infections, as well as non-self antigenic motifs from other sources. T cells have also been implicated in the rejection of cancerous cells. Autoimmune disorders have also been linked to antigen-specific T cell attack against various parts of the body. One of the major problems hampering the understanding of and intervention on the mechanisms involved in these disorders is the difficulty in identifying T cells specific for the antigen to be studied. Accordingly, it is of great interest to be able to identify antigen-specific T cells. Additionally, it would be of great therapeutic benefit if T cells specific for a particular antigen could be (i) enriched and then reintroduced in a disease situation, (ii) selectively depleted in the case of an autoimmune disorder, or (iii) modified to alter their functional and/or phenotypic characteristics. Thus, identification and isolation of antigen-specific T cells is an essential requirement in immunology and medicine to understand and modulate immune responses.

Identification of antigen-specific T cell populations is generally accomplished by indirect means in animal models, such as by evaluating membrane markers correlated to activation or maturation of these cells. The majority of these studies were performed in transgenic systems (Ignatowicz, et al., *Cell*, 84:521-29; Sebzda et al., *Science*, Vol. 263:1615-18; Jameson et al., *Ann. Rev. Immunol.*, Vol. 13:93-126). Analysis is generally done by means of flow cytometry, where a detector on a machine is capable of identifying cells bound to fluorescent substrates, such as fluoresceinated antibodies. Positively identified cells can be sorted for further use. Quantitation and isolation of antigen-specific T cells is usually accomplished by limiting dilution and cloning techniques. When using sorted cells, these approaches become quite cumbersome and are sometimes inaccurate, since the biological effects of antigen recognition can spread beyond the cells recognizing the antigen. For instance, upon engagement of the specific MHC:antigenic peptide complex, T cells produce cytokines that can affect expression of the same markers of activation in non-specific bystander T cells. Hence, in order to isolate and characterize cells with specificity for a given antigen, alternative procedures, such as T cell cloning, need to be applied. These techniques often require many months of technical procedures before

results can be obtained. The rate of success, in particular for human systems, is quite low, and the population selected may not necessarily represent the biologically relevant component of the immune response to a given peptide. The direct interaction of a specific T cell with the antigen:MHC complex would thus be a preferred basis for T cell isolation.

5

Theory of the Invention

The immunoregulation art has advanced steadily in recent years. The scientific literature contains many studies showing interactions and modulation effects between specific molecules and cell types. However, no discovery has been presented that is able to
10 apply the knowledge that has been gained by the extensive research in the field toward a method or device that can be used in a comprehensive package for carrying out the identification, isolation, and modulation of immunoregulatory cells for the purpose of advancing the ultimate goal of such knowledge, *i.e.*, improved treatment regimens for various states of disease.

15 We have discovered a platform technology for advancing treatment regimens requiring the immunoregulation of immune cells that centers around the use of an artificial antigen presenting cell (APC). This platform technology may be designed or programmed on demand for use in the treatment of a broad spectrum of specific disease states. Moreover, this system is versatile and applicable to all situations where the isolation,
20 identification, and modulation of T cells is of clinical import. We have recognized the relevance of several types of molecular entities to the stimulation/activation and modulation response of T cells in their role within the immune system and have incorporated these entities into artificial APCs. We use such artificial APCs to capture and manipulate antigen specific T cells.

25 Historically, programming and using T cells therapeutically has been hampered by the problem of finding a means by which the cells can be handled for such manipulation and observation of the effectiveness of the manipulation applied. We have solved this problem by adopting the theory that a T cell can best be manipulated by using APC like structures and incorporating into such structures molecules constructed to (1) bind the
30 “artificial” APC to specific T cell types, (2) stimulate or modulate only specifically bound

T cells for any desired response, and (3) bind the artificial APC to a solid support in situations where anchoring the APC to a specific location is desired.

Prior to our invention, no comprehensive system has been disclosed, nor was it obvious that such a system would function as desired, to achieve a platform that is
5 universally applicable to activating and modulation T cells. As can be seen by the numerous following distinctions, much of the art has centered only on basic research relating to molecules and their association with T cell response.

Distinctions

10 Kendrick et al., U.S. Patent No. 5,595,881 (the '881 disclosure) discuss a method for the detection and isolation of MHC:antigen-restricted T cells which is performed by preparing the MHC:antigen complex, which complex is isolated by using metal chelating technology. The complex is then bound to a planar solid support (*i.e.*, a glass coverslip), followed in turn by combining the immobilized complex with a biological sample so that
15 the MHC:antigen complex may bind to and retain antigen-specific T cells. Determination of the presence of reactive MHC:antigen complexes is carried out by observation of cell proliferation.

The method described in the '881 disclosure differs from the current invention in a number of substantial structural and functional ways. First, the MHC component of the
20 complexes in the '881 disclosure are immobilized on a solid support. The MHC component of the current invention is not bound to a solid support but is freely "floating" within the bilayer of a polysome membrane comprising a phosphatidylcholine and cholesterol component. The difference is substantial in that the MHC:antigen complex of the '881 disclosure is not able to participate in the migration or concentration of such
25 complexes in "capping" which is important to improved binding and activation of bound T cells. Second, the '881 method is only directed to the detection of the presence of "natural" APCs that are specific for pre-selected antigen-specific T cells after such T cells have been isolated. The isolation of antigen-specific T cells is carried out by first performing a series of steps including binding antigen via a metal chelating process to a
30 solid support, capturing on to the antigen MHC the components that are antigen-specific,

then isolating the MHC:antigen complexes which are in turn bound to a planar solid support via a linker.

The current invention is also much more versatile. It is not concerned with detecting natural APCs but is instead directed to the isolation and manipulation of antigen-specific T cells. The manipulation of such T cells is carried out for numerous applications such as directly impacting T cell function by modulating the T cell response. The manipulation can be performed in either a column format, with means for supporting the artificial APCs, and/or in free solution via flow cytometry (FACS). The current invention is able to modulate T cell function because the artificial APCs may be designed to specification in that various functional molecules are incorporated into the APC that activate specific T cell responses. For example, in one embodiment of the current invention, known MHC molecules may be incorporated into liposomes along with a labeled antigenic peptide for which such MHC has specificity (*e.g.*, in the case of FACS a biotinylated antigen). The liposome:MHC:biotinylated antigen complex may be used to bind to antigen-specific T cells and the fact of binding can be visualized by FACS followed by the sorting of the bound cells. Thus, no cell proliferation is necessary to identify and isolate antigen-specific T cells.

In addition to the MHC:antigen complex, the “artificial APCs” used to capture the antigen-specific T cells include accessory molecules to help stabilize the MHC:antigen:TCR interaction, and may also include functional molecules such as co-stimulatory molecules which in one embodiment may be used to activate T cells, adhesion molecules which may be used to bind cells destined for a certain area of the body, and other accessory or functional molecules such as cytokines or antibodies to cytokine receptors, which are known to have immunomodulatory effects upon T cells. Moreover, the current invention further provides for proper orientation of each of these molecules within the artificial APC membrane by a novel use of an anchoring mechanism comprising GM-1 protein and the β subunit of cholera toxin. In this aspect, the protein of interest may be connected to the cholera toxin subunit as a fusion protein or by use of a linking moiety. By attaching the cholera toxin subunit to the molecule of interest, the cholera toxin may be

bound by the GM-1 protein that is incorporated into and has affinity for the nonpolar region of the artificial APC membrane.

All of these molecules are incorporated into the liposomes of the artificial APCs in a free floating format. Other molecules may be included that do not influence the modulation of T cell response such as proteins that may be used to anchor the artificial APC to a solid support. Such molecules may also be produced as fusion proteins for proper orientation. As used herein such molecules that are not associated with modulation or T cell binding are termed "irrelevant" molecules.

Additionally, a label may be attached to the antigen, the irrelevant molecule, or the liposome component. Moreover, label may also be noncovalently associated within the lipids of the liposome.

The designs of these artificial APCs also allow for optional expansion experimentation of T cell populations responding to the MHC:antigen complexes associated in the cell like liposomes using a solution based (e.g., roller bottle) cell culture. The concept of the current invention represents a substantial and heretofore unrecognized advance in the MHC:antigen complex T cell binding art in that the artificial APC (e.g. the example comprising liposome:MHC:antigen:accessory molecule:functional molecule complex) is not restricted to complexes of MHC:antigen alone or to a planar surface as is the case with much of the prior art. The importance of the structural differences can not be over emphasized. The addition of the accessory molecules, as well as co-stimulatory molecules, and other proteins in proper orientation in the liposomes of the current invention allow for substantially improved binding association and manipulation of T cells which is very important in the identification and stimulation of antigen-specific T cells. This is especially true in solution based FACS analysis where functionality of the antigen-specific T cells can be interpreted directly. For example, prior studies (Watts, T. H. *Annals of the New York Academy of Sciences*. 81:7564-7568.) respecting the modulation of T cells may be erroneous. There, it was demonstrated that planar membranes containing purified MHC loaded with antigen fused to glass cover slips elicited IL-2 production by T cells through the interaction of the T cell with the MHC:antigen complex. It was also shown that the same complex when formed in unilamellar vesicles (i.e., liposomes) elicited

no response. Contrary to such teaching, we have found that liposome vesicles containing MHC:antigen complexes can in fact elicit strong response when combined with accessory molecules such as LFA-1, and other molecules such as co-stimulatory and adhesion molecules. We based our theory that liposomes could function without use of a planar array on the observation (by the same study cited immediately above) that crude membrane preparations of cellular material from which the MHC was purified were effective in eliciting T cell responses in both planar and vesicular forms. Subsequently, we have discovered that “extraneous” matter existing in cell extracts that might be hypothesized to impart functionality to vesicular forms of lipid bilayers (as opposed to unilamellar liposomes alone) are not important to T cell binding and response. Rather, T cell binding and response is possible using vesicular forms of liposomes containing specific molecules applied in combination with liposomes (*e.g.*, accessory molecules, co-stimulatory molecules, and adhesion molecules).

Prior research has also been inconclusive respecting the use of MHC molecules. For example, it has been shown (Buus, S. *Cell*. 47:1071-1077.) that a particular antigenic peptide binds solely to the alpha chain of the class II MHC IA^d molecule while other investigations have shown that binding interactions between T cell receptors and MHC:antigen ternary complexes use whole MHC, not just single chains of the MHC, to determine peptide sequence motifs. Exactly how much of a MHC:antigen complex must be presented is not absolutely known and may vary with T cell specificity. We have directed our invention to the use of either whole MHC molecules or those parts of the α and β subunits of Class I and Class II MHC necessary for forming antigen binding cleft regions in the binding of antigen peptides.

The current invention's use of co-stimulatory, adhesion and other accessory molecules in a “free floating” format also helps to both anchor and direct the interaction between MHC:antigen:accessory molecule and T cell receptors by providing a means by which T cells in the sample will be presented with a structure more similar to that found in the natural state. Specifically, the MHC:antigen:accessory molecule complexes in conjunction with other functional molecules are able to migrate in proper orientation in the lipid bilayer of the liposome because of the use of a unique combination of lipids and

surfactant molecules, namely an optimal ratio of phosphatidylcholine and cholesterol respectively, included in the liposome matrix. These provide particular protein presentation characteristics and easy protein migration properties to the surface of the liposome structure so that the MHC:antigen complexes can easily migrate to T cell binding loci similar to “capping” events seen in natural APCs. Moreover, as shown in the figures, the structure of our artificial APC liposomes allows for specific “capping” of the liposomes on the surface of the T cells to which the liposomes are bound. Additionally, interaction between the T cell and artificial APC-associated molecules is further enhanced by the molecules being oriented in the lipid membrane such that their active sites are positioned facing outward on the APC. Without such orientation, the ratio of properly oriented molecules to improperly oriented molecules is around 50:50. This ratio is greatly increased using MHC, functional and accessory proteins that have attached thereto (either by fusion protein construction or by use of a linker) a cholera β toxin subunit moiety which is placed in relation to the active center of the protein of interest such that upon the β subunit being bound by GM-1 which is incorporated into the lipid layer of the artificial APC, the protein of interest will lay in the APC with the active site facing outward.

Additional versatility is available with the current invention in that the artificial APCs may incorporate irrelevant molecules to be used in conjunction with separate solid support-based capture moieties for capturing generic target motifs such as irrelevant molecules. Because of the capacity for the functional molecules to migrate in the liposome, the irrelevant molecules may be nonspecifically directed away from the binding position of the T cells thus avoiding steric hindrances. Additionally, the system avoids a need for manufacturing specialized solid phase capture substrates for each antigen-specific complex.

With regard to the capture of the APC by the solid phase component of the invention, we refer to target molecules used in the artificial APC for binding to capture molecules of the solid support as “irrelevant” molecules because they do not impact the APC:T cell interaction. Such a design further preserves the ability of the other molecules inserted into the liposome to move freely and accommodate any capping of the T cell's activation related molecules.

It has been recognized that the number of receptors on a T cell is variable (Rothenberg, E. *Science*. 273:78-79.). It is also known that the number of TCRs and combination of co-stimulatory molecules and accessory molecules varies with the maturation of the T cell (Dubey, C. *J Immunol*. 157:3820-3289.). How many such
5 receptors are needed in all situations to elicit a T cell response is unknown. Moreover, it is known that presence of a co-stimulatory signal decreases the number of receptors necessary to activate a T cell (Viola, A. and Lanzavecchia, A. *Science*. 273:104-106.). We have provided for the uncertainties presented by such data by providing a system that allows control over the number of MHC:antigen:accessory molecule complexes relative to
10 other functional molecules such as co-stimulatory, and adhesion molecules. The binding and modulation of the T cell response at different stages of cell maturation may be "fine tuned" using our invention.

In another system, Nag et al. in U.S. Patent No. 5,734,023 (the '023 disclosure), disclosed MHC subunits which were complexed with antigenic peptides and "effector"
15 molecules wherein such complexes were used to identify T cell populations that were associated with autoimmune diseases. The complexes were used to destroy and anergize such T cell populations from a patient's blood cell population.

The effector molecules are described as such things as toxins, radiolabels, etc. which may be conjugated to the MHC or antigen portion of the complexes and which may
20 effectuate the identification, removal, anergy, or death of such T cell populations. Such effector molecules are not related to the attractive binding interactions or T cell responses to effectuate a phenotype change in the cells. They are merely designed and intended to aid in the recognition and/or destruction of specific T cell populations. Additionally, the '023 disclosure uses lipids in the construction of micelles which are designed for
25 intravenous injection as therapeutics. The use of negatively charged acidic phospholipids (such as phosphatidylserine) and the lack of cholesterol or GM-1 and cholera toxin subunit in the design of such micelles differs from that of the current invention in substantial ways. For example, our invention uses neutrally charged phospholipids such as phosphatidylcholine (Pc). We have found that the design of our artificial APCs
30 substantially increases stability because of the Pc and cholesterol in environments where

IL-1 is present. IL-1 is known to interact with charged phospholipids and destabilize liposome structure. Likewise, in environments where TNF is present, the permeability of liposomes comprised of charged phospholipids (*e.g.*, phosphatidylserine) is greatly affected. In the same manner, environments where RNase is present may also affect charged phospholipid liposome structures. We have avoided the disruptive effects caused by molecules that are often present in media from which T cells are isolated by designing artificial APCs using neutral phospholipids.

Additionally, the use of liposomes and the parameters associated with micelle construction that are disclosed in the '023 disclosure are wholly associated only with the *stability* of MHC:antigen:effector molecule complexes in the *in vivo* circulatory environment. There is no relation inherent or otherwise to the current invention, nor is there insight disclosed as to liposome construction containing co-stimulatory and adhesion molecules or protein orientation mechanisms such as the binding of cholera toxin by GM-1 protein, or fused or linked moieties to the MHC, functional or accessory proteins of interest. Further, the '023 disclosure does not discuss use of its micelle construction in the context of use of a MHC:antigen complex *ex vivo* where manipulation of T cell function and the binding attraction between T cells and MHC:antigen complexes with respect to the current invention is of import. Moreover, the current invention does not use the technology disclosed in the '023 disclosure of single chain MHC in liposomes. In contrast, in a preferred embodiment, our invention uses either whole MHC molecules or those portions of the α and β subunits necessary to bind antigens and that may be designed to have substantially favorable liposome stabilizing characteristics as well as binding capabilities when in the presence of other functional molecules in the artificial APC as disclosed herein.

In yet another recent disclosure, Spack et al. in U.S. Patent No. 5,750,356 (the '356 disclosure) describe a method for monitoring T cell reactivity using a modified ELISPOT assay which detects various factors produced by the stimulation of T cells with numerous factors in the presence of natural antigen presenting cells. The current invention is distinguishable from the '356 disclosed method in that the current invention uses artificial

antigen presenting cells which have incorporated therein various accessory, co-stimulatory, adhesion, cytokine, and chemokine molecules that provide substantial effect in the binding and modulation of T cell responses. Additionally, in embodiments that require solid support binding, our APC includes irrelevant molecules. Moreover, in another
5 embodiment, our invention includes mechanisms to properly orient proteins of interest in the lipid membrane.

In still another disclosure, Wilson et al. in U.S. Patent No. 5,776,487 disclose a use of liposome structures for determining analyte in a test sample wherein the liposome contains only an analyte specific ligand and a haptenated component used to bind to a
10 receptor moiety on a solid phase. This combination allows for capturing a test analyte onto a solid support for detection. Thus, it is vastly divergent from the concept of the current invention.

Our methods and artificial APCs are further distinguished from other recent disclosures. For example, Altman et al., in U.S. Patent No. 5,635,363 (the '363
15 disclosure), discuss a method for labeling T cells according to the specificity of their antigen receptor by preparing a "stable multimeric complex" comprised of four or more MHC molecules having a substantially homogenous bound peptide population. The multimeric antigen:MHC complex was said to form a stable structure that because of its "stable multimeric" design, purportedly increases the affinity of a T cell receptor for its
20 specific antigen thereby allowing for the labeling, identification and separation of T cells. Although such multimeric MHC components are known to bind T cells, they are not incorporated into liposome structures. Thus, the MHC complexes are unable to participate in capping type concentration. Moreover, the '363 method does not use accessory, co-stimulatory, adhesion, or other molecules to assist T cell binding and/or activation or
25 modulation.

The current invention is further distinguishable over prior disclosures in that our invention is based on the recognition that the valency of the liposome:MHC structure is multiple, and empirically determined. Moreover, we have provided for greater specificity in following APC:T cell interaction due to one embodiment of our invention wherein the

antigen is labeled rather than the MHC component (*e.g.* a biotinylated antigen with a streptavidin molecule conjugated to a fluorochrome).

In light of the above noted distinctions, the disclosed artificial APC and use of a separate solid support containing a binding protein to bind irrelevant molecules on the artificial APC represents an especially notable improvement over prior art. For example, in the above mentioned prior technologies the design of complexes are such that simultaneous binding and capping of the MHC:antigen and TCR/CD3/accessory molecules cannot occur. Capping is the phenomenon by which the T cell focuses the relevant molecules to the portion of the cell where binding has occurred, thus amplifying the binding, and subsequently the signaling of the event to the cell's other components. The current invention provides a specifically designed lipid bilayer similar to that of a natural cell which allows protein molecules, such as the MHC:antigen complexes to float freely, thus enabling the complexes to conform to any capping events the T cell may undergo. The consequence is a greater ability of the current invention to bind to, stimulate, and modulate T cells on demand.

SUMMARY OF THE INVENTION

The present invention is directed to novel methods of isolating T cells specific for particular antigens of interest and modulating T cell function *ex vivo* which methods use, in various embodiments, flow cytometry and immunoaffinity chromatography. Additionally, the present invention is directed to artificial antigen presenting cells (artificial APCs) and methods of making artificial APCs. In a preferred embodiment, such artificial APCs are used to isolate, expand, and modulate antigen-specific T cells. Additionally, the present invention is directed to methods of treating conditions which would benefit from the modulation of T cell responses, for example, transplantation therapies, autoimmune disorders, allergies, cancers and viral infections or virtually any T cell mediated disease. The present invention is further directed to a T cell modulation column device as well as a kit for isolating and modulating antigen-specific T cell populations.

Artificial APCs and APC content

In one aspect, artificial APCs are provided having a synthetic membrane-based vesicle, such as a liposome containing cholesterol and neutral phospholipids such as phosphatidylcholine, that functions as an APC having capacities equivalent to a natural APC to bind to and induce an antigen-specific T cell response. Such an artificial APC
5 comprises multiples of homo- or heterogenous combinations of MHC:antigen complexes incorporated therein as well as other functional molecules including accessory molecules, co-stimulation molecules, adhesion molecules, and other immunomodulatory molecules such as cytokines, cytokine receptors, chemokines, and chemokine receptors. Additionally, these APCs may include a mechanism to properly orient these molecules of
10 interest in the APC membrane.

In one embodiment, accessory molecules may be used to facilitate and stabilize the interaction between the antigen specific T cell and the MHC:antigen complex. In this embodiment, an example of an accessory molecule is LFA-1. Other accessory molecules include, but are not limited to CD11a/18, CD54(ICAM-1), CD106(VCAM), and
15 CD49d/29(VLA-4), as well as antibodies to each of these molecule's ligands.

In another embodiment, the artificial APC includes co-stimulatory molecules that function to stimulate or activate an antigen-specific T cell. One form of activation is cell proliferation. Suitable co-stimulatory molecules include, but are not limited to, B7-1, B7-2, CD5, CD9, CD2, CD40 and antibodies to their ligands. Preferably, such co-stimulatory
20 molecules can be produced by recombinant methods. Co-stimulatory molecules can be used for a variety of purposes in addition to eliciting cell proliferation. For example, it is known that memory CD4+ T cells express B7-2 whereas naive CD4+ T cells do not. Neither type cell expresses B7-1 (Hakamada-Taguchi, R. *European Journal of Immunology*. 28:865-873.). Thus, the current invention may be used to selectively target
25 memory T cells by incorporating anti-B7-2 into the artificial APC complex.

In another embodiment, the artificial APC also includes adhesion molecules to facilitate strong and selective binding between the artificial APC and antigen-specific T cells. Suitable adhesion molecules include, but are not limited to, proteins of the ICAM
30 family, for example ICAM-1 and ICAM-2, GlyCAM-1, as well as CD34, anti-LFA-1, anti-

CD44 and anti-beta7 antibodies, chemokines, and chemokine receptors such as CXCR4 and CCR5, and antibodies to Selectins L, E, and P. Such molecules are known to be important as homing molecules for cells destined for specific locations *in vivo*. For example, Alpha4beta7 and L-selectin have been proposed as gut and peripheral lymphnode homing molecules respectively. Alpha4beta7 is expressed mainly on memory T cells while L-selectin is expressed mainly on naïve T cells (Abitorabi, M. A. *J Immunol.* 156:3111-3117.). It is also known that endothelial selectins (E-selectin and P-selectin) are associated with the extravasation of T cells into inflammatory sites in the skin (Tietz, W. *J Immunol.* 161:963-970.). In the current invention a beta7 binding molecule and gut addressin MAdCAM-1, or an anti-L-selectin antibody may be incorporated into the artificial APC to distinguish further the type of T cell binding to the MHC:antigen complex.

In another example, it is known that CD44, which binds hyaluronan, is involved in leukocyte extravasation. Anti-CD44 antibody will bind to CD44 and strip it from the leukocyte surface. In one embodiment of the invention, anti-CD44 is incorporated into an artificial APC for use in stripping CD44 from leukocytes as desired thereby helping to inhibit the extravasation of the cells into extracellular spaces once the treated cells are returned to the patient. In another embodiment the anti-CD44 can be infused into an immunomodulatory column where the leukocytes have been captured by artificial APCs for the same purpose.

In another embodiment, other functional molecules (*i.e.*, modulation molecules) may be incorporated into the artificial APC to facilitate T cell modulation. Examples of such molecules which may be incorporated into the artificial APC include, but are not limited to, CD72, CD22, and CD58, or antibodies to their ligands, antibodies to cytokine or chemokine receptors or small molecules which mimic the actions of the various cytokines or neuropeptides. These modulation molecules may be used for example to modulate the phenotype of antigen-specific T cells.

In another embodiment of the invention, the artificial APCs may also comprise irrelevant molecules which are included for the purpose of providing a means to anchor the

APC to a solid support or to carry a label. Such molecules are termed irrelevant because they do not interact with the binding, activation, or modulation of the T cells.

In still another embodiment, any of the aforementioned molecules of interest (i.e., MHC, functional, accessory, irrelevant) may be bound to a cholera toxin subunit moiety by
5 either a linking moiety or by a recombinant construction of a fusion peptide wherein the toxin subunit is linked directly to the protein of interest. In such embodiment, the cholera toxin subunit is positioned with respect to the molecule of interest such that the active portion of the molecule of interest is available for contact with T cells while the toxin portion remains in the nonpolar region of the lipid layer of the APC. In a preferred
10 embodiment, the cholera toxin moiety remains in the APC's interior by binding to GM-1 protein that is incorporated into the APC's lipid interior.

In still another embodiment, the APC comprises phospholipids, cholesterol, and GM-1 molecules each present in an appropriate ratio to allow free migration of molecules of interest around the lipid layer. Phospholipids contemplated include neutrally charged
15 phospholipids such as phosphatidylcholine and cholesterol. Additionally, the cholesterol provides a surfactant property allowing the phospholipid to carry the various molecules of interest (accessory, irrelevant, modulation, adhesion, and co-stimulatory) in a manner that aids the free mobility of such molecules within the liposome membrane layer without disruption of the membrane in ex vivo environments.

20 In still another embodiment, the APC comprises antigens wherein the antigens are presented by an MHC components for contact with and recognition by a T cell receptor. Such antigens may be selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide
25 derived by epitope mapping, a self-derived molecule, a self-derived molecule that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

In still another embodiment, the APC comprises labels wherein a label is associated
30 with at least one of the group selected from the group consisting of a lipid bilayer of the

liposome components, a lipid of the liposome, an antigen, an MHC molecule, a co-stimulatory molecule, an adhesion molecule, a cell modulation molecule, GM-1 protein, cholera toxin β subunit, an irrelevant molecule, and an accessory molecule.

5 Artificial APC formation

In a preferred embodiment, artificial APCs may be made by:

- (a) obtaining MHC:antigen complexes of interest;
- (b) combining said MHC:antigen complexes and accessory molecules such as ICAM-1, with an artificial lipid membrane comprising the aforementioned lipids, cholesterol,
10 and GM-1 molecules to form membrane-associated MHC:antigen:accessory molecule complexes, (*i.e.*, liposome:MHC:antigen:accessory molecule complexes); and
- (c) combining said liposome:MHC:antigen:accessory molecule complexes resulting from step (b) with one or more types of functional molecules (*i.e.*, other accessory molecules, co-stimulatory molecules, adhesion molecules, modulation molecules, and
15 irrelevant molecules) to form an artificial APC comprising liposome:MHC:antigen:accessory molecule:functional molecule complex. Preferably, steps (b) and (c) are performed simultaneously. Additionally, in this embodiment example, as well as all others mentioned herein, each of these molecules incorporated may be prelinked to cholera toxin (as by fusion protein construction or linker moiety).
20 In one embodiment, the functional molecules are individually optional. In another embodiment the irrelevant molecules are optional.

In another preferred embodiment, the artificial APCs may be made by:

- (a) obtaining a spheroid solid support of interest having affinity for non-polar regions of a phospholipid; and
- 25 (b) combining MHC:antigen complexes, accessory molecules such as LFA-1, and functional molecules (*i.e.*, other accessory molecules, co-stimulatory molecules, modulation molecules, irrelevant molecules, and adhesion molecules) with the phospholipid, cholesterol, GM-1 components and solid support to form a solid support associated:membrane-bound:MHC:antigen:accessory molecule:functional molecule
30 complexes (*i.e.*, solid support:phospholipid:MHC:antigen:accessory

molecule:functional molecule complex) wherein of the molecules of (b), none are covalently bound to the solid support except optionally the lipid component.

In this embodiment, the solid support is preferably a glass bead or magnetic bead. It is also preferred that the phospholipid be phosphatidylcholine. In one embodiment of this aspect, the functional molecules are individually optional. In another embodiment, the solid support is either a glass or magnetic bead and has a diameter of between 25 and 300 μm . Additionally, another solid-support APC construct has only lipids, cholesterol and a capture moiety having affinity for capturing an irrelevant molecule that is located on a non-solid-support APC. In such construct, the lipid layer is generally a monolayer.

Artificial APC methods of use

In another embodiment, the present invention is directed to a method of isolating T cells specific for an antigen of interest using an artificial APC comprising:

- (a) obtaining a biological sample containing T cells which are specific for an antigen of interest;
- (b) preparing a liposome:MHC:antigen:accessory molecule:functional molecule complex (*i.e.* artificial APC), wherein the antigen in said complex is said antigen of interest;
- (c) contacting the biological sample obtained in step (a) with the artificial APC obtained in step (b) to form a artificial APC:T cell complex;
- (d) removing said complex formed in step (c) from said biological sample; and
- (e) separating T cells specific for said antigen of interest from said complex formed in step (c).

Optionally, such a method of isolating T cells specific for a particular antigen of interest may include the step of determining the quantity of such T cells complexed with the artificial APC, and/or may include the step of characterizing the functional phenotype of such T cells. Preferred biological samples containing T cells specific for an antigen of interest include bodily fluids such as blood, blood plasma, and cerebrospinal fluid. Other suitable biological samples include solid tissue, for example histological specimens.

In a preferred embodiment, the method uses FACS technology, and the antigen is labeled. Preferred labels include biotin, fluorochromes and radioactive labels. For example, one type of label which may be used is vancomycin (Rao et al., *Science*, Vol. 280:5364:708-11, 1998). In another embodiment of the method, also using FACS

5 technology, the liposome may be labeled or the label may be noncovalently enclosed within the liposome matrix. If the label is within the liposome matrix, the label may be either enclosed within the liposome or incorporated within the lipids of the outer membrane of the liposome. In another embodiment, the irrelevant molecule, if present, may be labeled. In yet another embodiment, the complex of the artificial APC and T cell

10 may be removed from the biological sample by capturing the complex via the irrelevant molecule on to a solid support. In such case, a solid support comprises an irrelevant molecule binding or capture molecule (*e.g.* anti-irrelevant molecule antibody) bound either directly to the solid support or noncovalently associated with a phospholipid bound to the support.

15 In another embodiment, the present invention provides an alternate method of isolating T cells specific for an antigen of interest. This alternate method comprises:

- (a) contacting an artificial APC having a MHC:antigen:accessory molecule component of interest with a solid support to form a solid support:artificial APC (The liposome of the APC contains a binding molecule *i.e.*, an “irrelevant” binding molecule. The capture molecule that captures the irrelevant molecule may be bound to said solid support via a linker or may be associate with a phospholipid layer on the solid support). In this embodiment, the antigen binding region of said MHC:antigen component is available for binding to a T cell receptor without steric hindrance because the MHC:antigen component is free to move within the liposome membrane of the APC while the irrelevant binding protein allows the APC to be anchored to the solid support;
- (b) contacting said solid support:artificial APC with a biological sample containing T cells specific for an antigen of interest to form a solid support:artificial APC:T cell complex;

- (c) removing said solid support:artificial APC:T cell complex from said biological sample; and
- (d) separating the T cells specific for said antigen of interest from said complex.

5 In a further aspect of the present invention, kits for the isolation of T cells specific for an antigen of interest are provided. In one embodiment, the kits comprise:

(a) APCs and solid supports such that there is included APCs having MHC (and other functional molecule where desired) complexes; and

(b) materials well known to those knowledgeable in the art which facilitate the

10 completion of the isolation of an antigen-specific T cell population including, but not limited to, buffers, culture medium. (included in buffers may be cytokines, antibodies to various transmembrane or soluble molecules, chemokines, neuropeptides, or steroids), (included in culture medium may be cytokines, antibodies to various transmembrane or soluble molecules,

15 chemokines, neuropeptides, or steroids), antigens, MHC molecules, accessory molecules, co-stimulatory molecules, modulatory molecules and adhesion molecules.

In another kit embodiment, the kit may comprise a solid support having a means to capture an irrelevant molecule located in an artificial APC, and an artificial APC constructed as

20 described above. In another embodiment, the kit may comprise virtual artificial APCs or solid supports comprising a lipid layer.

In another preferred embodiment, the invention includes an antigen-specific T cell isolation and modulation column device. In this embodiment, the device comprises compartments that may be isolated from one another having entrance and exit flow ports

25 between said compartments and between the compartments and external apparatuses. Any of the compartments of such column device may further comprise solid supports capable of binding irrelevant molecules of artificial APCs or solid supports that function directly as artificial APCs as described above. Moreover, such a device may be used in connection with soluble immunomodulatory molecules that are neither bound to a solid support or

incorporated into an artificial APC. Examples of such molecules include cytokines, chemokines and hormones.

In another such example, if leukopheresis is being performed with the intention of reintroducing the cells back into the patient's body, soluble factors may be introduced into
5 a column device to induce production of IL2 in naïve T cells, IL2 being necessary for T cell growth. Likewise, IL4 or soluble IL4 receptor antibody may be introduced into an immunomodulatory column to enhance the Th2 phenotype in specific T cells of interest.

The invention further comprises a method of modulating T cell responses (*i.e.*,
10 altering a T cell's phenotype). In such embodiment, methods of regulating or modifying T cell responses *ex vivo*, such as in a column device of the invention, are provided comprising the steps of isolating T cells which are specific for an antigen of interest and combining said isolated T cells with an artificial antigen presenting cell. The
15 aforementioned steps may be performed simultaneously or separately as by addressing antigen-specific T cells from one compartment to another after first capturing the T cell followed by introduction of an artificial APC. Preferably, the T cells specific for an antigen of interest are isolated using the T cell isolation methods described above.

The modulation of T cell response may comprise changing, in whole or in part, the functional pattern of cytokine receptor expression, cytokine production, chemokine
20 production, and/or chemokine receptor expression by the isolated T cells specific for a given antigen. For example, a T cell may be stimulated to shift its phenotype from a Th0 to a Th1. In another example, a T cell may be stimulated to shift its phenotype from a Th1 response to a Th2 response. In yet another example, a T cell may be stimulated to shift from any other phenotype to a Th3 phenotype. Amongst the many possible means to
25 induce modulation of a T cell response for the purpose of increasing its Th2 response and/or decrease its Th1 response, preferably the artificial APC used in such method expresses the co-stimulatory molecule B7-2.

In another embodiment, the modulation of T cell response may comprise changing, in whole or in part, the functional pattern of cytokine production by said isolated T cells
30 from a Th2 response to a Th1 response. Preferably, to modify a T cell response to induce

it to increase its Th1 response and/or decrease its Th2 response, the artificial APC used in such method expresses the co-stimulatory molecule B7-1.

In another example of T cell modulation, it is known that ST2L expression is Th2-type specific. In the current invention, ST2L may be included in the APC in order to
5 identify, isolate and extract antigen-specific T cells of the Th2 phenotype and/or enrich T cell population for antigen-specific Th1 phenotype in the treatment of autoimmune disease.

In another example, OX40 ligand is known to induce a Th2-like phenotype in naïve T cells (Flynn, S. *Journal of Experimental Medicine*. 188:2:297-304.). In the current invention, OX40 may be incorporated into an artificial APC to selectively induce a Th2
10 phenotype.

In another example, CD30 is known to have association with asthma (Spinozzi, F. *Mol Med*. 1:7:821-826.). In the current invention, CD30 may be incorporated into artificial APCs to identify, isolate and remove antigen-specific T cells of the Th2 phenotype or to
15 augment T cell response away from harmful T helper cells in the treatment of allergic conditions.

In yet another embodiment, the modulation of T cell response may comprise inducing anergy and/or apoptosis. Since it is known that the same cell need not present both the specific antigen and the co-stimulatory molecule for T cell activation (Ding, L and Shevach, E. M. *European Journal of Immunology*. 24:4:859-866.), our system is applicable
20 to situations where the artificial APC does not express a co-stimulatory molecule, or contains another effector molecule, *e.g.* Fas ligand, to induce anergy. Thus, the artificial APC used in such method would not express a co-stimulatory molecule but may alternatively express Fas ligand.

In yet another embodiment, the modulation of T cell response may comprise
25 inducing T cell proliferation in general, without regard to modifying Th1 or Th2 response, and without regard for inducing anergy. Preferably, this is accomplished by an artificial APC that expresses an anti-CD28 antibody.

In yet another preferred embodiment, the present invention provides methods of
30 treating a condition in a subject who would be benefited by modulating the functional

pattern of active factors expressed by a T cell. Such method of treatment could include in addition to the use of artificial APCs, the use of a column device described herein. For example, in such a treatment regimen, production of cytokines by a T cell may be modified in certain antigen-specific T cells to increase Th2 response and/or decrease Th1 response.

- 5 In such a method, a subject's T cells that are specific for an antigen capable of triggering a Th1 response are isolated by contacting said cells with an APC having an MHC:antigen complex containing an appropriate antigen. By also including the co-stimulatory molecule B7-2 on the APC, the T cells may be directed to modify their response and cytokine production to increase a Th2 response. Conditions which would be benefited by altering
- 10 the functional pattern of response toward a Th2 response include, for example, autoimmune diseases such as type 1 diabetes mellitus, multiple sclerosis, rheumatoid arthritis, dermatomyositis, juvenile rheumatoid arthritis and uveitis.

- In another example of a method of treatment, it is known that the cross-linking of the CD40 ligand by means of antibodies induces cell proliferation and IL4 production
- 15 (Blotta, M. H. *J Immunol.* 156:3133-3140.). Additionally, it is known that blockade of CD40/CD40 ligand pathway induces tolerance in murine contact hypersensitivity (Tang, A. *European Journal of Immunology.* 27:3143-3150.). In the current invention, CD40 or anti-CD40 ligand antibody may be incorporated into an artificial APC to induce T cell modulation toward production of IL4 and/or tolerance to alleviate inflammatory
 - 20 autoimmune disorders.

- In yet another example of a method of treatment, a subject may be benefited by altering the functional pattern of cytokine production by certain antigen-specific T cells to increase Th1 response and/or decrease Th2 response. Such methods comprise isolating a subject's T cells that are specific for an antigen capable of triggering a Th2 response by
- 25 contacting said cells with an APC containing an MHC:antigen complex having an appropriate antigen, wherein said artificial APC also expresses the co-stimulatory molecule B7-1. Conditions which would be benefited by altering the functional pattern of cytokine production to increase Th1 response and/or decrease Th2 response include, for example, allergy, for example allergy to dust, animal skin bypass products, vegetables, fruits, pollen

and chemicals. Other conditions which may be benefited include cancers and some types of infections (*e.g.*, viral, protozoan, fungal and bacterial).

In another example of a method of treatment, it is known that anti-B7-1 antibody will reduce the incidence of EAE, an animal model of multiple sclerosis. Anti-B7-2 antibody is known to increase the severity of EAE, while co-treatment with anti-IL4 antibody will prevent disease amelioration. In the current invention, more than one level of control with respect to this disease is possible. For example, artificial APCs may be generated that express anti-B7-1 antibody and/or IL4 to elicit T cell response favorable to treating the disease.

In another example, a regimen may be developed for treating melanoma by screening for T cell responses to epitopes derived from MAGE-1, MAGE-3, MART-1/melan-A, gp100, tyrosinase, gp75, gp15, CDK4 and beta-catenin, all of which are known to be associated with the disease. T cells having specificity for these molecules may be activated and modulated in various ways. For example, T cells that are specific for a unique cancer related antigen can act to cause destruction of the cancerous cells may be proliferated and infused into a patient.

In another example of a method of treatment, artificial APCs may be designed to augment antigen-specific T cell response away from the harmful helper type T cells or used to deplete offending T cells in the treatment of multiple sclerosis. Such depletion or modulation of the T cells may be carried out in combination with the infusion into a column device of either Fas, Fas Ligand, anti-Fas or anti-Fas ligand antibody. Additionally, artificial APCs may be designed to incorporate SLAM reactive molecules into the liposome complex which functions to induce a suppressive phenotype.

In another treatment example, SLAM reactive molecules incorporated in an artificial APC may be used to treat Th2-mediated autoimmune diseases by modulating the T cell response to shift from a Th2 profile to a Th0/Th1 profile while at the same time inducing IL-2 independent, co-stimulation independent proliferation.

In yet another treatment example, cartilage degradation that is associated with rheumatoid arthritis can be prevented by use of IL-10 and IL-4 in an artificial APC or by

infusion of the soluble molecules into a column device to modulate antigen-specific T cells away from activated Th1 state.

In yet another treatment example, IL-12 can be used such as by infusion into a column device or incorporation in an artificial APC to induce Th1 type inflammatory
5 response to help treat Th2 mediated autoimmune diseases.

In another example of a treatment method, T cell mediated milk intolerance may be treated by isolation and depletion of T cells specific for the allergen which is incorporated as an MHC bound antigen on an artificial APC.

In still another example of using the invention to treat cancerous conditions, T cells
10 specific for the *ras* peptide, or variants thereof, may be stimulated by response to an artificial APC containing the *ras* peptide in the treatment of cancerous cells expressing the *ras* mutation.

In another example of the advance of the current invention over that of currently applied art, instead of observing the effects of specific molecules on T cell response *in*
15 *vivo*, the current invention allows one to follow T cell modulation *ex vivo*. For example, previous studies (Gaur, A. *J of Neuroimmunol.* 74:149-158.) showed that using I.V. injection of non-encephalitogenic APL91 peptide of MBP ameliorates disease by shifting cytokines from Th1 to Th2 phenotype. The same type of injections using encephalitogenic superagonist APL A97 ameliorates disease by causing deletion of specific T cells. The
20 problem arises that understanding the bioavailability of the injected complexes is difficult at best while the *ex vivo* methodology of the current invention allows one to follow the specific actions of the peptides when used either in an artificial APC or in soluble form in a column device.

In another situation, prior studies have indicated that *in vivo* application of peptides
25 to treat autoimmune disease states is related to epitope spreading resulting in relapsing episodes of disease (Lehmann, P. V. *Nature.* 358:6382:155-157.), (McRae, B. L. *Journal of Experimental Medicine.* 182:75-85.). The *ex vivo* application of the current invention is preferred because specific peptides can be used to isolate and identify antigen-specific T cells without exposing a patient to the danger of epitope spreading that is associated with
30 relapses of certain autoimmune diseases.

In a further preferred embodiment of the invention, a method of identifying T cells that express MHC epitopes important to graft versus host rejection in transplantation therapy is provided. In this embodiment, such MHCs are identified followed by their
5 incorporation into the artificial APC. Such APCs may be used to capture and deplete the recipient's T cells having specificity for such epitopes so as to allow a favorable modulation of the recipient's immune response to the graft. More specifically, peptides derived from the MHC of a recipient are bound to the MHC of a donor that are incorporated into artificial APCs. Such APCs are used in combination with tolerogenic
10 stimuli also on the APC or infused into the immunomodulatory column. The donor's T cells are then screened to bind reactive T cells that can then be discarded. In a preferred embodiment, the column device of the invention can be used to carry out such immunoleukaphoresis.

In another embodiment, the method contemplates treatment of an individual to cause a
15 favorable immune modulation to an allograft comprising:

- (a) predicting a donor's MHC to which a recipient may react;
- (b) testing the predicted MHC epitopes with a recipient's T cells to identify antigenic epitopes;
- (c) using identified epitopes in an artificial APC to deplete the recipient's antigen-specific
20 (*i.e.*, donor-specific) T cells while additionally desensitizing the recipient to the epitope by contacting the recipient (as by feeding or nasal injection) with increasing doses of the donor-specific antigen.

In still another preferred embodiment, the invention provides a method of identifying an individuals' MHC epitopes that are of import in immunologic responses to
25 pathogenic agents. In this embodiment, an individual's MHC is screened for epitopes that have appreciable sequence or molecular structure recognition with pathogen-derived molecules. The identified MHC epitopes can be used to elicit immunity that may be employed directly as a vaccine against such MHC epitopes that have sequence recognition with pathogen-derived peptides. For example, such a vaccine may be used to reduce
30 natural APCs that express MHC molecules associated with autoimmune diseases

including, but not limited to, multiple sclerosis, rheumatoid arthritis, and diabetes. In another preferred embodiment, the identified MHC epitopes can be incorporated into a liposome structure as a co-stimulatory molecule to enhance the effect of artificial APCs that express other disease related antigens.

5 In yet another preferred embodiment, antigenic moieties of the pathogen which have or are likely to have MHC mimics may be used in artificial APC MHC:antigen complexes to isolate T cells specific for such pathogen-derived antigenic motifs or mimics thereof for the production of a T cell vaccine. Such a vaccine may be used to directly fight progression of an infection or disease caused by a pathogen or that is the result of a
10 pathogen-derived antigen induced autoimmune associated inflammatory response. Usually a self-derived molecule that mimics a pathogen-derived antigen comprises a polypeptide. As used herein, such a mimic has an amino acid sequence identity with said pathogen-derived antigen to an extent necessary for the MHC to bind to the mimic. The range of sequence identity may be anywhere between 5 and 100% depending upon which amino
15 acids in a peptide sequence elicits either recognition by the MHC and/or stimulation of a T cell response. Generally, the range is between 5 and 100%, usually, the range is between of a range of 15 and 100%, preferably the range is between 35 and 100%, and most preferably the range is between 50 and 100%.

20 In still other embodiments, the invention provides a means to address other immunologic conditions relevant to T cell response. For example, apoptosis of T cells induced by MHC molecules through the CD95/CD95 ligand pathway can be controlled by incorporating anti CD95 into an artificial APC and modulating antigen-specific T cells.

In another application, dendritic cells important to immune response may be
25 manipulated *ex vivo* in the same fashion as T cells in the many examples provided above.

BRIEF DESCRIPTION OF THE DRAWINGS

The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee. The invention will be further described with reference to the accompanying drawings in which:

5 FIG. 1 is a schematic representation of the basic features of the invention and its interaction with various molecules on a T cell, where (1) is an artificial APC whose embedded molecules have conformed to the capping of the T cell, where (2) is an artificial APC that has not interacted with a T cell and whose molecules are randomly dispersed through the membrane, where (T) is a T cell whose molecules have capped in response to
10 the interaction with the artificial APC, where (3) is an accessory molecule for stabilizing the binding between the TCR and MHC:antigen complex, where (4) may be T cell accessory or adhesion molecule ligands, where (5) may be T cell co-stimulatory molecule ligands, where (6) may be an MHC:ag complex, where (7) may be cytokine related molecules, where (8) may be chemokine related molecules, where (9) may be an irrelevant
15 molecule used in binding of the artificial APC to a solid support or a molecule which is tagged with a molecule used in visualization.

 FIG. 2 is a schematic representation of an embodiment of the invention representative of a portion of an artificial APC (10) in which the peptide (11) complexed to the MHC (12) is tagged, wherein the tag, for example, is biotin (13). The visualization of
20 the complex comprising the above components may occur (while a TCR (14) on a T cell (15) is bound to the APC) by FACS through the addition of a streptavidin molecule complexed to a fluorochrome (16).

 FIG. 3 is a schematic representation of an embodiment of the invention represented by a portion of an artificial APC (17) interacting with a T cell (18) through the TCR (19),
25 using the artificial APC's MHC (20) and unlabeled peptide (21). The visualization by FACS is performed by the inclusion of an irrelevant molecule (22) having an attached label (23). The irrelevant molecule minus the label may also be used to bind the liposome to a solid support.

 FIG. 4 is a schematic representation of an embodiment of the invention represented
30 by a portion of an artificial APC (24) interacting with a T cell (25) through the TCR (26),

using the artificial APC's MHC (27) and unlabeled peptide (28). A fluorochrome (29) may be added to the dialysis buffer during the formation of the liposomes so that visualization may be carried out by FACS.

FIG. 5 is a schematic representation of an embodiment wherein the artificial APC (30) includes a functional molecule (31) (such as an accessory, co-stimulatory, adhesion, modulation, cytokine, or chemokine molecule) that interacts with a molecule (33) expressed by a T cell 32.

FIG. 6 is a schematic showing the capture of artificial APCs (35) and (37) by capture molecules (39) which are noncovalently associated with a lipid layer (38) (*e.g.*, a neutral phospholipid) attached to a solid support (34).

FIG. 7 is a schematic showing other embodiments of artificial APC designs wherein Fig. 7a represents a solid support (40) having a non-covalently associated lipid layer (42) containing various components of artificial APCs (41) that can bind a T cell (43). Fig. 7b shows a solid support (44) having the various components of artificial APCs (45) without a lipid component that can bind to a T cell (46).

FIG. 8 shows a column device having a multiplicity of compartments for processing antigen-specific T cells. The column, as shown, also contains APCs and various embodiments of solid supports.

FIG. 9A and B is a series of FACS figures detailing the specificity of the embodiment of the method diagramed in FIG. 2 using two different murine hybridomas specific for the OVA peptide in the context of either I-A^d or I-A^s. The Hi15 peptide has two identities and one conservative substitution with the OVA peptide, thus being a stringent control of specificity.

FIG. 10A, B, and C shows a series of experiments from a non-transgenic murine model in which the characterization of the antigen specificity (the I α 52 peptide) of a T cell population without the use of the current invention was attempted.

FIG. 11 shows the ability of the invention to determine directly the antigen specificity of a T cell population in the non-transgenic mouse model that could only be inferred in FIG. 10.

FIG. 12 shows the ability of the invention to determine the cross-reactivity of a singular group of antigen-specifically defined T cells seen first in FIG. 10, then in FIG. 11. Such a technique represents an improvement over prior art, as internalized antigen can not be removed.

5 FIG. 13A-E. is a series of FACS figures showing the use of the invention to identify T cells based on the specificity of the TCR in the PBMC of a patient with RA.

FIG. 14A-D is a series of FACS figures showing the use of the invention to identify T cells based on the specificity of the TCR in the PBMC of a patient with JDM.

FIG. 15 shows the identification of antigen specific cells with T cell capture in a
10 monoclonal TCR population wherein OVA³²³⁻³³⁹/IA^d specific T cell hybridoma 8D0 cells were incubated with artificial APCs complexed with IA^d and biotinylated OVA³²³⁻³³⁹. Prior to the incubation, the hybridoma cells were stained with CD4 PE (phycoerithrin, i.e., a fluorochrome) and the artificial APCs, complexed with IA^d and biotinylated OVA³²³⁻³³⁹, were stained with streptavidin labeled with CY. As control for specificity of the binding, T
15 cells of the same hybridoma were incubated with liposomes complexed with IE^d and biotinylated OVA³²³⁻³³⁹. Binding of hybridoma T cells to artificial APCs could be inhibited by co-incubation with monoclonal anti-IA^d antibody. The histograms show the intensity for staining for streptavidin CY in CD4 gated hybridoma cells. Gates were set on irrelevant isotype controls for CD4, and on binding of cychrome-conjugated streptavidin to
20 T cells/artificial APC with unbiotinylated OVA³²³⁻³³⁹ peptide.

Figures 16 (A-D), 17 (A-D), and 18 (A-D) are color photos showing that the interaction of T cells with artificial APCs allows physiological migration of TCR proteins toward the interaction side, i.e., "capping". Resting 8DO T cells were stained with FITC-cholera toxin, incubated with artificial APCs presenting IA^d/ OVA³²³⁻³³⁹ complexes and
25 analyzed by confocal microscopy. Panels A and B of each of Figs. 16-18 show the red and green fluorescent dyes, respectively. Panel C shows the cells as seen by phase contrast. Panel D is the combination of the two fluorescent dyes with phase contrast. Panel D shows the combined fluorescence of the red and green dyes so that co-localization (Fig. 16D), and capping (Figs.17D, and 18D) are observed. Specifically, Fig 16A-D shows 8DO cells
30 alone stained with Alexa 568-anti CD3 (red) bound to the T cell receptor and FITC-cholera

toxin (green) bound to the cholera toxin. Thus, Fig. 16A-D shows that the T cell receptor is associated with the cholera toxin antigen. This further shows that cholera toxin is a good tool for identifying the T cell receptor in this system. Fig. 17A-D shows 8DO cells incubated for 20 minutes with artificial APCs expressing IA^d/ OVA³²³⁻³³⁹ complexes.

- 5 Artificial APCs were stained with Alexa568 anti MHC (red) (i.e., the MHC is labeled red), and FITC cholera toxin (green) (i.e., the cholera toxin bound to the T cell receptor is labeled green). Thus, Fig. 17A-D shows that the interaction between T cells and artificial APCs allows physiologic migration and capping of the T cell receptor in the T cell membrane. Fig. 18A-D shows 8DO cells incubated for 20 minutes with artificial APCs expressing IA^d/ OVA³²³⁻³³⁹ complexes. Artificial APCs lipid membranes were labeled using FITC (green). The T cell receptor were labeled with Alexa568 anti CD3 (red). Thus, Fig. 18A-D further confirms the data shown in Fig. 17A-D.
- 10

- Figure 19 A-D are PAGE photos showing optimization of peptide (antigen) loading of human and mouse MHC class II molecules wherein detergent solubilized MHC class II molecules were incubated with biotinylated peptides at the designated pH and temperature for 16 and 24 hrs. Peptide loading was analyzed through ECL. Fig. 19A and B show binding of biotinylated PADRE peptide to HLA-DR4. Figure 19D and C show binding of biotinylated OVA 323-339 to mouse IAd. The photos show output signal of the level of binding of the peptides to MHC. Results indicate that an incubation of 16hrs at room temperature and pH 7 and a molar ratio of 200 to 1 provide for optimal results with respect to the human MHC and 1000 to 1 for the mouse.
- 15
- 20

- Figure 20 is a graph showing characterization of the artificial APCs by flow cytometric analysis wherein the approximate size of the fluorescent-labeled liposomes was determined through comparison with single size fluorescent particles with a mean size between 0.05 μ m and 0.85 μ m. The 0.85 μ m labeled curve represents beads of 0.85 μ m diameter, while the curve labeled 0.05 represents beads of 0.05 μ m in diameter, the shaded curve represents the size of APC.
- 25

- Figure 21 is a graph showing determination of the optimum incorporation of MHC class II in liposomes. Optimum incorporation is a factor of the ratio of the phospholipid and cholesterol. The ratio of the lipid components were tested such that fluorescent labeled
- 30

liposomes were complexed with HLA DR4 where the ratio was from 3.5:1 (w/w) to 14:1 and stained with anti-HLA DR PE. The incorporation of DR4 was measured by means of flow cytometric analysis of the signal for HLA DR-PE in FL2 (X-axis). As shown the number of incorporating events is highest (x axis) at a lipid/cholesterol ratio of 7:1.

Figure 22 is a graph showing incorporation of biotinylated PADRE in fluorescent labeled liposomes, complexed with HLA DR4 and specificity of the binding of biotinylated PADRE peptide to HLA DR4 complexed with liposomes. Biotinylated PADRE peptide is incubated with HLA DR4 or MHC Class I, both at a molar ratio of 10:1 (peptide to MHC) prior to incorporation in artificial APCs with fluorescent lipids. As an additional control, non- biotinylated PADRE peptide and biotinylated PADRE peptide (at a 1:1 w/w ratio) were incubated with HLA DR4 before incorporation in artificial APCs. The PADRE is a pan DR binding peptide. The graph indicates specificity and that label bound to the PADRE does not interfere with binding to the MHC component. Specifically, where non-biotinylated peptide is used at the same time, it will compete out biotinylated. The Class I binding shows that there must be specificity for such binding as use of the Class I fails to bind PADRE.

Figure 23A-F show plots of FACS analysis showing that T Cell capture is an effective method to identify class II restricted human polyclonal T Cells. The panels show a comparison of CD3+ cells binding PADRE/HLA or HA/HLA (HA is hemagglutinin A) complexes. PADRE is used as positive control because it will bind many MHC molecular species thereby providing an easy means to visualize populations of specific cells. HA is also a pan DR binding peptide but because cells in this example are expanded using PADRE peptide, use of HA for binding should serve as a negative control. The Y axis represents CD3+ cells; The x axis represents HLA/PADRE or HLA/HA complexes. Panels A and B show the % of PADRE antigen specific T cells at day 0 of culture (A) (i.e., 2.9%), and the % of antigen specific T cells at day 10 of culture with PADRE (B) (i.e., 8.1%). Thus, cells appear to be expanding as an antigen specific fashion. To test the specificity of the cell population, the % of HA cells are tested. As shown in panels C and D respectively, the % of HA specific T cells after 0 days of culture with PADRE/ HA (C) (i.e. 1.0%) drops to 0.3% HA specific T cells after 10 days of culture with PADRE (D). Panels E and F

show the % of antigen specific T cells at day 10 of culture wherein T Cell Capture using APCs was inhibited with an equimolar ratio of non-biotynilated PADRE. Panel E shows that 50% of inhibition was achieved, (i.e., the label does not interfere with testing of specificity using the APC). Panel F shows that 50% of inhibition was also achieved showing that the T cell/APC binding depends on the specific interaction of the T cell receptor, i.e., inhibition of binding using Anti HLA DR antibody at a molar ratio of 0.5:1 antibody to HLA. The FACS plots show results from an experiment wherein PBMC from a HLA DR4 0401+ donor were stimulated with 10µg/ml of PADRE peptide, K(X)VAAWTLKAA (Seq. Id. No. 7) where X is a derivatized amino acid such as cyclohexylalanine. At days 4 and 7, 10 ng/ml IL-2 was added. At day 10 cells were harvested for T Cell capture. HLADR4 was complexed with NBD-labeled liposomes (1:7 ratio HLA to liposomes) through 48 hours dialysis against PBS in 10.000 M cutoff dialysis membrane (Pierce). Complexes were then incubated for 48 hours at RT with n-terminus biotinylated peptides at a molar ratio of 10:1 for peptide/HLA. Excess of unbound peptide was removed through 24 hours of dialysis against PBS. Liposome-HLA-peptide complexes were incubated for 30 minutes with streptavidin-Cy before adding to the cells. The liposome-HLA-peptide complexes were then incubated with the stained cells and run on a Becton Dickinson FACS Star. Gates were set on viable cells, isotype controls and cells incubated with streptavidin CY alone.

Fig. 24 is a bar graph showing cytokine production by PADRE-stimulated cells. Production of IL2 and IFN in vitro of PBMC from HLA DR 0401 healthy adults. PBMCs were initially stimulated with 10 µg/ml of Pan DR Epitope binding peptide (PADRE) and cultured for 10 days. The cells were restimulated with autologous APCs and 10 µg/ml of peptide. Culture supernatants were collected at different days and measured for cytokine production by capture ELISA method. The result indicates that cell specificity can be shown by measuring cytokine production as cells proliferate. However, measuring cytokine production is actually less specific than the method of the invention as demonstrated in Fig. 23.

Figure 25A and B are FACS plots showing identification by T cell capture using artificial APCs of class II-restricted antigen specific mouse T cells upon

immunization and shows increase of IAd/Ia52 specific cells measured after immunization of the mice (at the base of the tail) with Ia52 or IFA (adjuvant) alone. Cells were harvested three days after the last immunization from inguinal draining lymphnodes, stained with anti-mouse CD4 PE and incubated with fluorescein
5 labeled artificial APCs complexed with IAd/Ia52. Fig 25A shows IFA only-immunized mice; Fig. 25B shows IAd/Ia52 - specific CD4 cells. Y axis: CD4; X axis: IAd/Ia52 specific T cells. The result indicates that the adjuvant immunized cells showed only 0.7 % specific cells whereas the Ia52 immunized cells comprised 5.4%. Thus, T cell capture using artificial APCs is useful to show antigen specificity.

10 Fig. 26 is a bar graph showing T cell proliferation to Ia52 after immunization. Cells were harvested from inguinal lymphnodes and incubated for three days with 10 mg/ml of Ia52 peptide. Proliferation was measured by thymidine incorporation and is expressed as stimulation index "SI": cpm of stimulated/unstimulated cultures. The result indicates that conducting T cell proliferation tests to determine specificity is
15 effective in measuring the specificity of T cell populations. However, the specificity is not to the same extent as that using the current invention shown in Fig 25.

Fig. 27A-C is a schematic showing methodology for orienting molecules of interest in the APC liposome matrix. In 27A, a molecule of interest such as MHC, functional, accessory, adhesion, or irrelevant molecule, may be synthesized by recombinant methods
20 well known to those skilled in the art and linked to GM-1 protein by a linker and properly oriented in the APC membrane. In 27B, a molecule of interest may be constructed as a fusion protein with cholera toxin β subunit and the fusion protein anchored in proper orientation in the APC membrane by the cholera toxin moiety binding to GM-1 protein. In 27C, a cholera toxin subunit may be chemically linked to SPDP linker (Pierce) and then
25 attached to a molecule of interest followed by anchoring to a GM-1 containing APC. In any of the above, the cholera toxin, GM-1 protein, linkers may be synthetically produced. In the figure, A represents a gene for a molecule of interest, B represents the gene for the β subunit of cholera toxin, A1 is an expression vector, A2 represents expression and isolation of the cloned gene, A3 is an expressed molecule of interest, B1 is a fusion protein of a

molecule of interest and cholera toxin, A4 is a linker, A5 is an artificial APC containing GM-1 protein, A7 is a partial view of an artificial APC wherein the molecule of interest is directly linked to the GM-1 protein, C is cholera toxin subunit, C1 is a linker, C2 is a molecule of interest, C3 is a cholera toxin subunit attached to a linker, C4 is a molecule of interest linked to a cholera toxin subunit, E represents a liposome bilayer, E1 shows GM-1 proteins, E2 is an artificial APC containing GM-1 protein, and F is a partial view of an artificial APC having a molecule of interest bound to the APC by the binding interaction of the GM-1 protein and cholera moiety.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to novel methods of isolating T cells specific for particular antigens of interest and modulating T cell function *ex vivo* which methods use, in various embodiments, flow cytometry and immunoaffinity chromatography. Additionally, the present invention is directed to artificial APCs and methods of making artificial APCs.

In a preferred embodiment, such artificial APCs are used to isolate, expand, and modulate antigen-specific T cells. Additionally, the present invention is directed to methods of treating conditions that would benefit from the modulation of T cell responses, for example, transplantation therapies, autoimmune disorders, allergies, cancers and viral infections, and virtually any T cell mediated disease. The present invention is further directed to a T cell modulation column device as well as a kit for isolating and modulating antigen-specific T cell populations.

Artificial APC composition

According to preferred embodiments of the current invention, an artificial APC may comprise MHC:antigen complexes, accessory molecules and other functional molecules including, but not limited to, co-stimulatory molecules, adhesion molecules, modulation molecules, irrelevant molecules, GM-1 and subunits of cholera toxin attached to any of the aforementioned molecules, and labels which are collectively incorporated within or are associated with the lipids of a liposome or other membrane-based vesicle

such as depicted in Fig. 1. Such incorporated or associated molecules may also include GPI anchored proteins.

In a first embodiment, the lipid membrane component comprises neutral phospholipids such as phosphatidylcholine and surfactant elements such as cholesterol.

5 These materials are provided in a proper ratio that allows the other molecules of interest to freely migrate in the membrane layer. Other lipid membrane components include GM-1 protein which is a transmembrane pentasaccharide protein and associates in part with nonpolar regions of the liposome matrix. This GM-1 protein can be used in association with cholera toxin β subunit to orient molecules of interest in the liposome matrix.

10 Accessory molecules may be included for the purpose of stabilizing the interaction between a TCR and an MHC:antigen complex. Suitable accessory molecules may include, but are not limited to, LFA-1, CD49d/29(VLA-4), CD11a/18, CD54(ICAM-1), and CD106(VCAM) and antibodies to their ligands. In a preferred embodiment, the artificial APC includes ICAM-1 as such an accessory molecule.

15 Co-stimulatory molecules may be included for the purpose of stimulating or activating a TCR. Suitable co-stimulatory molecules may include, but are not limited to, B7-1, B7-2, CD5, CD9, CD2, CD40, and antibodies to their ligands such as anti-CD28.

Adhesion molecules may be included for the purpose of enhancing the binding association between the artificial APC and a T cell. Suitable adhesion molecules may
20 include, but are not limited to, members of the ICAM family such as ICAM 1, ICAM 2 and GlyCAM-1, as well as CD 34, anti-LFA-1, anti-B7, and chemokines such as CXCR4 and CCR5, and antibodies to selectins L, E, and P.

Modulation molecules may be included for the purpose of modulating the phenotype of a T cell. Suitable modulation molecules may include, but are not limited to,
25 CD72, CD22, and CD58 and antibodies to their ligands, antibodies to cytokine or chemokine receptors or small molecules which mimic the actions of the various cytokines or neuropeptides.

Irrelevant molecules may be included for the purpose of either carrying a label or serving as a scaffold for binding to a solid support. Such a molecule can be any peptide or
30 other molecule having characteristics that make it suitable for use with a liposome and

antigen carrier. Such molecule should not interfere with the binding of a T cell to the artificial APC.

With respect to the incorporation of each of the aforementioned MHC, accessory, co-stimulatory, adhesion, modulation, and irrelevant molecules in the artificial APC, proper orientation of these molecule's active centers may be provided by combining the molecules with the β subunit of cholera toxin so that the cholera toxin subunit can be recognized and bound by GM-1 protein which is incorporated into the liposome membrane matrix. The incorporation of the cholera toxin and orientation mechanism markedly increases the ability of the artificial APC to interact with T cells and other cells and molecules due to the proper orientation of incorporated molecules from about 50% without such orienting to 90% or more with such orienting.

In another embodiment, the aforementioned molecules of interest may be produced by recombinant technology as is well known to those skilled in the art. Use of recombinantly produced molecules further provides the opportunity to produce such molecules as fusion molecules comprising the molecule of interest attached to the β subunit of cholera toxin. In another embodiment, the recombinantly produced (or for that matter a purified natural molecule) may be linked to cholera toxin by a commercial linker.

In still another embodiment, the APC comprises antigens wherein the antigens are presented by an MHC components for contact with and recognition by a T cell receptor.

Such antigens may be selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

Examples of some antigens noted above include the peptide QKRAAYDQYGHAAFE (Seq. Id. No. 10) which is derived from *E. coli* dnaJp1 heat shock protein. A human self-derived peptide is QKRAAVDTYCRHNYG (Seq. Id. No. 11) derived from the HLA. This peptide also has sequence identity with the pathogen

Sequence Id. No. 10. Peptides derived from epitope mapping include human peptides from the HA I matrix GILGFVFTL (Seq. Id. No. 12), VKLGEFYNQ (Seq. Id. No. 13) which is a HA I nucleoprotein, and PKYVKQNTLKLAT (Seq. Id. No. 14) derived from the HA II locus.

5 In still another embodiment, the APC comprises labels wherein a label is associated with at least one of the group selected from the group consisting of a lipid bilayer of the liposome components, a lipid of the liposome, an antigen, an MHC molecule, a co-stimulatory molecule, an adhesion molecule, a cell modulation molecule, GM-1 protein, cholera toxin β subunit, an irrelevant molecule, and an accessory molecule.

10

Artificial APC formation

Such artificial APCs may be made by:

- (a) obtaining an MHC:antigen complex of interest;
- (b) combining said MHC:antigen complex with an artificial lipid membrane to form a
15 membrane-associated MHC:antigen complex, (*i.e.*, a liposome:MHC:antigen complex); and
- (c) combining said liposome:MHC:antigen complex resulting from step (b) with any of the following: accessory molecule, a co-stimulatory molecule, an adhesion molecule, a modulation molecule, and an irrelevant molecule to form an artificial APC comprising
20 a liposome:MHC:antigen:functional molecule: complex. Steps (b) and (c) may be performed simultaneously. In one embodiment of this method, step (c) is optional in whole or in part with respect to any of co-stimulatory, adhesion, modulation, irrelevant molecules or GPI proteins. In another embodiment, any of the molecules of interest (MHC, accessory, co-stimulatory, adhesion, modulation, irrelevant molecules) can be
25 bound to the β subunit of cholera toxin and GM-1 protein can be included in the APC lipid matrix to provide a means for proper orientation of the molecules of interest such that their active centers are oriented to facilitate interaction with T cells and other components external to the APC.

30 By "membrane-associated" is meant the non-covalent attraction between the lipid molecules of a liposome and MHCs, antigens, accessory molecules, co-stimulatory

molecules, adhesion molecules, modulation molecules, irrelevant molecules, GM-1, and cholera toxin β subunit.

In another preferred embodiment, the artificial APCs may be made by:

- (a) obtaining a spheroid solid support of interest having affinity for non-polar regions of a phospholipid; and
- (b) combining MHC:antigen complexes, accessory molecules such as ICAM-1, and functional molecules (*i.e.*, other accessory molecules, co-stimulatory molecules, modulation molecules, irrelevant molecules and adhesion molecules) with the phospholipid and solid support to form a solid support associated:membrane-bound:MHC:antigen:accessory molecule:functional molecule complexes (*i.e.*, solid support:phospholipid:MHC:antigen:accessory molecule:functional molecule complex).

In this embodiment, the solid support is preferably a glass bead or magnetic bead. It is also preferred that the phospholipid be phosphatidylcholine. In one embodiment of this aspect, the functional molecules are individually optional. In another preferred embodiment, the molecules may be properly oriented by inclusion of a molecule bound to cholera toxin and GM-1 in the APC membrane matrix. In another embodiment the complex may include an irrelevant molecule for carrying a label. In still other embodiments, the antigen may have a label. In still other embodiments, a label may be noncovalently associated with the lipid layer.

In yet more embodiments of this solid-support APC construct, the solid support is a glass or magnetic bead having a diameter of about between 25 to 300 μm . In still another embodiment, the solid-support APC construct has only lipids, cholesterol and a molecule having affinity for binding to an irrelevant molecule that is located on another APC (either solid-support based or non-solid support bases). This construct allows for such molecule (which is also an "irrelevant" molecule) to float freely in the lipid layer for proper migration to aid binding of APCs that have bound to T cells.

Artificial APC uses and methods

In another aspect, the present invention is directed to a method of isolating T cells specific for an antigen of interest comprising:

- (a) obtaining a biological sample containing T cells which are specific for an antigen of interest;
- (b) preparing an artificial APC as described herein comprising an MHC:antigen component, wherein the antigen in said component is said antigen of interest;
- (c) contacting the biological sample obtained in step (a) with the artificial APC obtained in step (b) to form an artificial APC:T cell complex;
- (d) removing said complex formed in step (c) from said biological sample; and
- (e) separating T cells specific for said antigen of interest from said complex.

Any suitable biological sample which contains T cells specific for the antigen of interest may be used in the method. Suitable biological samples containing T cells specific for an antigen of interest include fluid biological samples, such as blood, plasma and cerebrospinal fluid, and solid biological samples, such as tissue, for example, histological samples. In one embodiment of the above example, the artificial APC may be complexed to a solid support in addition to the T cell. The complexing of the APC to the solid support provides a means to anchor the APC so that it and any T cell binding to it can be preferentially captured and isolated from extraneous matter. In such case, the solid support may be a glass or magnetic bead that is coated with a lipid mono layer that is bound to the bead by, for example, a linker. The solid support may additionally have noncovalently bound accessory molecules associated with the lipid layer such as binding molecules that recognize and bind to irrelevant molecules associated with the artificial APC. In another embodiment, the binding molecules may be covalently bound to the solid support by a linker. Additionally, the lipid layer may further include GM-1 for binding to a molecule of interest that is connected to cholera toxin subunit for orienting said molecule of interest.

By "T cells specific for an antigen of interest" is meant the T cells expressing receptors for a relevant target of an immune response. As noted above, the specificity of the T cell receptor (TCR) determines which antigens bind to the TCR with sufficient affinity to activate a particular T cell. Optionally, the above outlined method of isolating T

cells specific for a particular antigen of interest may include determining the quantity of such T cells that bind to the artificial APC, or may include characterizing the functional phenotype of such T cells. Such method may also include the use of a solid support containing a molecule which is able to recognize and bind to the irrelevant molecule
5 located in the lipid layer of the APC. Such solid support may further be confined to an accessible chamber of a column device.

By "MHC:antigen component" is meant MHC molecules that have affinity for antigens of interest which antigens are associated with such MHC and together form a complex of molecules that are inserted into or are associated with the lipid membrane.

10 Artificial lipid membranes such as liposomes may be prepared in a fashion similar to methods known in the art, (*e.g.*, Watts, et al., *PNAS*, Vol. 81:7564-68; Buus, et al., *Cell*, Vol. 47;1071:77 herein incorporated by reference). In a preferred embodiment, the liposome forms a bilayer having eukaryotic cell-like properties in that non-lipid molecules (*e.g.* MHC: antigen complexes, GM-1 bound to cholera-molecule of interest) may freely
15 migrate within the matrix of the lipid molecules of the liposome's lipid bilayer. An example of a liposome:MHC:antigen combination is provided in Fig. 1 and such a complex may also be prepared, for example, as described in Example 1 below. Moreover, the lipid bilayer may also include accessory molecules such as cholesterol to provide elasticity in the bilayer and GM-1 protein to provide an anchor for orientation of cholera β subunit
20 comprising molecules of interest.

In one embodiment, a biological sample derived from a tissue sample of interest in the form of a single cell suspension is contacted with an artificial APC followed by incubation of the artificial APC tissue sample mixture with antigen-specific staining compounds (*i.e.* for example, fluorochrome conjugated antibodies against T cell surface
25 markers of interest *e.g.*, CD3, CD4, or CD8). The cells may also be stained prior to incubation with the complexes. The resulting artificial APC:T cell complex may be separated from the cell suspension by, for example, flow cytometry, capture by a solid support in a column device, or centrifugation of such complexes bound to a solid support such as glass beads or magnetic beads.

In one embodiment of the T cell isolation method, the antigen is labeled (Fig. 2). In another embodiment, the irrelevant molecule may be labeled (Fig. 3). In another embodiment of the method, label is associated either covalently or non-covalently with the lipid molecules making up the liposome (Fig. 4). Preferred labels include biotin, fluorochromes such as FITC, radioactive labels and vancomycin. Use of such labels is well understood in the art. In embodiments where the label is associated with lipids of the liposome, the label may be either enclosed within the liposome or incorporated within the lipids of the outer membrane of the liposome. Preferably, the label is a fluorochrome, for example FITC. Such labeled liposomes may be made by mixing FITC with lipids during liposome formation, or may be obtained from commercial sources (*e.g.*, Polar Lipids).

In another embodiment, the present invention provides an alternate method of isolating T cells specific for an antigen of interest. This alternate method comprises:

- (a) contacting an artificial APC comprising a MHC:antigen:accessory molecule component of interest with a solid support to form a solid support:artificial APC (The liposome of the APC contains a binding molecule *i.e.*, an “irrelevant” binding molecule. The capture molecule that binds to the irrelevant molecule may be bound to said solid support via a linker or may be associated with a phospholipid layer on the solid support). In this embodiment, the antigen binding region of said MHC:antigen component is available for binding to a T cell receptor without steric hindrance because the MHC:antigen component is free to move within the liposome membrane of the APC while the irrelevant binding protein allows the APC to be anchored to the solid support;
- (b) contacting said solid support:artificial APC with a biological sample containing T cells specific for an antigen of interest to form a solid support:artificial APC:T cell complex;
- (c) removing said solid support:artificial APC:T cell complex from said biological sample; and
- (d) separating the T cells specific for said antigen of interest from said complex.

In this embodiment, the T cells are separated by either the physical removal of the T cell bound solid support from the biological sample, or separation may occur by retention of the bound T cells in a solid support containing compartment of a column device.

5 In another embodiment, the present invention is directed to other alternate methods of isolating T cells specific for an antigen of interest. One such method comprises:

- (a) obtaining a solid support of interest having affinity for non-polar regions of a phospholipid;
- (b) combining the solid support and MHC:antigen complexes, accessory molecules such as LFA-1, and functional molecules (*i.e.*, other accessory molecules, co-stimulatory molecules, modulation molecules, adhesion molecules, and irrelevant molecules) with the phospholipid support to form a solid support associated:membrane-bound:MHC:antigen:accessory molecule:functional molecule complexes (*i.e.*, solid support:phospholipid:MHC:antigen:accessory molecule:functional molecule complex;
- 10 (c) contacting said solid support:phospholipid:MHC:antigen: accessory molecule:functional molecule complex formed in (b) with a biological sample containing T cells specific for an antigen of interest to form a solid support:phospholipid:MHC:antigen: accessory molecule:functional molecule:T cell complex;
- 15 (d) removing said complex formed in (c) from said biological sample; and
- (e) separating the T cells specific for said antigen of interest from said complex.

In this embodiment, the solid support is preferably a glass bead or magnetic bead of about 25 to 300 μm in diameter. Additionally, the MHC, accessory, and functional molecules are not covalently bound directly to the solid support but are noncovalently associated with the lipid layer having the capacity to migrate on the surface of the solid support. Moreover, in a preferred embodiment of this example, the molecule of interest (e.g., MHC, accessory and functional molecules) are connected to cholera toxin β subunit. Further, GM-1 protein is incorporated into the lipid layer matrix providing a means by which the cholera toxin portion can be bound and the molecule of interest properly oriented in the lipid layer.

In still another aspect, a spheroid solid support may comprise lipid monolayer coating the solid support with only a irrelevant molecule having affinity for bonding another irrelevant molecule located on an APC that either does not have a solid support interior or does have a solid support interior. This aspect adds versatility to the capture process for isolation of APCs that are bound to antigen-specific T cells.

In a further preferred aspect of the invention, kits are provided for the isolation of T cells specific for an antigen of interest comprising any of the following: solid supports, phospholipids, antigen-specific artificial APCs, TCR-specific artificial APCs, solid supports containing lipid associated capture molecules for capturing irrelevant molecules, solid supports containing capture molecules bound to the solid support. buffers, media, labels and column devices.

In another embodiment, the invention contemplates a method of characterizing the functional state of antigen-specific T cells comprising:

- (a) isolating T cells;
- (b) extracting mRNA from said isolated T cells;
- (c) obtaining cDNA corresponding to said extracted mRNA;
- (d) evaluating the mRNA encoding proteins that govern function and phenotype of the antigen-specific T cells wherein the evaluation is carried out by a method selected from the group consisting of (1) mRNA translation of the proteins and testing such proteins using antibodies against the proteins, and (2) rtPCR of the mRNA using primers specific for the proteins.

In this method, the evaluation of the mRNA encoding proteins that govern function and phenotype of the antigen-specific T cell may be used to determine efficacy of an immunomodulation treatment regimen such as the administering of a vaccine. The immunomodulation treatment can comprise inducing tolerance in autoimmunity, reducing allergic response, inducing an immune response against cancer cells. Additionally, the proteins that govern function and phenotype of the antigen-specific T cells include cytokines, chemokines, chemokine receptors, and cytokine receptors.

The genes encoding antigens may also be identified. In another aspect, the invention contemplates a method for identifying a gene which is expressed by a T cell specific for an antigen of interest comprising:

- 5 (a) obtaining a biological sample containing T cells which are specific for an antigen of interest;
- (b) labeling with a first label at least the intracellular gene product of interest produced by T cells in said biological sample;
- (c) preparing a liposome:MHC:antigen complex, wherein the antigen in said liposome:MHC:antigen complex is said antigen of interest;
- 10 (d) contacting the biological sample obtained in step (a), as labeled in accordance with step (b), with the liposome:MHC: antigen complex obtained in step (c) to form a liposome:MHC:antigen:T cell complex;
- (e) labeling with a second label the liposome:MHC:antigen:T cell complex obtained in step (d); and
- 15 (f) discriminating, according to antigen specificity, cells producing the intracellular gene product of interest, which cells have both the first label and the second label.

In such method, the first and said second label may be selected from the group consisting of biotin, a flurochrome, FITC, and a radioactive label; provided that the first
20 and second labels are not the same.

In yet another preferred embodiment, methods are provided for modulating T cell responses. In this embodiment, T cells are isolated from a subject which are specific for an antigen of interest followed by combining said isolated T cells with an artificial APC
25 having functional molecules specific for modulating a T cell. In a preferred embodiment, the T cells specific for an antigen of interest are isolated using any of the T cell isolation methods described herein. In one preferred embodiment, modulation to activate T cells generally is caused by contacting said T cells with an artificial APC that expresses the co-stimulatory molecule B7 or anti-CD28, as well as MHC:antigen.

By "modulating T cell response" is meant the intentional intervention in the functional characteristics of antigen-specific T cells, including, but not limited to, functional pattern of cytokines produced, change in phenotype of T cells, and modulation in the expression of activation markers, cytokines and their receptors and chemokines and their receptors. Such modulations can be carried out for numerous purposes as discussed in the numerous examples above.

The modulation of T cell response may further comprise changing in whole or in part the functional pattern of cytokine production by the isolated T cells specific for a given antigen from a Th1 response to a Th2 response. In a preferred embodiment, modification of a T cell response for the purpose of increasing its Th2 response and/or decreasing its Th1 response includes the expression by the artificial antigen presenting cell used in such method of a co-stimulatory molecule, such as B7-2.

In another embodiment, the modulation of T cell response may comprise changing in whole or in part the functional pattern of cytokine production by said isolated T cells from a Th2 response to a Th1 response. Preferably, modulation of a T cell response for the purpose of increasing its Th1 response and/or decreasing its Th2 response includes the expression by the artificial APC used in such method of a co-stimulatory molecule such as B7-1.

The two subsets of CD4 T cells represented by Th1 and Th2 cytokine markers, have very different functions from one another. These two CD4 T cell subsets can also regulate each other. Once one subset becomes dominant, it is often difficult to shift the response of the T cell (*i.e.* expression of the cytokine) to the other type. One reason for this is that expressed cytokines of one type of CD4 T cell will inhibit the activation of the T cell to expression of another cytokine. For example, IL-10, a product of Th2 cells, can help to inhibit the development of a Th1 response. Therefore, in one embodiment, IL-10 is incorporated into artificial APCs and the resulting APC may be used to inhibit development of Th1 response.

In another example, interferon- γ (INF γ), a product of Th1 cells, can help to prevent the activation of a Th2 response. If a particular CD4 T cell type is activated preferentially in a response so that the cytokine (Th1 or 2) is highly expressed, such high expression can

suppress the development of the other subset. The overall effect of T cell populations expressing one or the other subset is that various tissues become either suppressive (Th2) or inflammatory (Th1). Thus, INF γ can be incorporated into artificial APCs and the resulting APC used to modulate cell populations to become either suppressive or inflammatory.

The ability to manipulate T cell response (as exemplified by the Th1/Th2 subsets) provides a novel method by which treatment can be provided for numerous disease states. For example, a response to an allergen can be manipulated so as to shift the antibody response away from an IgE-dominated response. Such a shift will prevent the allergen from activating IgE-mediated effector pathways. For example, a technique that has been used for many years to generate a desensitization response is carried out by contacting patients with escalating doses of the allergen (such as by feeding, nasal delivery, or by injection). This immunization schedule appears to gradually divert an IgE-dominated response, which diversion is driven by Th2 cells, to one driven by Th1 cells, with the consequent down-regulation of IgE production. Thus, the activation of a Th2 response in such a manner may be of use in the treatment of allergy.

Similarly, other conditions which are associated with a Th2 T cell response, as for example, responses in which the functional phenotype of cytokine secretion is tolerogenic to viral infections and some types of cancer, may also benefit from a modification of the Th2 T cell response so that Th2 is reduced and/or a Th1 T cell response is increased.

Autoimmune conditions, in which the functional phenotype of cytokine secretion is pro-inflammatory (as is the case with Th1), will benefit from a modification of the Th1 T cell response so that it is reduced and/or a Th2 T cell response is increased. As noted above, cytokines are cell-derived soluble mediators associated with immune responses that may act both within a microenvironment and/or systemically. Immune cells secrete specific cytokine profiles, each having markedly different effects. Th2-type cells secrete low levels of TGF β , no INF γ and high levels of IL-4 and IL-10, the presence of which in turn produce an immunosuppressive or tolerogenic immune environment. Th1-type cells on the other hand secrete very low TGF β , high INF γ and no IL-4 or IL-10. High expression of INF γ is associated with cell mediated proinflammatory immune

environments. As discussed herein, the artificial APC of the current invention can be used to modulate T cell responses by affecting these and other cytokines. Moreover, such cytokines as well as other soluble factors to which a T cell responds may be used in conjunction with a column device as described below.

5 In yet another embodiment, the regulation of T cell responses may comprise inducing anergy. Specifically, T cell responses may be modified for the purpose of inducing anergy through the Fas/Fas Ligand pathway.

In yet another aspect, the present invention provides methods of treating a condition in a subject who would be benefited by modulating the functional patterns of cytokine production by certain of such subject's antigen-specific T cells to increase Th2
10 response and/or decrease Th1 response, comprising:

- (a) isolating T cells capable of triggering a Th1 response from a subject;
- (b) combining said isolated T cells with artificial APCs which express MHC capable of binding an antigen recognized by said T cells wherein said artificial
15 APC also expresses the co-stimulatory molecule B7-2;
- (c) separating T cells that have bound to said artificial APCs in step (b); and
- (d) administering said T cells isolated in step (c) to said subject.

T cells that have been in contact with an artificial APC as described above will be
20 stimulated to shift their Th1 response to a Th2 response. Conditions which would be benefited by modulating the functional pattern of cytokine production to increase Th2 response and/or decrease Th1 response include autoimmune diseases such as, for example, type 1 diabetes mellitus, multiple sclerosis, rheumatoid arthritis, dermatomyositis, juvenile rheumatoid arthritis and uveitis.

25 In yet another aspect, the present invention provides methods of treating a condition in a subject that would be benefited by altering the functional pattern of cytokine production by certain antigen-specific T cells to increase Th1 response and/or decrease Th2 response comprising:

- (a) isolating T cells that are specific for an antigen capable of triggering a Th2
30 response from a subject;

- (b) combining said isolated T cells with an artificial APC which expresses an MHC capable of binding an antigen that is recognized by said T cells so that the functional pattern of said T cells may be modulated, wherein said artificial APC also expresses the co-stimulatory molecule B7-1;
- 5 (c) separating the T cells modulated in step (b); and
- (d) administering said T cells isolated in step (c) to said subject.

Conditions which would be benefited by modulating the functional pattern of cytokine production to increase Th1 response and/or decrease Th2 response include for
10 example, allergy, allergy to dust, animal skin bypass products, vegetables, fruits, pollen, chemicals, and some infections (*e.g.*, viral, fungal, protozan and bacterial).

As noted above, the present invention provides methods for isolating antigen-specific T cells. It is desirable to isolate antigen-specific T cells in a variety of contexts. For example, in adoptive immunotherapy, lymphocytes are removed from a patient,
15 expanded *ex vivo*, and then reinfused back into the patient to augment the patient's immune response. *See* Rosenberg et al., *N. Engl. J. Med.* 313:1485-1492 (1985); U.S. Patent No. 4,690,915. This approach has been effective in the treatment of various cancers (*see, e.g.*, Rosenberg et al., *N. Engl. J. Med.* 319:1676-1680 (1988). Isolation and expansion of T cells specific for a particular antigen will increase the specificity and effectiveness of
20 adoptive immunotherapeutic approaches. Such expansion may be benefited by obtaining a population of monoclonal T cells. Thus, the invention contemplates a method of obtaining a monoclonal population of T cells specific for an antigen of interest comprising:

- (a) isolating T cells specific for an antigen of interest; and
- (b) culturing the isolated T cells in an individual well with the antigen of interest
25 and an artificial APC.

Isolated T cells specific for a particular antigen may also be used as a diagnostic to screen for the presence of, or amount of a particular antigen and thus detect the presence, absence, or status of an immune response. Early detection of an immune response will
30 facilitate selection of a particular treatment regimen in a variety of pathological conditions

such as autoimmune diseases, allergies, allograft rejection, and infectious diseases. In a diagnosis of this type, the isolated T cells are used both as a means of detection and as reporters. The T cells proliferate when contacted with the antigen for which they are specific. This proliferation is easily detected as an increase in cell number or as an increase in growth rate measured, for example, by the rate of uptake of a label (*e.g.*, observation of the uptake of tritiated thymidine or bromodeoxyuricyl (BrdU)). Thus, the presence or absence of target antigen can be detected by exposing the isolated T cells to a tissue sample (*e.g.*, peripheral blood) and monitoring their proliferation rate. In the current invention, a preferred embodiment includes the observation of bound T cells using a FACS which allows the avoidance of time consuming proliferation experiments.

Isolation of antigen-specific T cells also provides a homogenous source of T cell receptors. A homogenous source of T cell receptors is an aid to the elucidation of structure-function relationships of particular receptors. A homogenous source of T cell receptors also facilitates the development of solubilized T cell receptors that are of use in a number of therapeutic applications (*See, e.g.*, U.S. Patent No. 5,283,058). In the current invention, solubilized receptors may be used in conjunction with an immunomodulation column device.

In another preferred embodiment, the invention provides for a method of identifying epitopes expressed on the MHC that are of import to acceptance or rejection of grafts in transplantation therapy. In this embodiment, a donor's MHC is examined by computer modeling to identify peptide moieties likely to be recognized by a recipient's T cells. The recipient's T cells are tested by FACS analysis for binding against the peptides. Upon positively identifying reactive peptides, such peptides may then be used to deplete the recipient's graft rejecting T cells thereby modulating the recipient's immune response in the transplantation regimen. This modulation is carried out within a comprehensive treatment that includes further modulating the recipient's sensitivity to the graft epitopes by exposing the recipient to the donor's epitopes by feeding, nasal delivery, or injection of increasing concentrations of the peptides.

In another aspect, the invention provides for a method to identify antigenic motifs of pathogens that are recognized by the MHC. In this embodiment the identification of

such motifs allows the development of anti-pathogen vaccines comprising either pools of such motifs in the form of peptides that are recognized by T cells in the general human population *i.e.*, the pathogen's antigenic moieties responsible for generating immune responses are identified so that for any disease, a vaccine comprising such antigens may be produced. Additionally, a vaccine may be produced against such antigenic moieties comprising a population of a patient's pathogen-specific T cells that have been expanded *ex vivo*.

In yet another aspect of the invention, a column device is provided comprising a multiplicity of compartments that are arranged in series. As shown in FIG. 8, one embodiment of such device has compartments A, B, and C. Each compartment is contiguous with the adjacent compartment by a valve 1. The valve between each compartment may be opened or closed. Compartment A also has entrance ports 2 and exit ports 3 for receiving a flowable medium. Any of the compartments may contain solid supports as seen in FIGs. 6, and 7 for binding either a molecule that can bind to an irrelevant molecule for immobilizing an artificial APC, or for binding directly MHC:antigen:functional molecule complexes. The entrance port 4 of compartment A is attached to an external device 5 (*e.g.*, a device where a patient's T cells are separated from whole blood and concentrated) prior to export through a sterile tube 6 to entrance port 4. Once the patient's enriched T cell population is transported into compartment A via entrance port 4, the T cells containing TCR specific for the MHC:antigen complexes bind to MHC:antigen complexes that are themselves attached either directly to the solid supports or are associated with an artificial APC which is bound to a solid support via an irrelevant molecule. In the configuration demonstrated in Fig. 8, artificial APCs 14 are attached to solid supports in compartment A awaiting interaction with incoming cell through entrance port 4. Compartment A thus provides a chamber wherein the APCs and cells can interact so that antigen-specific T cells can be isolated while non-binding T cells are allowed to wash out of the compartment A via exit port 3a. After the non-binding cells are removed (and either discarded or returned to the patient's circulatory system, or addressed to a device for monitoring the cells such as a FACS), the bound antigen-specific T cells may be released from the solid supports in A and allowed to channel or flow

through valve **1** located between compartment **A** and **B** and into compartment **B**. The artificial APC-cell bound complexes or just the antigen-specific T cells alone may be released from solid support of compartment **A** by adjusting the temperature of the medium in the compartment **A**. Once the antigen-specific T cells are in compartment **B**, they may

5 again be captured as shown in Fig. **8**, or simply be treated without recapture in any number of ways to induce cell modulation. For example, artificial APCs containing antigen-specific MHC:antigen:functional molecule complexes may be infused into compartment **B** via entrance port **7**. With the infusion of the antigen-specific APCs into compartment **B**, the antigen-specific T cells may then bind and be induced to modulate their respective

10 response or be acted upon otherwise as desired. Fig. **8** shows T cells **13** that have been released from compartment **A** and are shown bound to APCs that are in turn bound to solid supports. As described above, and hereinafter, numerous types of modulation of the T cells may occur. For example, the T cells may be modulated to (1) increase a Th1 and/or decrease a Th2 response, (2) increase a Th2 and/or decrease and Th1 response, (3) be

15 generally induced to proliferate regardless of Th1 or Th2 response, (4) enter a state of anergy, (5) become apoptotic, (6) shed certain adhesion molecules known to those skilled in the art to be involved in the entry of cells into specific diseased areas, (7) upregulate/downregulate chemokine or cytokine receptors associated with a Th1-type response, (8) upregulate/downregulate chemokine or cytokine receptors associated with a

20 Th2-type response. The T cells may also be captured on such APCs for the purpose of (1) depleting allo-antigen-specific T cells from a donor's T cell population in transplantation oriented therapy, such as bone marrow transplant therapy or (2) from a patient's T cell population such as to facilitate a graft of allogenic solid organs, or (3) used in identifying TCRs that bind to pathogen-recognizing MHCs or self-derived pathogen-mimic antigenic

25 motifs. Moreover, soluble molecules may be added to the device for inducing such modulation including cytokines, adjuvants, and hormones.

Once isolation or other modulation has been performed in compartment **B**, the T cell:artificial APC complex may be addressed to compartment **C** via the valve **1** between compartments **B** and **C**. The entrance port **7** of compartment **B** may be additionally

30 connected to external units for supplying buffers and the like that may be necessary for

carrying out manipulations of the T cells in compartment **B**. The exit port **8** of compartment **B** may also be used to transport modulated T cell:artificial APC complexes to sampling devices such as FACS or to other devices for such things as cell proliferation and the like.

5 Compartment C may also contain solid supports and the like for binding artificial APC:T cell complexes and further treatment. In compartment C, the modulated and isolated T cells may be eluted from the APCs (via the adjustment of the medium's temperature) and addressed to other devices through ports 9 and 10, or addressed out of the column through exit port 11 to, for example, the patient, a FACS, a culture device, or to
10 another location for further manipulation.

Specific embodiments of the present invention are exemplified in the following Examples. These Examples are not to be interpreted as limiting the scope of the invention in any way, the scope being disclosed in the entire specification and claims.

15

EXAMPLE 1

LIPOSOME ASSAY FOR DETECTION OF ANTIGEN-SPECIFIC T CELLS

In this example, experiments are described which demonstrate the capacity of T cells to bind to liposomes containing cholesterol having MHC:antigen complexes inserted into the liposome membrane. The capacity of T cell binding was quantified by flow cytometry analysis (FACS). Negative controls for the binding include the use of a control T cell line (*i.e.*, non-reactive) having specificity for an irrelevant peptide, incorrect MHC restriction, peptide and antibody inhibitions, limiting dilutions, and the use of MHC without peptide.

The ability of the method to provide for discrimination between antigen-specific T cells was facilitated by use of two T cell hybridomas specific for the same peptide. These hybridomas were OVA³²³⁻³³⁶ (which correspond to residues 323-326 of ovalbumin) (obtained from Research Genetics, Huntsville AL) which were restricted by two different MHCs, I-A^s and I-A^d. Specifically, the designations for the restrictions were I-A^s restricted OVA³²³⁻³³⁶ specific T cell hybridoma, AG111.207, and the I-A^d restricted OVA³²³⁻³³⁶ specific T cell hybridoma 8D051.15. A peptide containing 2 identities and one

conservative substitution, Hi15 (Research Genetics), which corresponds to residues 15-31 of *H. influenzae* isoleucyl tRNA transferase, was used as a negative control.

MATERIALS AND METHODS

5 Preparation of Liposome:MHC:Antigen Complexes.

Liposomes were prepared similarly to that described by Brian et al., *PNAS*, 81:6159-63. Briefly, cholesterol (Ch) and L- α -phosphatidylcholine (PC) (Sigma) were mixed at a molar ratio of 2:7 of Ch and PC respectively. The mixture was placed under an argon stream for 30 minutes to evaporate chloroform used in the preparation, and
10 resuspended in 140mM NaCl, 10mM Tris HCl, and 0.5% deoxycholate at pH 8. The suspension was sonicated for three minutes or until clear.

Complexes of affinity-purified MHC molecules I-A^s and I-A^d (each expressed in a B cell lymphoma and purified via immunoaffinity column) were inserted into liposomes by a 72 hour 4°C dialysis against three changes of PBS (Slidealyzer, Pierce) at a 1:10 molar
15 ratio of MHC to liposomes to form liposome:MHC complexes.

The OVA³²³⁻³²⁶ peptide and the control peptide, Hi15, were biotinylated, (post synthesis, Sigma), and the biotinylated peptides (b-peptides) were incubated with the liposome:MHC complexes for 18 hours at room temperature at a physiologic pH to form liposome:MHC:b-peptide complexes.

20 Flow Cytometry.

Viable cells were separated from debris using a ficol-hypaque gradient. (Lymphocyte M) Cells were blocked with 10% FCS in PBS for 10 minutes on ice, then washed in PBS. Incubations with antibodies (used at concentrations of 400-600ng/ml)
25 were performed on ice in the dark for 20 minutes. The antibodies used included anti-CD3e (clone 145-2C11), anti-CD4 (clone GK 1.5), anti-CD8a (clone 53-6.7), anti-HSA (clone M1/69), and anti-CD69 (H1.2F3) (Pharmingen, San Diego, CA). Liposome:MHC:b-peptide complexes were preincubated with fluorescent streptavidin molecule (f-strep) at room temperature for 1/2 hour. When two peptides were used in the same assay, the
30 liposome:MHC:b-peptide complex was preincubated with streptavidin molecules of

differing fluorescence prior to addition to cells. Sorted cells were either (a) cultured (using a 3:1 ratio of irradiated BALB/c spleen cells, 20U/ml rIL-2, 10µg/ml Hi15 or Iα52, 10% FCS, 1%Penicillin/Streptomycin/Glutamine (P/S/G), in RPMI 1640 at 37°C and 6% CO₂), (b) processed for variable beta chain (Vb) analysis by PCR, or (c) reanalyzed by a fluorescent antibody cell sorter (FACS).

Yields ranged from 2,000 to 16,000 events. Bulk-sorted cells used for reanalysis were incubated for 1/2 hour on ice and spun down through 100% FCS at 325 x g for 10 minutes to remove liposome:MHC:b-peptide complexes, prior to restaining with liposome:MHC and a different b-peptide. Single-cell sorts were dispersed in 96-well culture plates containing fresh irradiated APCs obtained from the spleen of a syngeneic BALB/c mouse. Generally 8-12 wells showed proliferation over six weeks. Cells were visualized with a Becton Dickinson FACS Star equipped with LYSIS II software.

As shown in FIG. 9, specific recognition of MHC/peptide complexes by T-T hybridomas AG111.207 (I-A^S/OVA³²³⁻³³⁶ specific) and 8D051.15 (I-A^d/OVA³²³⁻³³⁶ specific) were observed. Cultured AG111.207 or 8D051.15 cells were analyzed by flow cytometry using anti-CD4 antibodies and I-A^d/b-peptide or I-A^S/b-peptide combinations complexed into liposomes and visualized by addition of f-strep. The ratio of cells specific to either the I-A^d/antigen or A^S/antigen was constant between experiments. (All figures are gated on CD4+ cells unless otherwise stated.) Fig. 9 (a) shows AG111.207 cells which were stained with anti-CD4 antibody and differing combinations of MHC/antigen including an irrelevant peptide known to bind to I-A^d (Hi15). Cellular specificity is shown by use of a B cell hybridoma (Fig. 9-a4). Fig. 9 (b) shows 8DO51.15 cells which were analyzed with differing combinations of MHC:antigen. Included is a control using biotinylated I-A^d alone to detect the T cell hybridoma (Fig. 9-b4).

RESULTS

In the series of experiments for which results are shown in FIG. 9, purified I-A^S or I-A^d MHCs were inserted into liposomes and then complexed to the biotinylated OVA³²³⁻³³⁶ peptide. These complexes were incubated with streptavidin-FITC, and then with a

standard amount of AG111.207 or 8D051.15 cells (final MHC concentration of 66µg/ml). When analyzed by flow cytometry, nearly 90% of the AG111.207 (Figure 9a1) and 87.2% of 8D051.15 (Figure 9b1) cells stained positive when using the correct restriction and peptide.

5 The specificity of the entire interaction was demonstrated by lack of staining of AG111.207 and 8D051.15 cells when incubated with anti-CD4 Ab and complexes of the incorrect restriction for each hybridoma, I-A^d and I-A^s respectively, and Hi15 which has two identities (p2, p10) and one conservative substitution (p5) with OVA³²³⁻³³⁶ (0% positive cells Figure 9a2; 2.5% positive cells, Figure 9b2). The peptide specificity of the
10 interaction was demonstrated when AG111.207 and 8D051.15 cells were incubated with anti-CD4 antibody, the correct restriction element, but irrelevant peptide for each hybridoma, I-A^s/b-Hi15 or I-A^d/b-Hi15 respectively (4.6% positive cells, Figure 9a3; 8.7% positive cells, Figure 9b3). The binding between MHC:b-peptide complexes and AG111.207 T cells was also concentration dependent. Only 13.1% of AG111.207 cells
15 tested positive when the I-A^s/OVA³²³⁻³³⁶ concentration in the assay was reduced five fold to 13µg/ml (not shown). The signal was also reduced by the addition of 300µg/ml of the same, non-biotinylated OVA³²³⁻³³⁶ peptide as a competitive inhibitor during preparation of the I-A^s /OVA complexes (5.1% of CD4⁺ cells positive, not shown). This finding suggests that biotinylation of the peptide does not interfere with the trimolecular interactions among
20 peptide, MHC and TCR. Moreover, this assay was seen to be dependent on both TCR and MHC:peptide complexes, insofar as binding can be inhibited by simultaneous addition of anti-TCR and anti-I-A antibodies (6.9% of CD4⁺ cells positive). As shown in Figure 9a4, no binding to TCR-negative cells, such as B cell hybridoma HT.01, was detected (0% of cells positive). Using biotinylated I-A^d in liposomes without peptide, 6.9% of 8D051.15
25 cells bound the MHC alone (Figure 9b4). Hence, the interaction requires the presence of the specific peptide.

Artificial APCs identify T cell hybridoma 8DO, specific for IA^d/OVA combination

In another experiment we evaluated the capability of artificial APC,
30 presenting synthetic biotinylated peptide OVA in the context of IA^d, to visualize by

FACS analysis hybridoma 8D0, which is OVA/IA^d specific. As shown in Fig. 15, the percentage of hybridoma cells was visualized by binding with cychrome-tagged artificial APC. This interaction was specific, insofar as TCR binding was dependent on the availability of the MHC/peptide complexes. The interaction was inhibitable
5 by addition of antibodies interfering with such interaction (%positive cells, Fig.15 middle graph), and 8DO hybridoma cells did not bind to the artificial APC presenting the correct peptide in the context of IE^d (% positive cells, Fig. 15 left graph). The result indicates that highly specific and sensitive interaction occurs between T cells and artificial APCs. Moreover, addition of competitive inhibitors in
10 reducing the specific binding proves that the labeling of this method does not interfere with the APC/T cell interaction.

EXAMPLE 2

IDENTIFICATION OF ANTIGEN SPECIFIC T CELLS IN MOUSE EMBRIONIC THYMUSES

15 In this example, a murine model is used to investigate the effects of a naturally processed self-peptide on the maintenance and proliferation of T cells which may cross-react with homologous peptides of exogenous origin, all performed in a non-transgenic system. The example emphasizes the fact that without a method such as that of the current invention to capture T cells, it is not possible to evaluate polyclonal antigen specific
20 chimeric T cell selection in a non-transgenic system. This is because conventional methods that examine cytokine presense or cell proliferation cannot identify cells specific for relevant antigen

The self-peptide Iα52 (ASF EAQGALANIAVDKA) (Seq. Id. No. 1), used in these experiments corresponds to residues 52 to 68 of the α chain of the I-E molecule. It
25 represents one of the most abundant peptides naturally processed and presented in the context of I-A^d (Hunt et al., *Science*, Vol. 256:1817-20; 1992; Rudensky et al., *Nature*, Vol. 353:622-27; 1991). These experiments demonstrate that T cells specific for a particular antigen can be identified from a polymorphic population of cells. In addition, functional and genetic characteristics of the cell population were demonstrated (Table 1).

Table I. Phenotypic and Functional Characteristics of Thymocytes Before and After Fetal Thymic Organ Culture

	<u>Day 16</u> <u>of</u> <u>Gestation</u>	<u>Day 6 of</u> <u>FTOC</u>	<u>Day 6 of</u> <u>FTOC +</u> <u>10⁻² mM</u> <u>Iα52</u>
CD3 ^{lo} CD4 ⁺ CD8 ⁺	6 %	1.3 %	1.1 %
CD3 ^{lo} HSA ^{hi}	99	3.9	4.1
CD3 ^{lo} CD69 ⁺	2	< 1	< 1
CD3 ^{hi}	< 1	47	34
CD4 ⁺ CD8 ⁺			
CD3 ^{hi} HSA ^{hi}	< 1	82	84
CD3 ^{hi} CD69 ⁺	< 1	10	11
Cell Number	N/D	1.55x10 ⁵ #	1.65x10 ⁵ #
Iα52 Stimulation Index	N/D	0.5x ^{+/-} 0.1	6.2x ^{+/-} 2.7
Hi15 Stimulation Index	N/D	0.1x ^{+/-} 0.06	2.5x ^{+/-} 1.1

- 5 BALB/c embryonic thymus lobes were made into single cell suspensions, and analyzed by flow cytometry. Cell numbers are an average of eight to ten thymus lobes from FTOC. Data in the table represent between two and four experiments.
- 10 #Standard deviations are 3.1x10⁴ and 1.5x10⁴ respectively.

MATERIALS AND METHODS

Antigens.

- 15 The I-A^d-derived peptide Iα52 (ASFEAQGALANIAVDKA) (Seq. Id. No. 1) was synthesized (Research Genetics) using standard solid phase peptide synthesis method. Peptides used for flow cytometry were biotinylated (b-peptides) using a kit (Sigma) and were separated from free biotin by HPLC.

Generation of Lymphocytes from Fetal Thymic Organ Cultures (FTOC).

BALB/c embryonic thymi were harvested day 16 of gestation and placed onto
5 0.4µm cell culture inserts (Fisher) in six-well plates containing RPMI 1640, 10% FCS, 1%
P/S/G, with or without Iα52 (10^{-1} mM to 10^{-10} mM), at 37°C and 6% CO₂ for six days.
Cells were dissociated with a glass grinder (Kontes). Cell recovery was between 1.0×10^5
and 2.8×10^5 cells/lobe. Post-FTOC cultures were performed using a 3:1 ratio of irradiated
BALB/c spleen cells, 20U/ml rIL-2, 10µg/ml Hi15 or Iα52, 10% FCS, 1% P/S/G, in RPMI
10 1640 at 37°C and 6% CO₂.

Preparation of Liposome:MHC:Antigen Complexes.

Liposomes were prepared as described in Example 1.

15 Flow Cytometry.

Flow cytometry was performed as described in Example 1.

RESULTS

It has been shown previously that different concentrations of the same peptide have
20 strong implications for T cell selection (*see* Sebzda et al., Science, Vol. 263:1615-18). We
confirmed this phenomenon using various concentrations of Iα52 peptide to demonstrate
its influence upon peptide-mediated positive selection and to define, directly, the antigen
specificity of a positively selected T cell population in a non-transgenic BALB/c model.

Figure 10 shows the influence of Iα52 on the maturation of antigen specific
25 thymocytes in fetal thymic organ cultures. Fig. 10 (a) represents differing concentrations
of Iα52 added to 6-day FTOC using day 16 of gestation BALB/c embryonic thymus lobes.
Thymocytes were analyzed by three color flow cytometry to determine the percentages of
CD3HI, CD4, and CD8 double positive and CD3HI CD4 single positive cells. With FTOC
alone in the absence of any added peptide, 20.7% of CD4⁺ cells bound liposome:I-
30 A^d:biotinylated-Iα52 complexes during one week. This finding reflects the availability of

I α 52 as an abundantly represented, naturally processed peptide available for thymic selection.

Fig. 10 (b) shows V β analysis by FACS of cells taken directly from day 16 of gestation embryonic thymus lobes, and from FTOC supplemented with 10⁻² mM I α 52.

5 Fig. 10 (c1) represents thymocytes from FTOC without antigen, or with addition of the I α 52 peptide (c2), which were analyzed by FACS using propidium iodide to measure cell viability. Analysis of CD4, CD8 ratios from the two cell cultures (c3,4) is representative of those used in the above titration.

Performance of the detection of antigen specific thymocytes by FACS using anti-
10 CD4 antibody and liposome:I-A^d:b-I α 52 complexes bound to f-strep is shown in Figure 11. When thymic lobes were cultured for one week without the presence of 10⁻² mM I α 52 (Figure 11-1), a relative increase (to 50.9%, Figure 11-2) of liposome:I-A^d:biotinylated-I α 52, CD4⁺ cells was seen in the presence of 10⁻² mM I α 52. These data demonstrate for the first time that a self-derived peptide can induce positive selection in a non-transgenic
15 system. As a control for antigen specificity in the T cell capture assay, the unrelated, biotinylated peptide EBV1 (TRDDAEYLLGRESVL), (Seq. Id. No. 2) derived from the EBV protein balf2 (residues 1030-1045) was used. EBV1 binds efficiently to I-A^d, and is a good immunogen in adult BALB/c mice (La Cava et al, submitted). Biotinylated EBV1 peptide complexed to I-A^d in liposomes bound 0% of CD4⁺ cells from FTOC (Figure 11-3).

20

EXAMPLE 3

IDENTIFICATION OF CROSS REACTIVE T CELLS WITH SPECIFICITY FOR HOMOLOGOUS PEPTIDES.

The method of the invention was used to further examine the capacity for closely
25 related antigenic moieties to cross-react, in this case using the murine model seen in Examples 1 and 2. Evidence of such cross-reaction provides the basis for an explanation of some autoimmune disease states. In this Example, the ability of T cells selected by the self-MHC-derived peptide I α 52 to cross-react with the homologous peptide of non-self origin Hi15, was examined by performing antigen-specific T cell analysis.

30

MATERIALS AND METHODS

Antigens.

5 The I-A^d derived peptide Iα52 was synthesized as described in Example 2. Hi15 (TSFPMRGDLAKREPDK) (Seq. Id. No. 3) was synthesized by standard solid phase peptide synthesis technique (Research Genetics). Hi15 was identified among 20 candidates with an arbitrary homology score of 20, based on homologies including potential MHC-binding residues. The search was performed on the non-redundant database scanned by
10 Blast 2 program, available on the NCBI website. Peptides were >90% pure (Research Genetics). Peptides used for flow cytometry were biotinylated (b-peptides) using a commercial kit (Sigma) and were separated from free biotin by HPLC. Experiments were performed to determine the possible interference of the biotin label on the specificity of T cell receptors for the Hi15 peptide using the post-synthesis biotinylated Hi15 and N-
15 terminus biotinylated peptide separately complexed to MHC molecules in liposomes and labeled with different colors of conjugation to streptavidin molecules. Results showed equal binding of the two preparations to a T cell line having specificity for both Iα52, and Hi15 (not shown).

20 Generation of Lymphocytes from Fetal Thymic Organ Cultures (FTOC).

FTOC was prepared as described in Example 2.

Preparation of Liposome:MHC:antigen Complexes.

Liposomes were prepared as described in Example 1.

25 Flow Cytometry.

Flow cytometry was performed as described in Example 1.

30

RESULTS

These experiments show that a T cell population derived from I α 52- supplemented FTOC can be determined, characterized and expanded. Essentially, an artificial APC will comprise MHC:peptide complexes stabilized into liposomes, with the addition of

5 transmembrane proteins which accomplish stabilizing, co-stimulatory, and/or modulatory functions. These accessory and co-stimulatory molecules comprise, but are not limited to, any or all of the following:

- (i) ICAM1 as adhesion molecule to facilitate initial interaction between the T cell and the APC.
- 10 (ii) anti-CD28 transmembrane antibody facilitates the propagation of antigen-specific T cells isolated by T cell capture using artificial APCs such that up to 20 replicative cycles have been obtained, which represents a valid alternative to T cell expansion and cloning using autologous APC systems, often an insurmountable hurdle in human systems.
- 15 (iii) B7-1 may be used instead of anti-CD28. The cells obtained from this treatment may exert immunoregulatory function in autoimmunity.
- (iv) B7-2 may be used instead of anti-CD28. Cells obtained from this treatment may have immunomodulatory properties in settings such as cancer or infectious disease.

20 All of the aforementioned molecules are transmembrane proteins which can be incorporated into liposomes according to above examples, or as an alternative, bound to a solid support as in above examples.

Isolation and immunomodulation of antigen specific T cells.

25 Antigen-specific T cells isolated according to above examples are incubated with the appropriate variant of the artificial antigen presenting cells according to the desired objective, *i.e.* expansion, functional phenotype switch, etc. Day 16 of gestation BALB/c embryonic thymus lobes were harvested and cultured on 0.4 μ m filters in medium supplemented with 10⁻² mM I α 52. Lobes were dissociated and cultured with autologous,
30 irradiated APC, IL-2 and the Hi15 peptide. After two weeks of incubation with 10 μ g/ml of

Hi15, FACS analysis showed that 52.8% of cells bound anti-CD4 and the self-derived I-A^d:Iα52 peptide complexes (Figure 12-1). The liposome:I-A^d:biotinylated Iα52⁺:CD4⁺ cell complexes were sorted and depleted of their liposome:I-A^d:Iα52⁺ components by incubation at 4°C for thirty minutes followed by centrifugation at 325xg for 10 minutes through 100% FCS (Figure 12-2). The sorted cells were then restained with liposome:I-A^d and the exogenous, biotinylated peptide Hi15 which was complexed to a streptavidin molecule conjugated to a fluorochrome. The restained T cells were then reanalyzed by three-color flow cytometry using anti-CD4 antibody, liposome:I-A^d:b-Hi15 complexes, and liposome:I-A^d:b-Iα52 complexes bound to different color f-strep molecules. Results showed that 52% of the cells tested positive (Fig. 12-3). To further demonstrate the ability of TCRs selected by Iα52 to recognize the exogenous antigen Hi15, T cell populations derived from Iα52 FTOC were expanded with Hi15 and incubated with anti-CD4 antibodies and liposome:I-A^d complexes bearing either biotinylated-Iα52 or Hi15 bound to streptavidin molecules labeled with different fluorochromes. Our results indicated that 31.1% of the CD4⁺ cells were positive for both peptides (double positive) (Figure 12-4). The results of this Example 3 show that positive selection by a self-peptide generates CD4⁺ T cells that can recognize a homologous, exogenous peptide.

EXAMPLE 4

IDENTIFICATION OF TCR USAGE BY ANTIGEN SPECIFIC T CELLS

Variable regions of TCRs on the cross-reactive cells identified in Example 3 were evaluated in order to demonstrate the absolute ability of the method of the current invention to evaluate TCR specificity and potential cross-reactivity seen at a molecular level.

MATERIALS AND METHODS

Antigens.

The Iα52 (ASFEAQGALANIAVDKA) (Seq. Id. No. 1) peptide (Research Genetics) and the Hi15 (TSFPMRGDLAKREPDK) (Seq. Id. No.3) peptide (Research

Genetics) were >90% pure. Peptides used for flow cytometry were biotinylated (b-peptides) using a commercial kit (Sigma) and were separated from free biotin by HPLC.

Generation of Lymphocytes from Fetal Thymic Organ Cultures (FTOC).

5 FTOC were prepared as described in Example 2.

Preparation of Liposome:MHC:Ag Complexes.

Liposomes:MHC:antigen complexes were prepared as described in Example 1.

10 Flow Cytometry.

Flow cytometry was performed as in Example 1.

Analysis of T Cell Receptor Gene Usage.

To analyze the TCR-V β repertoire, 500 FACS-sorted cells were washed twice and
15 poly (A) mRNA was isolated with the Invitrogen Micro Fast Track mRNA Isolation kit (Invitrogen, San Diego). The resulting mRNA was quantified with DNA DipStick kit (Invitrogen) and equal amounts of mRNA from each source were reverse transcribed using Invitrogen's cDNA Cycle kit. The cDNA was then submitted to a first PCR by using specific V β sense primers and a common C β antisense primer (Lessin, et al., *J. Invest.*
20 *Dermatol*, 96:299-302, (1991) herein incorporated by reference). PCR conditions were 200 μ M dNTPs, 1x Taq polymerase buffer, cDNA, 20 μ M each primer, 0.6U Taq DNA polymerase (Boehringer Mannheim) in a 25 μ l total reaction volume. After 3 minute hot start at 94°C and addition of Taq DNA polymerase at 80°C using a Perkin Elmer 2400 thermal cycler, reactions were cycled 40 times consisting of 30 seconds at 94°C, 30
25 seconds at 55°C and 40 seconds at 72°C, last extension 6 minutes. Five microliters were used as template for a second PCR, whose conditions were identical to the previous PCR, except that reactions were cycled 35 times and 0.125U of Taq DNA polymerase was used. Twenty-five microliters of the resulting PCR products were then analyzed by electrophoresis through a 4% agarose gel and ethidium bromide staining. DNA sequencing
30 was performed at The Scripps Research Institute Core Facility using an ABI system.

RESULTS

5 T cell lines obtained from either FTOC supplemented with 10^{-2} mM I α 52, or from peripheral lymph nodes of animals immunized with I α 52, were subsequently expanded in the presence of Hi15 and IL-2. Cells were sorted by FACS, as described in Example 1 using cytometry based on anti-CD4, liposome:I-A^d:biotinylated-Hi15 and liposome:I-A^d:biotinylated-I α 52 triple binding. Then, RT-PCR specific for the known TCR V β 10 families was performed.

The results of these experiments showed almost exclusive use of V β 1 by cells that recognized both the selecting self-peptide I α 52 and the cross-reactive, non-self homologue Hi15 (Table II). We also obtained DNA sequences from three representative clones. This analysis showed only modest differences in amino acid sequence for various representative 15 clones, which all utilized V β 1 genes (Table II). Molecular modeling showed that these amino acid sequences had little effect on the predicted conformation of the V β chain used by the different clones (Fig. 9).

20 Table II. CDR3 Sequence Comparison and Variable Region Gene Usage of I α 52 and Hi15 Cross-Reactive T Cell Receptors

<u>T Cell</u> <u>Line</u>	<u>Isolated VDJ</u> <u>sequences</u>
R3F17	LHISAVDPEDSAVYFCASSQEYFSSYEQYFGPGTRL*
R3F16	I
R3F15	T
<u>Variable Region (Vβ) Gene Usage</u>	
F7d	1, 8

25 Lines were generated from single cell sorting by flow cytometry using the T cell capture assay. Detection in the assay was based upon I-Ad/b-I α 52 and I-Ad/b-Hi15 double binding. These sequences contain the V β 1 region of murine TCR in positions 78-107. *Seq. Id. No. 4.

EXAMPLE 5

5 IDENTIFICATION, ISOLATION AND CHARACTERIZATION OF T CELLS SPECIFIC FOR RHEUMATOID ARTHRITIS-RELATED ANTIGENS

Initiation of autoimmune diseases such as rheumatoid arthritis is thought to be dependant on the recognition by T cells of one or more "pathogenic" antigens which may be responsible for triggering proinflammatory events which lead to chronic autoimmune
10 damage. Several different hypotheses and experimental approaches have led to the identification of a pool of potential pathogenic antigens.

In this Example 5, it is demonstrated how T cells specific for rheumatoid arthritis-related antigens can be identified and enumerated starting from polymorphic T cell populations with very diverse specificities. Peripheral blood mononuclear cells (PBMC)
15 from a patient with rheumatoid arthritis are incubated with a peptide called dnaJp1 (US patent 5,773,570) corresponding to certain positions of the *E. coli* heat shock protein dnaJ. Certain peptides derived from dnaJ are homologous to rheumatoid arthritis-associated HLA alleles, and have been shown to be immunogenic in patients with rheumatoid arthritis. (Albani et al., "Positive selection in autoimmunity: Abnormal immune responses
20 to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis," *Nat. Med.* 1:448-452 (1995); Albani & Carson, "A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis," *Immunology Today* 17:466-470 (1996); La Cava et al., "Genetic bias in immune response to a cassette shared by different microorganisms in patients with rheumatoid arthritis," *J. Clin. Invest.* 100:658-663 (1997). Each of the
25 above reference are herein incorporated by reference).

MATERIALS AND METHODS

Preparation of DNA.

Genomic DNA is prepared from white blood cells by methods known to those skilled in the art utilizing ammonium acetate and isopropyl alcohol precipitation with resuspension in TE (1mM Tris, 0.1mM EDTA, dH₂O, pH 7.5).

5 PCR amplification.

DNA is enzymatically amplified by the polymerase chain reaction and amplification primers that have previously been reported for DQA1 and DQB1, for level I DRB typing, for level 2 allele assignment of DRB1 specificities associated with DR52, and for DR4 and DR1 (Vooter, C. E. *Tissue Antigens*. 51:1:80-87.; Barnardo, M. C. *Tissue Antigens*. 51:3:293-300.; Mitsunaga, S. *Eur J Immunogenet*. 25:1:15-27.).

Genomic DNA (5-10 µl at 80-150 µg/ml) is added to PCR mix consisting of 5 µl of 2 mmole/µl dNTPs, 3 µl of each primer at 10 pmole/µl, 5 µl of 10x PCR buffer, 0.5 µl of Taq polymerase (5U/µl) and 23.5 µl sterile dH₂O. Total reaction volume is 50 µl. DNA is amplified for 30 cycles in a DNA Thermal Cycler (Perkin Elmer Cetus) with
15 denaturation, annealing and extension parameters that vary depending upon the locus studied. In general, annealing is at 53°C for DQ and DRB level I, and at 60°C for DRB1-specific families. Positive and negative controls are included with each run and care is taken to avoid any source of contamination.

20 SSOP hybridization and detection.

After amplification, 5.0 µl samples (10% of total PCR mixture) are run on a 1.0% agarose gel to verify sufficient quantity of amplified product. The remaining portion of the samples (90% of total PCR mixture) are denatured prior to blotting and hybridization using chem-luminescence using methods known to those skilled in the
25 art. Membranes are washed twice with 2xSSC + 0.1% SDS (0.3 M NaCl, 0.03 M Na-citrate, 0.1% SDS, dH₂O, pH 7.0) for five minutes at room temperature, and then twice with 3 M TMAC buffer in the appropriate temperature for the length of the probe. Fifteen-base pair probes are washed at 50-52°C and 18-base pair probes are washed at 59-61°C. Membranes are wetted with Lumi-Phos (Boehringer Mannheim), sealed in
30 acetate sheets, and exposed to X-ray film for 1 to 5 minutes. Results are graded using

11th International Workshop criteria as follows: 1:negative (definite) 2:negative (probable) 4:indefinite 6:positive (probable) 8:positive (definite) 9:positive (definite, more than double intensity). If unique hybridization patterns are found in the course of these studies sequence analysis is done. The patient employed in the example was

5 HLA typed by PCR.

HLA Purification.

Lymphoblastoid cell lines from RA patients are used as a source of HLA molecules, as known to those skilled in the art. Allele and species-specific monoclonal
10 antibodies, whose corresponding hybridomas are already available, are produced as ascites liquid from BALB/c mice and purified on protein A, and covalently bound to a solid support (AffiGel, Bio-Rad, Richmond, CA). HLA molecules are purified by immunoaffinity chromatography from lysates of 10^8 lymphoblastoid cells. The yield ranges from 1 to 4 mg/preparation. Purity is assessed by SDS/Page and Western
15 blotting. Molecules in an elution buffer containing 0.2% octasylglucoside are stable for more than 4 months at 4°C.

Preparation of Liposome:MHC:Antigen Complexes.

Liposomes are prepared as described in Example 1.

20

Flow Cytometry.

Flow cytometry is performed as described in Example 1.

RESULTS

25 T cells specific for the various combinations of the HLA, DR/DQ, and S1 or dnaJp1 peptides were enumerated. T cells binding the S1 or dnaJp1 peptides in the context of HLA DR are more abundant (Figure 13A-E). Seen in the figure are PMBC from an RA patient expressing disease associated alleles DRB*10401 and DQ*30301 captured with DQ/P1 (Figure 13-A), DQ/S1 (Figure 13-B), DR/P1 (Figure 13-C), DR/S1 (Figure 13-D),
30 and DQ/Mtd1 (Figure 13-E).

In order to demonstrate cross-reactivity, T cells specific for the various HLA/peptide combinations are sorted and RT-PCR for TCR V β gene usage is performed. The results, shown in Table III, demonstrate that T cells specific for the self-HLA derived peptide S1 cross-react with the homologous peptide dnaJp1. Identification and isolation of T cells with a high pathogenic potential, as described in this Example 5 allows manipulation *ex vivo* to induce tolerization.

TABLE III. TCR V β Usage of T cells Isolated by Detection with RA Associated HLA Molecules Bound by Self or Exogenous Peptides.

	HLA DQ	HLA DR
dnaJP1	1,8,12	8,14
S1	4,12,21	1,9,14

Peripheral blood mononuclear cells were isolated from an RA patient expressing the RA associated HLA alleles DRB*10401 and DQB*30301. The cells were cultured for five days in the presence of IL-2 and the bacterial heat shock protein peptide dnaJP1 then sorted by flow cytometry using HLA/Antigen combinations complexed into liposomes. RT-PCR was performed on sorted cells using primers specific for the known V β regions. Data are representative of two separate experiments.

The numbers in the above Table III show that of the 23 genes of the V β gene family, crossreaction occurs with only a few even though the family is highly related. Additionally, the results show that individual members of the family can be detected using the T cell capture method of the invention using artificial APCs.

EXAMPLE 6

IDENTIFICATION, ISOLATION AND CHARACTERIZATION OF T CELLS SPECIFIC FOR JUVENILE DERMATOMIOSYTIS-RELATED ANTIGENS

Juvenile Dermatomyositis is a chronic autoimmune disease of unknown etiology.

It has been reported that in several patients there is an association between relapse of the disease and documented *Streptococcus pyogenes* infection (Martin, A., Ravelli, A., Albani,

S., *J. Peds*, 121:739-742 1992). Sequences shared between *Streptococcus* M5 protein and the human skeletal myosin, the target of the autoimmune process have been reportedly identified. It has also been demonstrated that the shared sequences contain epitopes which elicit cross-reactive T cell responses. In this Example 6, it is demonstrated that the homologous sequences are actually recognized by T cells which bear the same TCR V β gene.

MATERIALS AND METHODS

Sequence-specific oligonucleotide probe HLA typing was performed as described in Example 5.

Preparation of Liposome:MHC:Antigen Complexes.

Liposome:MHC:antigen complexes are prepared as described in Example 1.

Flow Cytometry.

Flow Cytometry is performed as in Example 1.

Two alternative methods for visualization of the antigen-specific T cells were employed. In the first method, affinity-purified HLA molecules were stabilized by incorporation within the interior of liposomes using a method similar to that described in Examples 1-5 and then incubated with biotinylated peptides which were labeled using a method similar to that described in Examples 1-5. In a second alternate method, a label, in this case fluorescent (FITC), was incorporated directly into the liposomes themselves. Thus, the liposomes, rather than the peptides were labeled. Figure 14A-D shows data representing PBMC from a patient with JDM capture with a class I HLA and M61-1, M61-1*, M61-2, and M61-2* (Figures 14-A to 14-D respectively).

Results from these experiments show that T cells which recognize homologous peptides of either self or bacterial origin use the same TCR V β genes, confirming cross-reactivity at a molecular level. In addition, a direct identification and enumeration of CD3+ antigen-specific T cells is possible without detectable differences in sensitivity

between the two labeling methods used. These results also suggest that direct incorporation of a label, *e.g.*, FITC, into the liposomes themselves, or incorporation of a labeled (*e.g.*, biotinylated) transmembrane protein which may or may not interfere with the TCR:antigen:MHC interactions, represent valid methods as alternatives in labeling of the liposome. This may be advantageous in that a label (*e.g.*, a biotin molecule) when complexed with the peptide, may interfere with the interactions among agretopes and epitopes within the TCR:antigen:MHC complex. This may be especially true with class I MHC molecules, in which the antigen binding groove is open only at one end. Our diverse approaches bypass these potential limitations.

10

EXAMPLE 7

IDENTIFICATION AND ENUMERATION OF T CELLS SPECIFIC FOR PEPTIDES FROM PATHOGENIC ORGANISMS

Physiologic, as well as vaccine-induced, immune responses to infectious agents are based on T cell recognition of, and reactivity to, immunogenic epitopes of the infectious agents. In several instances, immunogenic epitopes of microorganisms employed in vaccines, and their HLA restrictions, have been identified. One example is the influenza vaccine.

In this Example, quantitative and qualitative T cell response abnormalities in response to influenza vaccination can be identified. Peptides encompassing the major epitopes of the influenza virus are employed for analysis. Antigen specific T cells are identified and isolated as described in Example 1. The population to be screened is comprised of elderly persons who are vaccinated and then screened for immune responses. Antigen specific T cells are quantified and isolated from both the responder and non-responder groups. Phenotypical and functional characteristics are then evaluated, and the results compared between the two groups to analyze whether hyporesponsiveness in some of the vaccinated subjects is related to lack of specific T cells.

PBMC are incubated with the relevant and control peptides for five days in order to increase precursor frequency. Cells are then incubated with HLA-peptide complexes, and

positive cells are enumerated by FACS. Commercially available cell lines are the source of soluble HLA molecules (Corriel Cell Repository).

Antigen specific T cells are evaluated for the production of cytokines which are related to either effective responses to viruses (IFN, IL-2) or associated with anergy (as in the case of using, for example, IL-10). This analysis elucidates differences, if any, between antigen specific T cells of responders versus non-responders. Hence, important functional differences are evaluated at an antigen-specific T cell level. Membrane phenotype of the isolated antigen specific T cells is evaluated, with particular attention to early activation markers, such as CD69, and memory, such as CD45RO. This test helps distinguishing anamnestic from recently induced responses. mRNA is purified and RT-PCR using V β chain for the T cell receptor specific primers is performed. The definition of the T cell receptor (TCR) used by the various subjects may help in pointing out differences between responders and non-responders due to genetic differences in the TCR repertoire. This shows the potential for the technology of the current invention to discriminate between anamnestic and recall immune responses at the level of antigen-specific T cells

MATERIALS AND METHODS

20 Lymphocyte proliferation assays.

Preliminary experiments are performed to identify the optimal conditions for culture. Initially, cell cultures are performed in duplicate for three to seven days, using 5 million cells/well. (All antigens have shown a range of optimal responses between 1 and 10 μ g/ml). The proliferation assays are conducted as controls to compare against the T cell capture specificity of the invention.

Lymphocyte cytotoxicity tests.

Cytotoxic responses are measured using a LDH-release kit (Promega). The tests are performed according to manufacturer's instructions. Effectors are incubated for 5 days with IL2 and the relevant peptides or with irrelevant antigens. Targets are irradiated

autologous PBMC or, when available, EBV-transformed lymphoblastoid cell lines. Targets are pulsed with the relevant antigens overnight. The cytotoxicity assays are conducted as controls to compare against the T cell capture specificity of the invention.

Antigens.

- 5 Synthetic peptides (Matrix 58-66:GILGFVFTL (Seq. Id. No. 5); Nucleoprotein 82-94:VKLGEFYNQ (Seq. Id. No. 6)) are purchased from Research Genetics.

MHC purification.

- Commercially available lymphoblastoid cell lines (Corriel Cell Repository) are used as a source of MHC molecules and purified by immunoaffinity chromatography using
10 anti-HLA class I antibodies in a manner similar to that shown in Example 5.

Liposome:MHC:antigen complexes are prepared as described in Example 1. Antigen specific T cells are prepared as described in Example 1. Intracellular immunofluorescence staining of cytokines was performed as described in Example 10.

- 15 Cytokine measurement by RT/PCR.

- mRNA is extracted from approximately 7×10^6 cells by using Oligotex Direct mRNA Kit (Qiagen, Chatsworth, CA). mRNA is reverse-transcribed into cDNA with the oligo dT primer (RT-PCR Kit, Stratagene, La Jolla, CA). Two μ l of single strand cDNA are amplified using the cytokine specific forward and reverse primer sets, IL-2, IL4, TNF- α , INF- γ . Quantitative measurement of various cytokines using competitive PCR is performed (Biosource reagents). In this method, a known copy number of an exogenously synthesized DNA used as an internal control sequence (ICS) is mixed with the sample prior to amplification. The ICS is constructed to contain identical primer binding sites as the cytokine to be analyzed, and a unique binding site that allows the resulting amplicon to
20 be distinguished from the cytokine product. Detection of the amplification product is by
25 non-radioactive microplate techniques.

T cell receptor analysis by PCR.

Messenger RNA is extracted from a minimum of 70 cells by using Micro-FastTrack Kit (Invitrogen, Carlsbad, CA). The yield of mRNA is about 2 µg that is resuspended into 20 µl of water. Two µl of mRNA for each reaction is reverse-transcribed into single strand cDNA with the oligo dT primer (cDNA Cycle Kit, Invitrogen, Carlsbad, CA). 1.5 µl of single strand cDNAs are amplified with constant primer and various V region primers (Vb1 - Vb24), the sequences of which may be designed by those knowledgeable in the art. For example, 20 pico moles of each primer and 1.25 units of Taq polymerase (Boehringer Mannheim, Germany) are used. The total volume is 25 µl. The cycling parameters for PCR is indicated as: heat PCR reaction mixture without Taq and dNTPs at 94°C for 4 min, then perform 40 cycles of 30 seconds at 94°C, 30 seconds at 58°C and 30 seconds at 72°C. The final elongation is 7 minutes at 72°C. Add 0.5 µl of 100 mM dNTPs and 0.25 µl of Taq Polymerase (1.25 units, Boehringer Mannheim) at end of 58°C of first cycle. The PCR-amplified products are analyzed on 4% agarose gel.

In summary, the experiments described in this Example 7 are accomplished according to the following steps:

- i) MHC typing by PCR of the test sample derived from a test subject, (e.g. a patient that is to receive treatment against an infectious agent);
- ii) Purification by immunoaffinity chromatography or by other methods known to those skilled in the art, of MHC molecules corresponding to that of the test subject's. The source for these molecules may be directly from an individual or from cell lines homozygous for the HLA alleles.
- iii) Synthesis of liposomes containing MHC:peptide complexes. (These liposomes may be tagged according to any of the methods described herein or known by those in the art.);
- iv) Incubation of PBMC from the test subject with the MHC:peptide tagged liposomes, and;
- v) counting of the binding T cells for the purpose of determining which peptides have bound thereby indicating the specific peptides effective in binding antigen-specific T cells.

Methods described in this Example are useful in determining the number of vaccine-specific T cells in peripheral blood, both in normal and immune compromised individuals, for example, as a tool for decisions regarding the opportunity for vaccination in immune compromised subjects, and in determining the efficacy of vaccination, measured as increase in the number of vaccine-specific T cells after vaccination.

EXAMPLE 8

DIAGNOSIS AND IMMUNOMODULATION OF ALLERGIC DISEASE

Allergy is mediated by release of pro-inflammatory and vasoactive mediators triggered by binding of allergen specific immunoglobulins with receptors of inflammatory cells at the site of allergen contact with cellular tissues. The production of allergen specific immunoglobulins appears to be mediated by strong interactions between B and T cells, an example being Casein in the pathogenesis of lactose intolerance (Albani, S. *Annals of Allergy*. 63:12:489-492.). It is therefore of importance to have the possibility to identify allergen specific T cells, isolate them and manipulate them *ex vivo*. An outline of the strategy to be employed is:

- i) MHC typing of the test subject by PCR technology;
- ii) Identification of candidate "allergenic" peptides, based on current knowledge of the field. (When a candidate epitope on a given proteic allergen will not be already available, computerized analysis of MHC binding motifs will enable the identification of candidate peptides to be used.)
- iii) Synthesis of liposomes containing relevant MHC:peptide complexes. (Such liposomes can be tagged using any of the techniques described herein or known by those in the art.);
- iv) Incubation of PBMC of the test subject with the MHC:peptide:tagged liposomes complexes;
- v) Identification and enumeration of allergen specific T cells;

- vi) manipulation *ex vivo* of such cells, by stimulation in culture with the antigenic peptide in the presence of stimuli related to induction of TH-1 phenotype

MATERIALS AND METHODS

5 Lymphocyte proliferation assays are performed as described in Example 7.

Lymphocyte cytotoxicity tests are performed as described in Example 7.

Antigens.

Peptides are identified based on scanning the sequences of the proposed allergens for MHC-binding motifs and synthesized according to standard peptide synthesis methods
10 know to those in the art.

MHC purification is performed as described in Example 7.

Liposome MHC:antigen complexes are prepared as described in Example 1.

15 T cells, generated as described in Example 1, are captured by separation using flow cytometry as described in Example 1.

Intracellular immunofluorescence staining of cytokines, is performed as described in Example 5.

20 Cytokine measurement by RT/PCR is performed as described in Example 7.

T cell receptor analysis by PCR is performed as described in Example 7.

This Example therefore shows that artificial APCs may be used to diagnose and monitor progress of therapies and modulation level of specific responses in a patient's T cells.

25

EXAMPLE 9

IDENTIFICATION OF CANCER-SPECIFIC T CELL EPITOPES

It is commonly accepted that lack of immunity to cancer (*e.g.*, melanoma), depends on low antigenicity of the neoplasm, as well as on functional and/or numerical deficiencies of antigen-specific T cells.

Several therapeutical approaches are currently underway to improve the efficiency of recognition of and reactivity to cancer antigens by T cells. Unfortunately, the efficiency of the treatment can be measured, to date, only in terms of clinical outcome. This Example 9 describes a solution to this problem, by enabling identification, enumeration, characterization and possible manipulation of cancer-specific T cells. Hence, efficiency of the treatment will be measured in terms of increase in antigen-specific precursor frequency, and also in terms of functional outcome of antigen recognition. This latter aspect is of particular importance in those instances where the therapy is aimed at activation of otherwise dormant T cells.

The following protocol is applied:

- i) MHC typing by PCR of the test subject;
- ii) Identification of candidate peptides. For example, sources for antigen in the treatment of melanoma include MAGE-1, MAGE-3, MART-1/melan-A, gp100, tyrosinase, gp75, gp15, CDK4 and beta-catenin. When a candidate epitope on a given protein allergen will not be already available, computerized analysis of MHC binding motifs will enable the identification of candidate peptides to be used;
- iii) Synthesis of liposomes containing relevant MHC:peptide complexes;
- iv) Incubation of PBMC of the test subject with the MHC:peptide:tagged liposomes complexes;
- v) Identification and enumeration of antigen specific T cells.

MATERIALS AND METHODS

Lymphocyte proliferation assays are performed as described in Example 7.

Lymphocyte cytotoxicity tests are performed as described in Example 7.

Antigens.

Synthetic peptides will be identified based on scanning the sequences of the proposed allergens for HLA-binding motifs.

MHC purification.

5 MHC purification is performed as described in Example 7. Commercially available lymphoblastoid cell lines (Corriel Cell Repository) are used as a source of MHC molecules, and purified by immunoaffinity chromatography using anti-MHC class I antibodies, available in our laboratory.

Liposome MHC:antigen complexes are prepared as described in Example 1.

10

T cells, generated as described in Example 1, are captured by separation using flow cytometry as described in Example 1.

15

Intracellular immunofluorescence staining of cytokines, is performed as described in Example 5.

Cytokine measurement by RT/PCR is performed as described in Example 7.

T cell receptor analysis by PCR is performed as described in Example 7.

20

As shown, a peptide based method for monitoring cancer therapy is established using antigen-specific artificial APCs. This methods allows for studying the progress of the therapy and the state of the cancer.

EXAMPLE 10

METHODS FOR DISTINGUISHING "BYSTANDER T CELLS" FROM
ANTIGEN-SPECIFIC T CELLS

25

The experiments described in this Example demonstrate that antigen-specific T cells can be identified and enumerated and distinguished from antigen non-specific T cells present in the same tissue. These latter cells (so-called "bystander T cells") may participate in pathogenic processes. This has particular relevance for autoimmune and

allergic diseases, where the initiating event may be the recognition of a pathogenic antigen by a specific T cell population. This interaction leads to production of pro-inflammatory or pro-allergic mediators (*i.e.*, cytokines) by the antigen-specific T cells. The cytokine cascade will subsequently involve T cells that are not specific for the antigen (bystander T cells), which may then participate in the pathogenic processes, amplifying significantly the degree of the damage. It is important in a clinical or research setting to discriminate between the antigen-specific and bystander populations in order to evaluate, for instance, the efficacy of a treatment. The strategy may be summarized as follows;

- 10 i) Identification of candidate peptides, based on current knowledge of the field. When a candidate epitope on a given protein antigen is not already available, computerized analysis of MHC binding motifs will enable the identification of candidate peptides to be used in the "T cell capture". Such analysis is standard practice to those skilled in the art;
- 15 ii) Synthesis of liposomes containing relevant MHC:peptide complexes. Such liposomes can be tagged using any of the techniques described herein;
- iii) Incubation of PBMC of the test subject with the MHC:peptide:tagged liposomes complexes;
- iv) Identification and enumeration of antigen specific T cells.

20

MATERIALS AND METHODS

Lymphocyte proliferation assays.

Preliminary experiments may be performed to identify the optimal conditions for culture. Cell cultures may be performed in duplicate for three to seven days, at 5 million
25 cells/well. All antigens have shown a range of optimal responses between 1 and 10 µg/ml.

Lymphocyte cytotoxicity tests.

Cytotoxic responses may be measured using a LDH-release kit (commercially available). The tests may be performed according to manufacturer's instructions. Effectors may be incubated for 5 days with IL2 and either the relevant peptides or with irrelevant

peptide antigens. Targets may be irradiated autologous PBMC or, when available, EBV-transformed lymphoblastoid cell lines. Targets may be pulsed with the relevant antigens overnight.

Antigens.

- 5 Synthetic peptides are identified based on scanning the sequences of the proposed allergens for MHC-binding motifs.

MHC purification.

- Commercially available lymphoblastoid cell lines (Corriel Cell Repository) may be used as a source of MHC molecules and purified by immunoaffinity chromatography using
10 anti-MHC class I antibodies.

Preparation of Liposome MHC:Ag Complexes.

Preparation of APCs are the same as that performed for Example 1.

- FACS. A Beckton Dickenson FACS Star with LYSIS II software was used to visualize
15 cells. Sortings were performed by the Flow Cytometry Core at UCSD.

T cell Capture.

- T cells, generated as described, are captured by separation using flow cytometry. Bulk sorted cells are either cultured as described, immediately used for DNA analysis, or
20 used directly for reanalysis using FACS. Yields from bulk sortings range from 2000-16,000. Single cell sorts utilized 96 well culture plates containing media previously described. Fresh irradiated APCs are added to the single cell cultures once per week, at which time analysis of clonal expansion is performed. Of 96 wells of sorted "events", generally 8-12 show good expansion over a six week period.

25

Intracellular immunofluorescence staining of cytokines.

Human PBMC are isolated by density centrifugation and stimulated for 36 hours

with peptides at 10 µg/ml in the presence of 2 µM monensin. Cells are washed in PBS with 2% FCS and incubated with Fc-block for 5 min. at 4°C. PE-conjugated anti-CD3 monoclonal antibodies (mABs) are added and cells are incubated for 30 min. at 4°C. Cells are washed, fixed 20 min. at 4°C, and resuspended in a solution containing either FITC conjugated anti-IFN γ mAbs or FITC conjugated anti-IL4 or IL2 mAbs. Cells are incubated for 30 min at 4°C, washed twice in PBS with 2% FCS and their fluorescence measured using a Becton Dickinson FACScan. Flow data are analyzed using Lysis II software (Becton Dickinson).

10 Cytokine measurement by RT/PCR.

Messenger RNA is extracted from approximately 7X10⁶ cells by using Oligotex Direct mRNA Kit (Qiagen, Chatsworth,CA). The mRNA is reverse-transcribed into cDNA using oligo dT primer (RT-PCR Kit, Stratagene, La Jolla, CA). Two µl of single strand cDNA are amplified using the cytokine specific forward and reverse primer sets for IL-2, IL4, TNF- α , and INF- γ . Quantitative measurement of the various cytokines was carried out using competitive PCR (Biosource). In this method, a known copy number of an exogenously synthesized DNA (ICS) is mixed with the sample prior to amplification. The ICS has been constructed to contain identical primer binding sites as the cytokine to be analyzed, and a unique binding site that allows the resulting amplicon to be distinguished from the cytokine product. Detection of amplicons is allowed by non-radioactive microplate techniques.

T cell receptor analysis by PCR.

Messenger RNA is extracted from a minimum of 70 cells by using Micro-FastTrack Kit (Invitrogen, Carlsbad, CA). The yield of mRNA is about 2 µg that is resuspended into 20 µl of water. 2 µl of mRNA for each reaction is reverse-transcribed into single strand cDNA with the oligo dT primer (cDNA Cycle Kit, Invitrogen, Carlsbad, CA). 1.5 µl of single strand cDNAs are amplified with constant primer and different V region primers (e.g., Vb1 - Vb24). 20 pico moles of each primer and 1.25 units of Taq polymerase (Boehringer Mannheim, Germany) were used. The total volume is 25 µl. The

cycling parameters for PCR are: heat PCR reaction mixture without Taq and dNTPs at 94°C for 4 min, performance of 40 cycles for 30 seconds at 94°C, 30 seconds at 58°C and 30 seconds at 72°C. The final elongation is 7 minutes at 72°C. Add 0.5 µl of 100 mM dNTPs and 0.25 µl of Taq Polymerase (1.25 units, Boehringer Mannheim) at end of 58°C of first cycle. The PCR-amplified products were analyzed on 4% agarose gel. The sequences of Vβ -specific primers which may be used may be designed by those knowledgeable in the art.

This example therefore shows that antigen-specific immunotherapy can be used to influence populations of T cells having different specificity which participate in the pathogenic process.

EXAMPLE 11

IMMUNOAFFINITY CHROMATOGRAPHY FOR POSITIVE SELECTION OF ANTIGEN-SPECIFIC T CELLS

As demonstrated in this Example, MHC:antigen complexes may be incorporated into liposomes as described in certain embodiments of the invention above and bound to a solid support. By orienting the complexes so as to optimize the chance of interaction between the T cell receptor and the complexes, antigen-specific T cells may be isolated from biological samples.

Immunoaffinity chromatography columns.

MHC:peptide complexes may be bound to hydrazide coated glass beads. Alternatively, molecules having affinity for irrelevant molecules may be bound to glass beads coated with a hydrazide linker and may be used to bind a irrelevant molecule-containing liposome:MHC:peptide complexes. A slurry of either of the above coated bead solid supports is incorporated into a compartment of a column such as that shown in Fig. 8 in a controlled fashion. Polymorphic T cell populations contained in a liquid medium are then introduced into the column, and the mixture is incubated at room temperature for 30 minutes, with gentle turning of the column. T cells with irrelevant specificity are not bound by the slurry and will flow through. Peptide or antigen-specific T cells that bind

during mixing are then removed from the solid supports by incubating the column at 4°C for 30 minutes.

EXAMPLE 12

5 *EX VIVO* DEPLETION OF CELLS RELATED TO A PATHOGENIC PROCESS: ANTIGEN-SPECIFIC LEUKAPHERESIS

In certain situations, it is desirable to deplete living systems of T cells having specificity for a given antigen. In the case of autoimmunity or allergy, these T cells may be involved in pathogenic processes and their depletion may therefore induce clinical
10 improvement. Likewise, in the case of transplantation, recognition of a donor's epitopes and ideotopes as non-self will cause graft vs. host rejection of a transplanted organ. In such instances, depletion of the recipient's T cell population that recognize the foreign epitopes/ideotopes is beneficial. Depletion of such reactive T cells may be accomplished by connecting in line with the general circulation of a patient a device comprising
15 MHC:antigen complexes bound to a solid support and oriented to optimize TCR:complex interaction. For example, MHC:peptide complexes may be associated in liposomes containing irrelevant molecules which may themselves be captured by glass beads coated with molecules having specificity for the irrelevant molecules. Appropriate filters, sterilization and heating procedures may be used in a manner similar to that currently
20 employed in conventional leukaphoresis procedures. In operation, whole blood or blood enriched for T cells is allowed to flow through the device. Antigen-specific T cells are bound and eliminated from solution. The slurry is continuously stirred, and after appropriate time periods portions of it are incubated at 4°C in order to elute the antigen-specific T cells that have bound to the solid support associated MHC:antigen complexes.
25 For clinical conditions where such antigen-specific T cells are harmful, such cells can be simply discarded.

The specific procedure with respect to autoimmunity comprises:

- (i) Preparing a column in which the MHC:antigen:accessory molecule:other molecule complex is designed to interact with T cells which may be involved in the pathogenesis of
30 autoimmune disease using methods described in Example 11.

- (ii) Allowing blood from the patient to flow through the column containing artificial APC prepared in step (i), by which means antigen specific T cells will be retained.

The specific procedure with respect to transplantation comprises:

- 5 (i) Preparing a column in which the MHC:antigen:accessory molecule:other molecule complex is designed to interact with T cells which may be involved in either the graft vs. host disease of bone marrow transplant or the pathogenesis of graft destruction in allogenic solid organ transplant using methods described in Example 11.
- 10 (ii) Allowing blood from the patient to flow through the column containing artificial APC prepared in step (i), by which means antigen specific T cells will be retained.

EXAMPLE 13

- 15 *EX VIVO* MANIPULATION OF ANTIGEN SPECIFIC T CELLS: BIDIRECTIONAL SWITCH FROM Th1 TO Th2-TYPE FUNCTIONAL PHENOTYPE

In the case of infectious disease or cancer, it may be beneficial to isolate cells with a given antigen specificity in order to change their functional phenotype, for example, by manipulating such cells using the artificial antigen presenting cells described in this

- 20 Example. Manipulated cells can then be reintroduced for immunomodulation.

Antigen-specific T cells, isolated according to Example 1 or Example 2, are incubated with the appropriate variant of the artificial antigen presenting cells according to the following examples.

Expansion of antigen-specific T cells.

- 25 Isolated cells (10,000/ml) are incubated in standard culture medium with APC expressing the relevant MHC:peptide combination, ICAM1 as adhesion molecule to facilitate initial interaction, and anti-CD28 transmembrane antibody. The latter is employed as a co-stimulatory molecule to induce T cell proliferation without affecting Th bias. This type of approach is the antigen-specific equivalent of the recent approach at T

cell expansion using anti-CD3/anti-CD28 molecules. Up to 20 replicative cycles have been obtained in this system, which represents a valid alternative to T cell expansion and cloning using autologous APC systems, often an insurmountable hurdle in human systems.

5 Expansion and immunomodulation of cells from a Th1 to a Th2 functional phenotype.

i) In one expansion, B7-1 may be used as a co-stimulatory molecule instead of anti-CD28. The cells obtained from this treatment may exert an immunoregulatory function in the autoimmunity condition.

- 10 ii) In another expansion, B7-2 may be used as a co-stimulatory molecule instead of anti-CD28. Cells obtained from this treatment may have immunomodulatory properties in settings such as cancer or infectious disease.

Specifically, an artificial APC comprises MHC:peptide complexes stabilized into
15 liposomes, with the addition of transmembrane proteins which accomplish co-stimulatory functions. The molecules may comprise any or all of the following:

- a) ICAM1 as adhesion molecule to facilitate initial interaction between the T cell and the APC.
- b) anti-CD28 transmembrane antibody is employed as a co-stimulatory molecule
20 which may induce T cell proliferation without affecting Th bias. This type of approach is the antigen-specific equivalent of T cell expansion using anti-CD3/anti-CD28 molecules. Up to 20 replicative cycles have been obtained in this system, which represents a valid alternative to T cell expansion and cloning using autologous APC systems.
- 25 c) B7.1 may be used instead of anti-CD28. The cells obtained from this treatment may exert immunoregulatory function in autoimmunity.
- d) B7.2 may be used instead of anti-CD28. The cells obtained from this treatment may have immunomodulatory properties in settings such as cancer or infectious disease.

All of the aforementioned molecules are transmembrane proteins which can be incorporated into liposomes according to above examples, or as an alternative, bound to a solid support as in above examples.

5 Isolation and immunomodulation of antigen specific T cells.

Antigen-specific T cells isolated according to the above examples are incubated with the appropriate variant of the APC according to the desired objective, *i.e.* expansion, functional phenotype switch, etc.

10

EXAMPLE 14

MONITORING IMMUNOLOGICAL OUTCOME OF INTERVENTION OF ANTIGEN-SPECIFIC T CELLS BY CORRELATION OF CLINICAL OUTCOME WITH T CELL PHENOTYPE

In this example, the invention is applied to evaluating the clinical outcome of treatment regimens by correlating the phenotype of antigen-specific T cells with clinical outcome. Specifically, the invention is applicable to clinical monitoring and clinical trials where there is a need to evaluate the effectiveness of artificial APC induced T cell responses. The antigen-specific T cells associated with a response (or disease state) are identified followed by the identification of their functional phenotype. The phenotype identified is then correlated and monitored against the progression of a patient's response to various treatment regimens.

20

EXAMPLE 15

INTERACTION OF ARTIFICIAL APCs WITH T CELLS TO INDUCE CAPPING OF TRANSMEMBRANE PROTEINS

25

The immune synapse is the cluster of transmembrane molecules which ensures specific interaction between antigen specific T cells and antigen presenting cells . The outcome of these interactions is antigen specific response by the T cells, mediated by signaling through the TCR. Several factors contribute to significant quantitative and qualitative differences in the response provided by the T cell. These factors include

30

affinity of interaction between MHC and peptide, and between the TCR and the MHC/peptide complex, the number of moieties available for interaction, and the relative concentration of the moieties available for interaction. In a physiological situation, the triggering number of interacting molecules is achieved by “capping”, a phenomenon, which occurs when transmembrane molecules are allowed to freely migrate to definite zones of the membrane, usually upon initial interaction between two of the ligands involved, in this case the TCR and the MHC/peptide complex. In order to emulate such physiologic mechanisms, we employed artificial APCs loaded with the combination IA^d/OVA, and hybridoma 8DO as the specific T cells. To visualize free movement of the TCR in the T cell membrane, we employed a system where FITC-conjugated cholera toxin, a molecule known to combine with the intracellular portion of transmembrane proteins, is introduced into the T cells. We show here for the first time that artificial APCs can effectively emulate the physiologic interactions between T cells and APC, particularly with respect to allowing migration of molecules whose proper density is an essential requirement to induce T cell activation. Our system has also the potential to be a tool to study physiological mechanisms of T cell activation, and to manipulate the intensity and quality of T cell response. This could be accomplished by controlling the affinity of the interaction, and by adding the proper co-stimulatory and adhesion molecules to the artificial APC.

Approximately 100 MHC/peptide binding sites are available on each artificial APC for interaction with a single T cell, increasing therefore the likelihood that artificial APCs will engage, through multiple interactions, low-affinity T cells. This may provide a significant advantage over current methods for the identification of low affinity, class II restricted antigen-specific T cells, such as the ones often involved in physiologic regulatory mechanisms or in disease related autoimmune responses.

We first identified the optimal incubation times for the artificial APC with the T cells, (i.e., about 20 minutes) at different stages of evolution in the capping mechanism. Unlike systems where the interacting molecules are fixed on planar membranes, interactions between T cells and artificial APCs occur in culture medium, and rely on random movement for molecular interactions. This results in the optimal period for a

result to be based on formation of “capping” of the TCR in the cell membrane rather than just binding of the TCR and target moieties. In the experiments shown in Figs. 16-18, we incubated the artificial APC with 8DO cells for 20 minutes, and evaluated the capping by confocal microscopy. In Fig. 16A-D, we visualized comigration of the colera raft and the TCR, by incubating T cells with PE-conjugated monoclonal antibody (Pharmigen). TCR molecules are uniformly distributed in the cells membrane, as expected for cells, which are not interacting with stimulatory triggers. In experiments described in Fig. 17A-D, we visualized interaction of TCR by using the cholera toxin raft, and the MHC in the artificial APC membrane using a specific anti-MHC (Pharmigen) monoclonal, Alexa-red conjugated. In the field shown, the phenomenon of progressive migration of the TCR molecules toward the point of initial interaction of the artificial APC with the TCR is evident at different stages for different cells. In experiments described in Fig. 18A-D, we visualized the TCR using an Alexa red-conjugated anti CD3 monoclonal (source) and the liposomes using FITC-conjugated streptavidin which bound to the biotin at the N-terminal of the OVA peptide. The results of this visualization procedure in Fig. 18 are overlapping with those shown in Fig. 17. Hence, we show here for the first time that artificial APCs can effectively emulate the physiologic interactions between T cells and APCs, particularly with respect to allowing migration of molecules whose proper density is an essential requirement to induce T cell activation. Our system also provides for studying physiological mechanisms of T cell activation and the manipulation of the intensity and quality of T cell response. This “modulation” of T cell response could further be accomplished by controlling the *affinity* of the interaction by adding the proper co-stimulatory and adhesion molecules to the artificial APC. An additional preferred advantage of the system of the invention is that it allows free movement of transmembrane proteins, enabling the sequential order of interactions among ligands, which occur upon first contact of the TCR with the APC in the immune system.

Immunohistochemistry Methods for Figs. 16-18

Liposomes and 0.5×10^5 cells were cytopinned at 300 g for 5 min on poly-L-lysine coated slides (Sigma, St. Louis, MO). The cells were fixed for 10 minutes in 4%

Paraformaldehyde, washed in PBS and then incubated for 1 hours with the antibodies anti-CD3 IAd (Pharmingen, San Diego, CA), at a concentration of 2-10 $\mu\text{g/ml}$ in I-Block blocking buffer (Tropix, Bedford, MA). Alexa 568 (red) species-specific secondary antibodies (Molecular Probes, OR) were used to visualize the proteins. Coverslips were washed successively in PBS and deionized H₂O for 5 min and mounted in Flouromount (Fisher, CA). Images were obtained with a Zeiss Confocal Laser Microscope.

EXAMPLE 16

IDENTIFICATION OF CLASS II RESTRICTED T CELLS IN POLYMORPHIC POPULATIONS

Identification of antigen-specific, class II restricted T cells is much more difficult than the same identification analysis for class I restricted T cells. These difficulties stem from the lower affinity of interaction of TCR/peptide/MHC for class II restricted responses, when compared to class I. Known methodologies have identified only high affinity antigen specific T cells based on soluble recombinant molecules that provide anywhere from one to four interaction sites for TCR binding, wherein steric hindrance problems are thought to affect correct folding of the recombinant molecules and their interactions with the TCR. In contrast, our results show that MHC/biotynilated peptide complexes can effectively visualize class II-restricted hybridoma T cells regardless of affinity.

To evaluate the efficiency of our artificial APC system to identify Class II restricted antigen specific T cells, we immunized BALB/c mice with the peptide Ia52. Ia52, is a naturally processed, abundantly presented IE^d-derived peptide, which has previously been described as antigenic in BALB/c mice. Cells from regional draining lymphnodes, both from IFA only and Ia52 immunized mice, were harvested. These cells were then incubated with artificial APC presenting IA^d/Ia52 complexes. As shown in Fig. **25B**, 5.4% of CD4⁺ T cells were Ia52 specific, while in comparison, only 0.7% CD4 cells were specific for the peptide in the IFA-only immunized mice (Fig. **25A**). These data related well to antigen-specific T cell proliferation, measured by standard thymidine incorporation assay (Fig. **26**).

Capture of T cells by artificial APCs is effective in identifying polyclonal class II restricted human T cells

To identify human antigen-specific T cells, we employed as model antigens a system comprising Pan-DR binder peptides (PADRE) of comparable affinity, and the influenza hemoagglutinin HA peptide. The peptides used were pan-DR binding peptide 965.10 PADRE (K(X)VAAWTLKAA Seq. Id. No. 7), HA 307-319 (PKYVKQNTLKLAT Seq. Id. No. 8), and IAd binding peptide OVA 323-339 (ISQAVHAAHAEINEAGR Seq. Id. No. 9). Peptides were synthesized as C-terminal amides, purified by reversed-phase HPLC, and checked by fast atom bombardment mass spectrometry. For use in MHC-binding assays and the T cell capture, peptides were biotinylated during peptide synthesis (only one biotin molecule, at the n-terminus, 100% biotinylation).

The choice of such antigens was based on the concept that a high number of polyclonal T cells could be found in PBMC if a peptide with high affinity would be employed in the assay. We first defined the optimal molar concentration to employ in loading PADRE pan-DR peptide KXVAAWTLKAA Seq. Id. No. 7, and showed the specificity of interaction between the PADRE peptide and the HLA molecules. T cells from a normal HLA DRB1*401 donor were first tested for the number of PADRE and HA-specific T cells (Fig. 23A), and then cultured with 10 µg/ml of PADRE for ten days. As shown in Figure 23B, PADRE-specific T cells were expanded to 8.1%, while the number of cells specific for the control HA peptide actually decreased from 1.0 to 0.3% (Fig. 23D). Interaction between antigen-specific T cells and artificial APC was, as expected, depending on availability of TCR and HLA/peptide molecules. Our experiment further showed that binding was inhibited by addition of anti-HLA antibody prior to incubation of artificial APCs with the T cells. Moreover, both total cell number and MFI were reduced by 62% when compared with panel 23B upon competition between biotinylated and non-biotinylated PADRE peptides. This control further supports the specificity of the interactions between the various components of the system, and rules out the possibility of steric hindrance from the biotin at the n-terminal of the peptide in interfering with the necessary molecular interactions.

Tcell capture by artificial APCs is more sensitive than measurement of cytokine production to assess the number of antigen specific T cells in a culture.

Measurement of production of cytokines in response to an antigen is often used to estimate the number of antigen specific T cells. To compare sensitivity of measuring cytokine production against T cell capture by artificial APCs, we harvested culture supernatants from PADRE-stimulated cultures, at the fourth and sixteenth day of culture and measured concentrations of IL-2 and IFN- γ by sandwich ELISA. As shown in Fig. 24, the differences in IL-2 and IFN- γ production between the two time points were not as evident as the increase in PADRE-specific T cells, as measured by our T cell capture method (Fig. 23A-F). Hence, from the comparisons of the T cell capture using artificial APCs with antigen induced T cell proliferation (Figs. 25 and 26) and cytokine production (Fig 24) it appears evident that T cell capture using artificial APCs is a tool for sensitive measurement of antigen-specific responses. The advantage of identifying specific T cells by T cell capture is also important for the fact that T cells may not directly participate in antigenic responses while retaining antigen specificity. This phenomenon may also provide an important tool for the understanding of the regulation of T cell responses to antigens.

METHODS

Short term T cell line

Peripheral Blood Mononuclear Cells (PBMC) from healthy donors were stimulated *in vitro* with the PADRE peptide. PBMC were isolated using a Ficoll-Isopaque gradient and stimulated *in vitro* with 10 μ g/ml PADRE peptide in a 24 well tissue culture plate (Costar, Cambridge, Ma) at 4×10^6 cells per well. The cells were cultured in RPMI containing 15% AB serum, at 37°C and 5% CO₂. At days 4 and 7, media were replaced with fresh medium containing recombinant human Interleukin-2 (IL-2) at a final concentration of 10 ng/ml. Culture supernatants taken at day 4 were analyzed for production of IL-2 and Interferon- γ by ELISA. At day 10 viable cells were harvested and analyzed in a T cell capture as described below.

Animals

Balb/C mice were obtained from Harlan. Mice were 4-6 weeks old at the beginning of each experiment

5

Immunizations

Balb/C mice were immunized with 100 mg of OVA 323-339 in Complete Freund's Adjuvant (CFA) subcutaneous, followed by immunizations with 100 mg of OVA 323-339 in Incomplete Freund's Adjuvant (IFA) at days 7, 14 and 21 after the initial immunization.

10 A subgroup of mice was sacrificed 5 days after each immunization.

Preparation of MHC

Balb/C MHC class II molecules I-Ad and I-Ed were purified from the lysate of B cell lymphoma A20.11 by immunoaffinity chromatography using anti-IAd monoclonal antibody MKD6 (Pierce) and anti-IEk monoclonal antibody 14-4-4S, essentially as previously described.

15

Human MHC Class II DRB1*0401 and MHC Class I molecules were purified from the lysate of the Epstein Barr virus transformed B cell lines.

Affinity purified MHC molecules were solubilized in a TRIS buffer containing 50mM diethylamine and 0.2% n-acetyl-octyl-glucopyranoside (Calbiochem, San Diego). Conditions tested: pH5 and 7, RT and 37°C, 16-24-40 hr peptide loading.

20

Competition/inhibition of non-biotinylated PADRE peptide on binding to HLA DR4*0401.

A modified ELSA using soluble HLA-DR 0401 assessed the competition/inhibition of biotinylated and non-biotinylated PADRE peptide. A ten-fold molar excess of biotinylated PADRE peptide was incubated with affinity purified DR4*0401 at pH 7.0 for 16 hrs in room temperature. In addition, a 250 fold molar excess of non-biotinylated PADRE was added. After 16 hours the complexes were transferred to a 96-well flat bottom ELISA plate (Costar) coated with an anti-DR capture antibody. The excess of

30

unbound peptides and complexes were removed through extensive washing with buffer. A 1:20,000 solution of Neutravidin-HRP was then added to the wells and incubated for 40 minutes in room temperature. After washing, a TMB developing solution was added and developed for approximately 15 minutes. 1M H₃PO₄ was used as a stop solution. The optical density was read at 450-650 nm using a micro-plate reader. Delta Soft program was used to analyze the data.

Preparation of cells

Cells were washed twice in staining buffer (PBS with 2% FCS and 0.05% sodium azide) and then incubated at 4°C for 20 minutes in blocking buffer (staining buffer with 10% FCS, for mouse cells FcBlock (Pharmingen) is used). The cells were stained for the surface markers and isotype controls for 20 minutes at 4°C, and washed twice and resuspended in staining buffer. The following monoclonal antibodies were used: PE-, CY- and FITC- labeled anti-mouse and anti-human CD3 and CD4.

T cell capture

The cells were incubated with the MHC-peptide liposomes for 20 minutes at room temperature. Before acquisition on the FACScan, cells were washed twice (5 minutes, 500 g) and resuspended in staining buffer. Partial inhibition of the interaction of cells to the liposomes was achieved with monoclonal antibodies against T cell receptor or MHC. For inhibition through partial blocking of the T cell receptor, cells were incubated for 20 minutes with 50 µg/ml unlabeled anti-TCR antibody (Pharmingen), prior to the incubation with the liposomes. For inhibition through partial blocking of MHC, the liposomes were incubated with unlabeled anti-MHC at a molar ratio of 1:1 to incorporated MHC. For competition/inhibition with non-biotinylated peptide, non-biotinylated peptide was added together with the biotinylated peptide, and at the same molar ratio to the MHC.

EXAMPLE 17

CHARACTERIZATION OF ARTIFICIAL APCS

Mean particle sizes of the MHC-containing liposomes were determined through

dynamic light scattering analysis with a Malvern 4700 system, using a 25mW Ne-He laser and the automeasure version 3.2 software (Malvern, Ltd.). For refractive index and viscosity the values for pure water were used. The particle size distribution was reflected in the polydispersity index (p.i.: 0, which ranges from 0.0 for a monodisperse to 1.0 for a polydisperse dispersion). Besides DLS analysis, liposomes were visualized through flow cytometric analysis as described before herein. Briefly, FITC-labeled liposomes were gated according to their FL1 fluorescence by placing a threshold at the FL1 channel, while for forward and side scattering the most sensitive settings were selected. The size of the FITC-liposomes was compared with the FSC of 2 types of FITC-labeled calibration beads ranging in sizes from 40 to 60 nm and from 700 to 900 nm (Pharmingen). The results are shown in Fig. 20 wherein the shaded area shows that the artificial APCs size peak is in the range of 0.05 μm .

For qualitative analysis of the MHC class II incorporation efficiency as explained in Example 16, MHC class-II liposomes were incubated with PE-labelled anti-MHC class II mAbs (anti-DR4 (Parmogen); anti-I-Ad (clone 0X-6, Harlan)) or PE-labelled isotype controls and analyzed for PE-staining on the FACS calibur. MHC incorporation was quantitatively analyzed by a Petterson modification of the Lowry protein assay. Briefly, a standard curve (0-1-2-4-6-8-12 ug of MHC) was made with the same detergent solubilized MHC batch as used for the preparation of the artificial APC. A reliable range for protein determination was between 2-12 mg of MHC. All samples were analyzed in duplicate and linear regression was performed on the standard curve to evaluate the amount of protein incorporated in the liposome preparation. To calculate the number of MHC molecules per liposome, the amount of MHC, as determined by the Petterson modified Lowry method, and the size of the liposomes, as determined by DLS, were used to convert the amount of incorporated MHC into the number of MHC per liposome, assuming that a 100 nm liposome contains approximately 80,000 phospholipid molecules/vesicle, and assuming that the average area per phospholipid molecule is 75 μm^2 .

For qualitative analysis of peptide loaded MHC class II molecules, MHC molecules were preloaded with biotinylated-peptide using the optimized peptide-MHC loading conditions. After MHC incorporation, the artificial APC were incubated with Streptavidin-

CY (Pharmingen), and analyzed for FL3 staining using the FACS calibur. The quantitative analysis of occupancy of the number of MHC molecules with the desired peptide was performed in 2 different ways, namely, soluble ELISA and by the analysis of unbound biotinylated peptide after SDS-PAGE and blotting of MHC molecules incubated with peptide.

In addition to the MHC samples incubated with a dose range of biotinylated peptide, the same dose range of biotinylated peptide was incubated under exactly the same experimental conditions without the addition of MHC. After 24 hrs., two gels were run under identical conditions in one minigel-system (Biorad). One gel was loaded with the MHC-peptide samples, while the other gel was loaded with the peptide samples. The fronts of the gels were scanned by using the Molecular Analyst software (Maxsott), and a standard curve was made by linear regression of the peptide loaded gel. After front analysis of the MHC-peptide gel the decrease of the peptide signal was quantified by comparison with the standard curve and consequently, the amount of MHC bound peptide could be determined. (see Fig. 19)

METHODS

Peptide loading of MHC class II molecules

To determine optimal loading conditions for MHC class II molecules a MHC class II binding assay was performed, essentially as described before with minor modifications. Briefly, detergent solubilized MHC class II molecules (0.5-1 μ M) were incubated with a 50-250-fold molar excess of biotinylated peptide for the designated time, pH and temperature without the addition of protease inhibitors. The following conditions were tested; pH 5 and pH 7; Room Temperature and 37°C; 16, 24 and 40 hours of peptide loading; 0.05-, 1-, 10-, 100-fold molar excess of peptide. For DRB1*0401 0.5 μ M, for I-Ad 3 μ M of MHC was used in binding assays.

MHC-peptide complexes were analyzed via a non-reducing SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Following Western Blotting (Highland-ECL, Amersham), the biotinylated peptides were visualized on preflashed films (Hyperfilm, Amersham) through enhanced chemiluminescence (Western blot ECL kit, Amersham).

Optimal binding conditions were established by evaluation of the density of the spots at the position of the MHC class II dimer-peptide complexes. The presence of the MHC Class II dimer under the tested conditions was checked with a non-reducing SDS-PAGE followed by silver staining (Biorad). (see Fig. 19A-D)

5

Preparation of liposomes

Liposomes were prepared as follows. Stock solutions of egg Phosphatidyl Choline (Sigma) and Cholesterol (Sigma) were combined in a glass tube at a molar ratio of 7:2. N-(fluorescein-5-thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt (fluorescein-DHPE, Molecular Probes Eugene, Oregon) was added at a final concentration of 1 mol % of Phosphatidyl Choline. The solvent was evaporated under an Argon stream for 30 minutes and the lipids were dissolved at a final concentration of 10 mg/ml in a buffer containing 140 mM NaCl, 10 mM TrisHCl (at pH 8) and 0.05% deoxycholate (Buffer A). The solution was sonicated until clear, and aliquoted in 500 µl Eppendorf tubes and stored at minus 200°C.

Incorporation of MHC-peptide in liposomes

After preincubation of biotinylated peptides and MHC at conditions based on *in vitro* MHC binding, MHC-peptide complexes were added to the lipids in Buffer A at a ratio (w/w) of MHC : liposomes of 1:7 (DR4) or 1:10 (IAd and IEd). Additionally, for each T cell capture sample a ratio of 1 µg MHC per 6000 cells was used.

The lipids and MHC-peptide complexes were dialyzed at 4°C against PBS in a 10K Slide A Lyzer (Pierce) for 48 hours with two buffer changes. The formed liposomes were then recovered from the Slide A lyzers and incubated with streptavidin-CY for 20 minutes before adding the liposomes to the cells. For MHC staining, liposomes were stained with a PE-labeled anti-MHC antibody at the same time.

Where other molecules of interest are to be incorporated into the artificial APC (i.e., accessory, adhesion, co-stimulatory, cell modulation, irrelevant, GM-1, and cholesterol molecules), such molecules can be added simultaneously with the incorporation of the MHC:antigen complexes.

Quantification of HLA-DR and PADRE peptide bound to liposomes

A modified ELISA was used to assess the amount of HLA-DR bound to the liposomes. Briefly, liposomes containing HLA DR4*0401 and biotinylated PADRE peptide were formed as described above. The resulting liposomes were counted and sorted by FACS on (FITC) fluorescence and forward scatter. The sorted samples were then divided into two lots for HLA and peptide quantification by ELISA.

DR quantification

10 The sorted liposome sample was initially incubated with 10x M excess of neutra-
avidin (Pierce) to cap the biotin on the peptide. This was followed by an extensive dialysis
with a 300k MWCO membrane (Pierce) to remove excess unbound neutra-avidin. The
sample was then incubated with biotinylated mouse anti-DR (Pharmagen) at 1:1 molar ratio,
which was again followed by extensive dialysis. The tagged complex was incubated with
15 neutra-avidin-HRP at 1:20,000 and the excess dialyzed as before. A known amount of
soluble DR pre-incubated with non-biotinylated PADRE peptide (standard) was incubated
with the same antibody used for detecting the DR in the liposomes. Multiple epitope
recognition by the antibody assured retention of the complex during dialysis steps. Both
the sorted sample and the standard were then developed with TMB-HRP substrate and read
20 at 450-650 nm.

PADRE peptide quantification

The sorted liposome sample was incubated with non-biotinylated anti-DR
(Pharmagen) at a 1:1 molar ratio. The sample was treated and developed in the same
25 manner as for DR quantification described above. The peptide was quantified based on its
biotin tag. Analysis of the data was adjusted to background and to appropriate negative
controls.

30

EXAMPLE 18

METHODS FOR ORIENTING MOLECULES OF INTEREST IN AN ARTIFICIAL APC

We have shown that incorporation of molecules of interest into the artificial APC liposome matrix yields insertion of such molecules in an orientation wherein the active center of the molecules face outward on the APC at a rate of about 50%. We have found that proper orientation can be dramatically increased to over 90% by applying a mechanism to direct the insertion of the molecules. This mechanism uses GM-1 pentasaccharide protein which is a transmembrane protein and has an affinity for binding the β subunit for cholera toxin. When the GM-1 protein is associated with the liposome membrane of the APC, it can be used to bind cholera toxin which in turn can be attached to the molecule of interest. By attaching the cholera toxin to a point distal to the active site of the molecule of interest, we can direct the orientation of the molecule of interest such that the active site will be placed in the artificial APC in an orientation favorable to interaction with T cells and various molecules. In a preferred embodiment, proper orientation is obtained using a recombinant fusion between the molecule of interest and the β subunit of cholera toxin the construction of which will be well understood by those skilled in the art of making recombinant fusion proteins. The β subunit can also be connected to a molecule of interest using a linker.

METHODS

GM1 pentasaccharide

The structure of GM-1 has been elucidated and shown to be pentasaccharide. The molecule is branched having terminal sugars, galactose and sialic acid (n-acetyl neuraminic acid), which exhibit substantial specific binding interactions with the β subunit of cholera toxin. A smaller contribution to binding is derived from the N-acetyl galactose residue of the molecule. This binding interaction is mediated through hydrogen bonding. Each of the 5 identical binding sites are primarily within a single monomer of the B-pentamer. GM1 ganglioside may be purchased from commercial sources (Sigma #G7641).

Cholera β subunit (CTB)

Cholera toxin (mw =84 kda) is comprised of two subunits; α (mw=27 kda) and β (mw=11.6 kda). The amino acid sequence has been determined at about 11,604 da. The primary structure of the β subunit, which is responsible for binding of the toxin to the cell
5 receptor ganglioside GM1, has been determined. Cholera toxin's ability to bind well to such transmembrane structures makes it very attractive anchor for membrane proteins (e.g. molecules of interest as disclosed herein). Since the β subunit is primarily involve in the binding to the GM1 pentasaccharide, the α subunits are not necessary. The use therefore of only the β subunit makes issues respecting toxicity less important with respect to use of
10 the toxin protein subunits in therapeutic applications such as drug delivery or transport and manipulation of T cells ex vivo.

The receptor binding site on the CTB is found to lie primarily within a single β -subunit, with a solvent-mediated hydrogen bond involving the two terminal sugars of GM1 (galactose and sialic acid). The binding of GM1 to cholera toxin thus resembles a 2-
15 fingered grip. Cholera toxin β -subunit may be purchased from commercial sources (Sigma #C9903 or C7771) or synthesized by recombinant methodology.

Linkers for attaching cholera toxin to molecules of interest

Linkers may be used to attach the cholera toxin subunit to the molecule of interest.
20 In a preferred embodiment, a linker such as N-succinimidyl[3-(2-pyridyl) dithio) propionate (SPDP, Sigma Prod. No. P3415). NHS-esters such as this yield stable products upon reaction with primary or secondary amines. Coupling is relatively efficient at physiological pH. Accessible α -amine groups present on the N-termini of proteins react with NHS-esters and form amides. In this regard, reaction with side chains of amino acids
25 can also occur. A covalent amide bond is formed when the NHS-ester cross-linking agent reacts with primary amines, releasing N-hydroxysuccinimide.

In another preferred embodiment, pyridyl disulfides can be used to react with sulfhydryl groups to form a disulfide bond. Pyridine -2-thione is released as a by-product of this reaction. These reagents can be used as cross-linkers and to introduce sulfhydryl
30 groups into proteins. Conjugates prepared using these reagents are cleavable. Pyrimidine -

2-thione groups are released upon reaction with free –SHs and the concentration can be determined by measuring the absorbance at 343 nm (Molar extinction coefficient = $8.08 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$).

5 RESULTS

The GM1 protein is a transmembrane protein which can be associated with the “raft” or freely mobile molecules of interest in the lipid membrane. GM1 has been used in studying movement and interactions of co-stimulatory molecules through cross-linking the molecule with flourescinated-tagged cholera toxin. This cross linking can be carried out in several ways as shown in Fig. 27. For example, in Fig. 27A, a synthetic gene encoding a molecule of interest is cloned into a commercial vector such as a generic expressions vector (for example, DES Expression Vector, Invitrogen) and expressed. The recombinant product can be purified and linked to GM-1 protein that is in an artificial APC. In a similar fashion (Fig. 27B) the molecule of interest can be cloned into an expression vector as a fusion protein with cholera toxin β subunit. The fusion product can be purified and mixed with an artificial APC containing GM-1 protein where the cholera moiety will bind to the GM-1 protein. Additionally, as shown in Fig. 27C, the cholera toxin (whether natural or recombinant) can be attached to a linker, such as N-succinimidyl [3-(2-pyridyl) dithio] propionate, either to a complete β subunit molecule or during synthesis of a recombinant toxin molecule, the product of which can be then mixed with a GM-1 protein containing artificial APC.

We have found that cross-linkers are useful as “flexible hinges” where protein molecules can be covalently linked to allow for intercellular interaction with transmembrane proteins (e.g., B7-CD28, ICAM-1-LFA-1, MHCs, TCRs, etc.). Once the GM1 protein is incorporated into the liposome of the APC, cholera toxin-cojugated surface proteins can then be cross-linked. The system containing properly oriented molecules of interest can then be tested through ELISA, WESTERN, and by FACS analysis.

Modifications and other embodiments of the invention will be apparent to those skilled in the art to which this invention relates having the benefit of the foregoing teachings, descriptions, and associated drawings. The present invention is therefore not to be limited to the specific embodiments disclosed but is to include modifications and other
5 embodiments which are within the scope of the appended claims. All references are herein incorporated by reference.

What is claimed is:

1. An artificial antigen presenting cell comprising:

a. a liposome components;

5 b. an MHC components;

c. an antigen components; and

10 d. an accessory molecule components, wherein said antigen components is in contact with at least said MHC components, and said MHC and said accessory components are in contact with at least said liposome components, said accessory molecule components further providing for a stabilizing property to an interaction between a T cell receptor and said MHC and said antigen components.

15 2. An artificial antigen presenting cell according to claim 1 wherein said liposome components comprises a lipid, said lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphotidylcholine.

3. An artificial antigen presenting cell according to claim 2 further comprising a surfactant components wherein said surfactant components is cholesterol and is in contact with at least said liposome components.

20 4. An artificial antigen presenting cell according to claim 3 wherein a label is associated with at least one of the group selected from the group consisting of a lipid bilayer of said liposome components, a lipid of said liposome components, an antigen components, an MHC components, and an accessory components.

5. An artificial antigen presenting cell according to claim 4 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.
- 5 6. An artificial antigen presenting cell according to claim 3 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a
10 peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.
- 15 7. An artificial antigen presenting cell according to claim 3 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient composition for binding an antigen, an $\alpha 1$ and $\alpha 2$ subunit set of a Class I MHC, an $\alpha 1$ and $\beta 2$ subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for
20 binding an antigen.
8. An artificial antigen presenting cell according to claim 3 wherein said accessory molecule components is selected from the group consisting of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the
25 ligands of the foregoing molecules.

9. An artificial antigen presenting cell according to claim 3 further comprising a GM-1 protein components, said GM-1 components contacting at least said liposome components.
- 5 10. An artificial antigen presenting cell according to claim 9 further comprising a cholera β subunit components, wherein said β subunit components are connected to at least one of said MHC, and said accessory components and further contacts at least said GM-1 components.
- 10 11. An artificial antigen presenting cell according to claim 1 further comprising molecular components selected from the group consisting of a co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, GM-1 protein components, cholera toxin β subunit components, an irrelevant molecule components for binding said artificial presenting cell to a solid support or binding a label, and a label components.
- 15 12. An artificial antigen presenting cell according to claim 11 wherein said liposome components comprises a lipid, said lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine.
- 20 13. An artificial antigen presenting cell according to claim 12 further comprising a surfactant components wherein said surfactant components is cholesterol and is in contact with at least said liposome components.
- 25 14. An artificial antigen presenting cell according to claim 13 wherein a label is associated with at least one of the group selected from the group consisting of a lipid bilayer of said liposome components, a lipid of said liposome components, an antigen

components, an MHC components, a co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, GM-1 protein components, cholera toxin β subunit components, an irrelevant molecule components and an accessory components.

5

15. An artificial antigen presenting cell according to claim 14 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.

10 16. An artificial antigen presenting cell according to claim 13 wherein said GM-1 component contacts at least said liposome components.

15 17. An artificial antigen presenting cell according to claim 16 wherein said cholera β subunit components is connected to at least one of said co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, an irrelevant molecule components, and said accessory components and further contacts at least said GM-1 components.

20 18. An artificial antigen presenting cell according to claim 13 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule
25 that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

19. An artificial antigen presenting cell according to claim 13 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient composition for binding an antigen, an $\alpha 1$ and $\alpha 2$ subunit set of a Class I MHC, an $\alpha 1$ and $\beta 2$ subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for binding an antigen.
20. An artificial antigen presenting cell according to claim 13 wherein said accessory molecule components is selected from the group consisting of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the ligands of the foregoing molecules.
21. An artificial antigen presenting cell according to claim 13 wherein said co-stimulatory molecule components is selected from the group consisting of B7-1, B7-2, CD5, CD9, CD2, CD40 and antibodies to their ligands.
22. An artificial antigen presenting cell according to claim 13 wherein said cell modulation molecule components is selected from the group consisting of CD72, CD22, CD58, anti-CD22, anti-CD58, anti-CD72, anti-cytokine receptor, and anti-chemokine receptor.
23. An artificial antigen presenting cell according to claim 13 wherein said adhesion molecule components is selected from the group consisting of ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1, anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L, anti-selectin E, and anti-selectin P.

24. An artificial antigen presenting cell according to 13 wherein said irrelevant molecule components, has a moiety for binding a solid support either directly or through an intermediate molecule, or for binding a label, said solid support further selected from the group consisting of a glass bead from 25 to 300 μm diameter, and a magnetic bead from 25 to 300 μm diameter.

25. An artificial antigen presenting cell according to claim 24 wherein said solid support is coated with a lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine, said solid support further having capture molecules, said capture molecules further having the capacity to bind specifically to said irrelevant molecule components.

26. An artificial antigen presenting cell according to claim 25 wherein said capture molecules are noncovalently associated with said lipid.

27. An artificial antigen presenting cell comprising:

- a. a liposome components;
- b. an MHC components;
- c. an antigen components,
- d. an accessory molecule components; and
- e. a co-stimulatory molecule components, wherein said antigen components is in contact with at least said MHC components, said MHC, accessory and co-stimulatory components are in contact with at least said liposome components, said accessory molecule components further providing for a stabilizing property to an interaction between a T cell receptor and said MHC and said antigen components.

28. An artificial antigen presenting cell according to claim 27 wherein said liposome components comprises a lipid, said lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine.
29. An artificial antigen presenting cell according to claim 28 further comprising a
5 surfactant components wherein said surfactant components is cholesterol and is in contact with at least said liposome components.
30. An artificial antigen presenting cell according to claim 29 wherein a label is associated with at least one of the group selected from the group consisting of a lipid bilayer of
10 said liposome components, a lipid of said liposome components, an antigen, an MHC components, a co-stimulatory components, and an accessory components.
31. An artificial antigen presenting cell according to claim 30 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a
15 radiolabel.
32. An artificial antigen presenting cell according to claim 29 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived
20 from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and
25 100%, 35 and 100%, and 50 and 100%.

33. An artificial antigen presenting cell according to claim 29 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient composition for binding an antigen, an $\alpha 1$ and $\alpha 2$ subunit set of a Class I MHC, an $\alpha 1$ and $\beta 2$ subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for binding an antigen.
34. An artificial antigen presenting cell according to claim 29 wherein said accessory molecule components is LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the ligands of the foregoing molecules.
35. An artificial antigen presenting cell according to claim 29 wherein said co-stimulatory molecule components is selected from the group consisting of B7-1, B7-2, CD5, CD9, CD2, CD40 and antibodies to their ligands.
36. An artificial antigen presenting cell according to claim 29 further comprising a GM-1 protein components, said GM-1 components contacting at least said liposome components.
37. An artificial antigen presenting cell according to claim 36 further comprising a cholera β subunit components wherein said β subunit components in connected to at least one of said MHC, said co-stimulatory, and said accessory components and further contacts at least said GM-1 components.
38. An artificial antigen presenting cell according to claim 27 further comprising molecular components selected from the group consisting of an adhesion molecule components, a cell modulation molecule components, GM-1 protein components, cholera toxin β

subunit components, an irrelevant molecule components for binding said artificial presenting cell to a solid support or binding a label, and a label components.

39. An artificial antigen presenting cell according to claim 38 wherein said liposome
5 components comprises a lipid, said lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine.

40. An artificial antigen presenting cell according to claim 39 further comprising a surfactant components wherein said surfactant components is cholesterol and is in contact with at least said liposome components.

10

41. An artificial antigen presenting cell according to claim 40 wherein a label is associated with at least one of the group selected from the group consisting of a lipid bilayer of said liposome components, a lipid of said liposome components, an antigen components, an MHC components, a co-stimulatory molecule components, an
15 adhesion molecule components, a cell modulation molecule components, GM-1 protein components, cholera toxin β subunit components, an irrelevant molecule components and an accessory components.

15

42. An artificial antigen presenting cell according to claim 41 wherein said label is selected
20 from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.

20

43. An artificial antigen presenting cell according to claim 40 wherein said GM-1 components contacts at least said liposome components.

25

44. An artificial antigen presenting cell according to claim 43 wherein said cholera β subunit components is connected to at least one of said co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, MHC components, an irrelevant molecule components, and said accessory components and further contacts at least said GM-1 components.

45. An artificial antigen presenting cell according to claim 40 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

46. An artificial antigen presenting cell according to claim 40 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient composition for binding an antigen, an $\alpha 1$ and $\alpha 2$ subunit set of a Class I MHC, an $\alpha 1$ and $\beta 2$ subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for binding an antigen.

47. An artificial antigen presenting cell according to claim 40 wherein said accessory molecule components is selected from the group consisting of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the ligands of the foregoing molecules.

48. An artificial antigen presenting cell according to claim 40 wherein said co-stimulatory molecule components is selected from the group consisting of B7-1, B7-2, CD5, CD9, CD2, CD40 and antibodies to their ligands.

5

49. An artificial antigen presenting cell according to claim 40 wherein said cell modulation molecule components is selected from the group consisting of CD72, CD22, CD58, anti-CD22, anti-CD58, anti-CD72, anti-cytokine receptor, and anti-chemokine receptor.

10 50. An artificial antigen presenting cell according to claim 40 wherein said adhesion molecule components is selected from the group consisting of ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1, anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L, anti-selectin E, and anti-selectin P.

15 51. An artificial antigen presenting cell according to 40 wherein said irrelevant molecule components, has a moiety for binding a solid support either directly or through an intermediate molecule, or for binding a label, said solid support further selected from the group consisting of a glass bead from 25 to 300 μm diameter, and a magnetic bead from 25 to 300 μm diameter.

20

52. An artificial antigen presenting cell according to claim 51 wherein said solid support is coated with a lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine, said solid support further having capture molecules, said capture molecules further having the capacity to bind specifically to
25 said irrelevant molecule components.

53. An artificial antigen presenting cell according to claim 52 wherein said capture molecules are noncovalently associated with said lipid.

54. An artificial antigen presenting cell comprising:

- 5 f. a liposome components;
 g. an MHC components;
 h. an antigen components,
 i. an accessory molecule components; and
 j. a cell modulation molecule components, wherein said antigen components is in
10 contact with at least said MHC components, said MHC, accessory and cell
 modulation components are in contact with at least said liposome components,
 said accessory molecule components further providing for a stabilizing property
 to an interaction between a T cell receptor and said MHC and said antigen
 components.

15

55. An artificial antigen presenting cell according to claim 54 wherein said liposome components comprises a lipid, said lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphotidylcholine.

56. An artificial antigen presenting cell according to claim 55 further comprising a
20 surfactant components wherein said surfactant components is cholesterol and is in
 contact with at least said liposome components.

57. An artificial antigen presenting cell according to claim 56 wherein a label is associated
 with at least one of the group selected from the group consisting of a lipid bilayer of
25 said liposome components, a lipid of said liposome components, an antigen
 components, an MHC components, a cell modulatory components, and an accessory
 components.

58. An artificial antigen presenting cell according to claim 57 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.

5

59. An artificial antigen presenting cell according to claim 56 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

10

15

60. An artificial antigen presenting cell according to claim 56 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient composition for binding an antigen, an $\alpha 1$ and $\alpha 2$ subunit set of a Class I MHC, an $\alpha 1$ and $\beta 2$ subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for binding an antigen.

20

61. An artificial antigen presenting cell according to claim 56 wherein said accessory molecule components is LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the ligands of the foregoing molecules.

25

62. An artificial antigen presenting cell according to claim 56 wherein said cell modulation molecule components is selected from the group consisting of CD72, CD22, CD58, anti-CD22, anti-CD58, anti-CD72, anti-cytokine receptor, and anti-chemokine receptor.
- 5 63. An artificial antigen presenting cell according to claim 56 further comprising a GM-1 protein components, said GM-1 components contacting at least said liposome components.
- 10 64. An artificial antigen presenting cell according to claim 63 further comprising a cholera β subunit components wherein said β subunit components is connected to at least one of said MHC, said cell modulation, and said accessory components and further contacts at least said GM-1 components.
- 15 65. An artificial antigen presenting cell according to claim 54 further comprising molecular components selected from the group consisting of an adhesion molecule components, a co-stimulatory molecule components, GM-1 protein components, cholera toxin β subunit components, an irrelevant molecule components for binding said artificial presenting cell to a solid support or binding a label, and a label components.
- 20 66. An artificial antigen presenting cell according to claim 65 wherein said liposome components comprises a lipid, said lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine.
- 25 67. An artificial antigen presenting cell according to claim 66 further comprising a surfactant components wherein said surfactant components is cholesterol and is in contact with at least said liposome components.

68. An artificial antigen presenting cell according to claim 67 wherein a label is associated with at least one of the group selected from the group consisting of a lipid bilayer of said liposome components, a lipid of said liposome components, an antigen components, an MHC components, a co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, GM-1 protein components, cholera toxin β subunit components, an irrelevant molecule components and an accessory components.

69. An artificial antigen presenting cell according to claim 68 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.

70. An artificial antigen presenting cell according to claim 67 wherein said GM-1 components contacts at least said liposome components.

71. An artificial antigen presenting cell according to claim 70 wherein said cholera β subunit component is connected to at least one of said co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, MHC components, an irrelevant molecule components, and said accessory components and further contacts at least said GM-1 components.

72. An artificial antigen presenting cell according to claim 67 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule

that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

5 73. An artificial antigen presenting cell according to claim 67 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient composition for binding an antigen, an α 1 and α 2 subunit set of a Class I MHC, an α 1 and β 2 subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for
10 binding an antigen.

74. An artificial antigen presenting cell according to claim 67 wherein said accessory molecule components is selected from the group consisting of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the
15 ligands of the foregoing molecules.

75. An artificial antigen presenting cell according to claim 67 wherein said co-stimulatory molecule components is selected from the group consisting of B7-1, B7-2, CD5, CD9, CD2, CD40 and antibodies to their ligands.
20

76. An artificial antigen presenting cell according to claim 67 wherein said cell modulation molecule components is selected from the group consisting of CD72, CD22, CD58, anti-CD22, anti-CD58, anti-CD72, anti-cytokine receptor, and anti-chemokine receptor.

25 77. An artificial antigen presenting cell according to claim 67 wherein said adhesion molecule components is selected from the group consisting of ICAM-1, ICAM-2,

GlyCAM-1, CD34, anti-LFA-1, anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L, anti-selectin E, and anti-selectin P.

78. An artificial antigen presenting cell according to 67 wherein said irrelevant molecule
5 components, has a moiety for binding a solid support either directly or through an intermediate molecule, or for binding a label, said solid support further selected from the group consisting of a glass bead from 25 to 300 μm diameter, and a magnetic bead from 25 to 300 μm diameter.

10 79. An artificial antigen presenting cell according to claim 78 wherein said solid support is coated with a lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine, said solid support further having capture molecules, said capture molecules further having the capacity to bind specifically to said irrelevant molecule components.

15 80. An artificial antigen presenting cell according to claim 79 wherein said capture molecules are noncovalently associated with said lipid.

20 81. An artificial antigen presenting cell comprising:

- (a) a liposome components;
- (b) an MHC components;
- (c) an antigen components,
- (d) an accessory molecule components,
- 25 (e) a co-stimulatory molecule components; and
- (f) a cell modulation molecule components, wherein said antigen components is in contact with at least said MHC components, said MHC, accessory, co-stimulatory, and cell modulation components are in contact with at least said

liposome components, said accessory molecule components further providing for a stabilizing property to an interaction between a T cell receptor and said MHC components and said antigen components.

5 82. An artificial antigen presenting cell according to claim 81 wherein said liposome components comprises a lipid, said lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine.

83. An artificial antigen presenting cell according to claim 82 further comprising a surfactant components wherein said surfactant component is cholesterol and is in
10 contact with at least said liposome components.

84. An artificial antigen presenting cell according to claim 83 wherein a label is associated with at least one of the group selected from the group consisting of a lipid bilayer of said liposome components, a lipid of said liposome components, an antigen
15 components, an MHC components, a co-stimulatory components, a cell modulation molecule components, and an accessory components.

85. An artificial antigen presenting cell according to claim 84 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a
20 radiolabel.

86. An artificial antigen presenting cell according to claim 83 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived
25 from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule

that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

- 5 87. An artificial antigen presenting cell according to claim 83 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient composition for binding an antigen, an α 1 and α 2 subunit set of a Class I MHC, an α 1 and β 2 subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for
- 10 binding an antigen.
88. An artificial antigen presenting cell according to claim 83 wherein said accessory molecule components is LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the ligands of the foregoing molecules.
- 15 89. An artificial antigen presenting cell according to claim 83 wherein said co-stimulatory molecule components is selected from the group consisting of B7-1, B7-2, CD5, CD9, CD2, CD40 and antibodies to their ligands.
- 20 90. An artificial antigen presenting cell according to claim 83 wherein said cell modulation molecule components is selected from the group consisting of a cytokine, a chemokine, CD72, CD22, CD58, anti-CD22, anti-CD58, anti-CD72, anti-cytokine receptor, and anti-chemokine receptor.
- 25 91. An artificial antigen presenting cell according to claim 83 further comprising a GM-1 protein components, said GM-1 components contacting at least said liposome components.

92. An artificial antigen presenting cell according to claim 91 further comprising a cholera
β subunit component wherein said β subunit component is connected to at least one of
said MHC, said co-stimulatory, cell modulation molecule component, and said
5 accessory components and further contacts at least said GM-1 components.

93. An artificial antigen presenting cell according to claim 81 further comprising molecular
components selected from the group consisting of an adhesion molecule components,
GM-1 protein components, cholera toxin β subunit components, an irrelevant molecule
10 components for binding said artificial presenting cell to a solid support or binding a
label, and a label components.

94. An artificial antigen presenting cell according to claim 93 wherein said liposome
components comprises a lipid, said lipid selected from the group consisting of a
15 phospholipid, a neutral phospholipid, and phosphotidylcholine.

95. An artificial antigen presenting cell according to claim 94 further comprising a
surfactant components wherein said surfactant components is cholesterol and is in
contact with at least said liposome components.

96. An artificial antigen presenting cell according to claim 95 wherein a label is associated
with at least one of the group selected from the group consisting of a lipid bilayer of
said liposome components, a lipid of said liposome components, an antigen
components, an MHC components, a co-stimulatory molecule components, an
adhesion molecule components, a cell modulation molecule components, GM-1 protein
20 components, cholera toxin β subunit components, an irrelevant molecule components
25 and an accessory components.

97. An artificial antigen presenting cell according to claim 96 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.

5

98. An artificial antigen presenting cell according to claim 95 wherein said GM-1 components contacts at least said liposome components.

99. An artificial antigen presenting cell according to claim 98 wherein said cholera β subunit component is connected to at least one of said MHC components, co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, an irrelevant molecule components, and said accessory components and further contacts at least said GM-1 components.

10

100. An artificial antigen presenting cell according to claim 95 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

20

101. An artificial antigen presenting cell according to claim 95 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient composition for binding an antigen, an $\alpha 1$ and $\alpha 2$ subunit set of

25

a Class I MHC, an α 1 and β 2 subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for binding an antigen.

5 102. An artificial antigen presenting cell according to claim 95 wherein said accessory molecule components is selected from the group consisting of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the ligands of the foregoing molecules.

10 103. An artificial antigen presenting cell according to claim 95 wherein said co-stimulatory molecule components is selected from the group consisting of B7-1, B7-2, CD5, CD9, CD2, CD40 and antibodies to their ligands.

15 104. An artificial antigen presenting cell according to claim 95 wherein said cell modulation molecule components is selected from the group consisting of CD72, CD22, CD58, anti-CD22, anti-CD58, anti-CD72, anti-cytokine receptor, and anti-chemokine receptor.

20 105. An artificial antigen presenting cell according to claim 95 wherein said adhesion molecule components is selected from the group consisting of ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1, anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L, anti-selectin E, and anti-selectin P.

25 106. An artificial antigen presenting cell according to 95 wherein said irrelevant molecule components, has a moiety for binding a solid support either directly or through an intermediate molecule, or for binding a label, said solid support further

selected from the group consisting of a glass bead from 25 to 300 μm diameter, and a magnetic bead from 25 to 300 μm diameter.

107. An artificial antigen presenting cell according to claim 106 wherein said solid
5 support is coated with a lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine, said solid support further having capture molecules, said capture molecules further having the capacity to bind specifically to said irrelevant molecule components.

10 108. An artificial antigen presenting cell according to claim 107 wherein said capture molecules are noncovalently associated with said lipid.

109. An artificial antigen presenting cell comprising:
15 a. a liposome components;
b. an MHC components;
c. an antigen components;
d. an accessory molecule components;
e. a co-stimulatory molecule components;
f. a cell modulation molecule components;
20 g. an adhesion molecule components;
h. an irrelevant molecule components; and
i. a cholesterol components, wherein said antigen components is in contact with at least said MHC components, said MHC, accessory, co-stimulatory, cell modulation, adhesion, irrelevant, and said cholesterol components are in contact
25 with at least said liposome components, said accessory molecule components further providing a stabilizing property to an interaction between a T cell receptor and said MHC components and said antigen components.

110. An artificial antigen presenting cell according to claim 109 wherein said liposome components comprises a lipid, said lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine.

111. An artificial antigen presenting cell according to claim 110 wherein a label is associated with at least one of the group selected from the group consisting of a lipid bilayer of said liposome components, a lipid of said liposome components, an antigen components, an MHC components, a co-stimulatory components, a cell modulation molecule components, an adhesion molecule components, an irrelevant molecule components, a cholesterol components, and an accessory components.

112. An artificial antigen presenting cell according to claim 111 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.

113. An artificial antigen presenting cell according to claim 110 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

114. An artificial antigen presenting cell according to claim 110 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant

MHC having sufficient composition for binding an antigen, an $\alpha 1$ and $\alpha 2$ subunit set of a Class I MHC, an $\alpha 1$ and $\beta 2$ subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for binding an antigen.

5

115. An artificial antigen presenting cell according to claim 110 wherein said accessory molecule components is LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the ligands of the foregoing molecules.

10 116. An artificial antigen presenting cell according to claim 110 wherein said co-stimulatory molecule components is selected from the group consisting of B7-1, B7-2, CD5, CD9, CD2, CD40 and antibodies to their ligands.

15 117. An artificial antigen presenting cell according to claim 110 wherein said cell modulation molecule components is selected from the group consisting of a cytokine, a chemokine, CD72, CD22, CD58, anti-CD22, anti-CD58, anti-CD72, anti-cytokine receptor, and anti-chemokine receptor.

20 118. An artificial antigen presenting cell according to claim 110 wherein said adhesion molecule components is selected from the group consisting of ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1, anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L, anti-selectin E, and anti-selectin P.

25 119. An artificial antigen presenting cell according to claim 110 wherein said irrelevant molecule components, has a moiety for binding a solid support either directly or through an intermediate molecule, or for binding a label, said solid support further

selected from the group consisting of a glass bead from 25 to 300 μm diameter, and a magnetic bead from 25 to 300 μm diameter.

120. An artificial antigen presenting cell according to claim 119 wherein said solid
5 support is coated with a lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine, said solid support further having capture molecules, said capture molecules further having the capacity to bind specifically to said irrelevant molecule components.

10 121. An artificial antigen presenting cell according to claim 120 wherein said capture molecules are noncovalently associated with said lipid.

122. An artificial antigen presenting cell according to claim 110 further comprising a
15 GM-1 protein components, said GM-1 components contacting at least said liposome components.

123. An artificial antigen presenting cell according to claim 122 further comprising a
cholera β subunit components wherein said β subunit components is connected to at least one of said MHC, said co-stimulatory, cell modulation molecule component,
20 adhesion, irrelevant, and said accessory components and further contacts at least said GM-1 components.

124. An artificial antigen presenting cell comprising:
a. a solid support components;
25 b. a liposome components;
c. an MHC components;
d. an antigen components; and

e. an accessory molecule components, wherein said solid support components comprise a glass or magnetic spheroid, liposome components is contacted either covalently or noncovalently with said solid support components, said antigen components is in contact with at least said MHC components, said MHC, and
5 accessory components are in contact with at least said liposome components, said accessory molecule components further providing a stabilizing property to an interaction between a T cell receptor and said MHC components and said antigen components.

10 125. An artificial antigen presenting cell according to claim 124 wherein said liposome components comprises a lipid, said lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphotidylcholine.

126. An artificial antigen presenting cell according to claim 125 further comprising a surfactant components wherein said surfactant components is cholesterol and is in
15 contact with at least said liposome components.

127. An artificial antigen presenting cell according to claim 126 wherein a label is associated with at least one of the group selected from the group consisting of a lipid layer of said liposome component, a lipid of said liposome component, an antigen, an
20 MHC, and an accessory components.

128. An artificial antigen presenting cell according to claim 127 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.
25

129. An artificial antigen presenting cell according to claim 126 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide
5 derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

10

130. An artificial antigen presenting cell according to claim 126 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient composition for binding an antigen, an $\alpha 1$ and $\alpha 2$ subunit set of a Class I MHC, an $\alpha 1$ and $\beta 2$ subunit set of a Class II MHC, a peptide derived from
15 said α and β subunits, and a portion of a natural MHC having sufficient composition for binding an antigen.

15

131. An artificial antigen presenting cell according to claim 126 wherein said accessory molecule components is selected from the group consisting of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the
20 ligands of the foregoing molecules.

20

132. An artificial antigen presenting cell according to claim 126 further comprising a GM-1 protein components, said GM-1 components contacting at least said liposome
25 components.

25

133. An artificial antigen presenting cell according to claim 132 further comprising a cholera β subunit components wherein said β subunit components is connected to at least one of said MHC, and said accessory components and further contacts at least said GM-1 components.

5

134. An artificial antigen presenting cell according to claim 124 further comprising molecular components selected from the group consisting of a co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, GM-1 protein components, cholera toxin β subunit components, an irrelevant molecule components for binding said artificial presenting cell to a solid support or binding a label, and a label components.

10

135. An artificial antigen presenting cell according to claim 134 wherein said liposome components comprises a lipid, said lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine.

15

136. An artificial antigen presenting cell according to claim 135 further comprising a surfactant components wherein said surfactant components is cholesterol and is in contact with at least said liposome components.

20 137. An artificial antigen presenting cell according to claim 136 wherein a label is associated with at least one of the group selected from the group consisting of a lipid layer of said liposome components, a lipid of said liposome components, an antigen components, an MHC components, a co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, GM-1 protein components, cholera toxin β subunit components, an irrelevant molecule components and an accessory components.

25

138. An artificial antigen presenting cell according to claim 137 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.

5

139. An artificial antigen presenting cell according to claim 136 wherein said GM-1 components contacts at least said liposome components.

10 140. An artificial antigen presenting cell according to claim 139 wherein said cholera β subunit component is connected to at least one of said co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, an irrelevant molecule components, and said accessory components and further contacts at least said GM-1 components.

15 141. An artificial antigen presenting cell according to claim 136 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a
20 peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

25 142. An artificial antigen presenting cell according to claim 136 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient composition for binding an antigen, an $\alpha 1$ and $\alpha 2$ subunit set of

a Class I MHC, an α 1 and β 2 subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for binding an antigen.

5 143. An artificial antigen presenting cell according to claim 136 wherein said accessory molecule components is selected from the group consisting of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the ligands of the foregoing molecules.

10 144. An artificial antigen presenting cell according to claim 136 wherein said co-stimulatory molecule components is selected from the group consisting of B7-1, B7-2, CD5, CD9, CD2, CD40 and antibodies to their ligands.

15 145. An artificial antigen presenting cell according to claim 136 wherein said cell modulation molecule components is selected from the group consisting of CD72, CD22, CD58, anti-CD22, anti-CD58, anti-CD72, anti-cytokine receptor, and anti-chemokine receptor.

20 146. An artificial antigen presenting cell according to claim 136 wherein said adhesion molecule components is selected from the group consisting of ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1, anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L, anti-selectin E, and anti-selectin P.

25 147. An artificial antigen presenting cell according to 136 wherein said irrelevant molecule components has a moiety for binding a solid support either directly or through an intermediate molecule or for binding a label, said solid support further

selected from the group consisting of a glass bead from 25 to 300 μm diameter, and a magnetic bead from 25 to 300 μm diameter.

148. An artificial antigen presenting cell according to claim 147 wherein said solid support is coated with a lipid selected from the group consisting of a phospholipid, a neutral phospholipid, and phosphatidylcholine, said solid support further having capture molecules, said capture molecules further having the capacity to bind specifically to said irrelevant molecule.

149. An artificial antigen presenting cell according to claim 148 wherein said capture molecules are noncovalently associated with said lipid.

150. A method of making an artificial antigen presenting cell comprising:

(a) obtaining an MHC:antigen complex of interest;

(b) contacting said MHC:antigen complex with a lipid and cholesterol and forming a lipid membrane-associated MHC:antigen complex; and

(c) contacting said membrane-associated MHC:antigen complex resulting from step (b) with a molecule of interest, said molecule of interest comprising at least one of molecules selected from the group consisting of an accessory molecule, a co-stimulatory molecule, a cell modulation molecule, an adhesion molecule, an irrelevant molecule, cholesterol, GM-1 protein, cholera toxin β subunit protein, and a label.

151. A method according to claim 150 wherein steps (b) and (c) are performed simultaneously.

152. A method according to claim 151 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient

composition for binding an antigen, an $\alpha 1$ and $\alpha 2$ subunit set of a Class I MHC, an $\alpha 1$ and $\beta 2$ subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for binding an antigen.

- 5 153. A method according to claim 151 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope
10 mapping, a self-derived molecule, a self-derived molecule that has sequence identity with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.
- 15 154. A method according to claim 151 wherein said accessory molecule components is selected from the group consisting of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the ligands of the foregoing molecules.
- 20 155. A method according to claim 151 wherein said co-stimulatory molecule components is selected from the group consisting of B7-1, B7-2, CD5, CD9, CD2, CD40 and antibodies to their ligands.
156. A method according to claim 151 wherein said cell modulation molecule
25 components is selected from the group consisting of CD72, CD22, CD58, anti-CD22, anti-CD58, anti-CD72, anti-cytokine receptor, and anti-chemokine receptor.

157. A method according to claim 151 wherein said adhesion molecule components is selected from the group consisting of ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1, anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L, anti-selectin E, and anti-selectin P.

5

158. A method according to claim 151 wherein a label is associated with at least one of the group selected from the group consisting of a lipid layer of said liposome components, a lipid of said liposome components, an antigen components, an MHC components, a co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, GM-1 protein components, cholera toxin β subunit components, an irrelevant molecule components and an accessory components.

10

159. A method according to claim 158 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.

15

160. A method according to claim 151 wherein said GM-1 component contacts at least said liposome components.

20

161. A method according to claim 160 wherein said cholera β subunit components is connected to at least one of said co-stimulatory molecule components, an adhesion molecule components, a cell modulation molecule components, an irrelevant molecule components, and said accessory components and further contacts at least said GM-1 components.

25

162. A method of identifying T cells specific for an antigen of interest comprising:
(a) obtaining a biological sample containing T cells which are specific for an antigen of interest;

- (b) preparing an artificial antigen presenting cell comprising attributes of any of the claims selected from the group consisting of claim 1, claim 3, claim 4, claim 11, claim 13, claim 14, claim 17, claim 27, claim 29, claim 30, claim 38, claim 40, claim 44, claim 54, claim 56, claim 57, claim 65, claim 67, claim 68, claim 71, claim 81, claim 83, claim 84, claim 93, claim 95, claim 96, claim 99, wherein the antigen in said artificial antigen presenting cell is said antigen of interest;
- (c) contacting the biological sample obtained in step (a) with the artificial antigen presenting cell obtained in step (b) to form an artificial antigen presenting cell:T cell complex; wherein at least one element of said artificial antigen presenting cell is associated with a label, said elements selected from the group consisting of said antigen of interest, an irrelevant molecule, a lipid layer, a lipid, an MHC molecule components, a co-stimulatory components, an adherent components, a cell modulation components, and an accessory molecule components; and
- (d) detecting said label.

163. A method of isolating T cells specific for an antigen of interest comprising:

- (a) obtaining a biological sample containing T cells which are specific for an antigen of interest;
- (b) preparing an artificial antigen presenting cell comprising attributes of any of the claims selected from the group consisting of claim 1, claim 3, claim 4, claim 11, claim 13, claim 14, claim 17, claim 27, claim 29, claim 30, claim 38, claim 40, claim 44, claim 54, claim 56, claim 57, claim 65, claim 67, claim 68, claim 71, claim 81, claim 83, claim 84, claim 93, claim 95, claim 96, claim 99, wherein the antigen in said artificial antigen presenting cell is said antigen of interest;
- (c) contacting the biological sample obtained in step (a) with the artificial antigen presenting cell obtained in step (b) to form an artificial antigen presenting cell:T cell complex; wherein at least one element of said artificial antigen presenting cell is associated with a label, said elements selected from the group consisting of said antigen of interest, an irrelevant molecule, a lipid layer, a lipid, an MHC

molecule components, a co-stimulatory components, an adherent components, a cell modulation components, and an accessory molecule components;

(d) removing said artificial antigen presenting cell:T cell complex formed in step (c) from said biological sample; and

5 (e) separating T cells specific for said antigen of interest from said artificial antigen presenting cell:T cell complex.

164. A method according to claim 163 further comprising the step of:

(f) determining a quantity of T cells specific for said antigen of interest.

10

165. A method according to claim 164 further comprising the step of:

(g) characterizing the functional phenotype of said isolated T cells specific for said antigen of interest.

15 166. A method according to claim 163 wherein said biological sample is selected from the group consisting of whole blood, blood cells, blood plasma, and tissue.

167. A method according to claim 166 wherein said biological sample is selected from the group consisting of whole blood, blood cells, blood plasma, and tissue.

20

168. A method of modulating T cell response comprising:

(a) isolating T cells which are specific for an antigen of interest using a method of claim 163; and

(b) contacting said isolated T cells with an artificial antigen presenting cell

25 comprising attributes of any of the claims selected from the group consisting of claim 1, claim 3, claim 4, claim 11, claim 13, claim 14, claim 17, claim 27, claim 29, claim 31, claim 38, claim 40, claim 44, claim 54, claim 56, claim 57, claim 65, claim 67, claim 68, claim 71, claim 81, claim 84, claim 93, claim 95, claim 96, claim 99, wherein said antigen presenting cell has an antigen of

interest or a homologue of said antigen of interest, said artificial antigen presenting cell further having at least one molecule selected from the group consisting of an accessory molecule components, a co-stimulatory components, an adhesion components, and a cell modulation components.

5

169. A method according to claim 168 wherein said modulation of T cell response comprises changing in whole or in part the functional pattern of cytokine production by said isolated T cells from a Th-1 response to a Th-2 response.

10 170. A method according to claim 169 wherein said artificial antigen presenting cell expresses a co-stimulatory molecule B7-2.

15 171. A method according to claim 168 wherein said modulation of T-cell response comprises changing in whole or in part the functional pattern of cytokine production by said isolated T cells from a Th-2 response to a Th-1 response.

172. A method according to claim 171 wherein said artificial antigen presenting cell expresses a co-stimulatory molecule B7-1.

20 173. A method according to claim 168 wherein said modulation of T cell response comprises inducing anergy.

174. A method according to claim 168 wherein said modulation of T cell response comprises inducing proliferation of T cells.

25

175. A method according to claim 168 wherein said artificial antigen presenting cell expresses anti-CD-28 so as to facilitate T-cell proliferation.

30 176. A method of characterizing the functional state of antigen-specific T cells comprising:

- (e) isolating T cells in accordance with the method of claim 163;
- (f) extracting mRNA from said isolated T cells;
- (g) obtaining cDNA corresponding to said extracted mRNA;
- (h) evaluating the mRNA encoding proteins that govern function and phenotype of
5 said antigen-specific T cells, said evaluation carried out by a method selected
 from the group consisting of (1) mRNA translation of said proteins and testing
 said proteins using antibodies against such proteins, and (2) rtPCR of the
 mRNA using primers specific for said proteins.

10 177. A method according to claim 176 wherein said evaluation of the mRNA encoding
 proteins that govern function and phenotype of said antigen-specific T cell is used to
 determine efficacy of an immunomodulation treatment regimen.

15 178. A method according to claim 177 wherein said immunomodulation treatment
 comprises administering a vaccine.

179. A method according to claim 177 wherein said immunomodulation treatment
 comprises inducing tolerance in autoimmunity.

20 180. A method according to claim 177 wherein said immunomodulation treatment
 comprises reducing allergic response.

181. A method according to claim 177 wherein said immunomodulation treatment
 comprises inducing an immune response against cancer cells.

25

182. A method according to claim 177 wherein said proteins that govern function and
 phenotype of said antigen-specific T cells include a cytokine.

30 183. A method according to claim 177 wherein said proteins that govern function and
 phenotype of said antigen-specific T cells include a chemokine.

184. A method according to claim 177 wherein said proteins that govern function and phenotype of said antigen-specific T cells include a chemokine receptor.

5 185. A method according to claim 177 wherein said proteins that govern function and phenotype of said antigen-specific T cells include a cytokine receptor.

186. A method of treating a condition in a subject which would be benefited by altering the functional pattern of cytokine production by certain antigen-specific T cells to
10 increase Th-2 response and/or decrease Th-1 response comprising:
(a) isolating T cells in accordance with the method of claim 163 which are specific for an antigen capable of triggering a Th-1 response upon recognition of said antigen by said subject's T cells; and
(b) combining said isolated T cells with an artificial antigen presenting cell having
15 a MHC component capable of binding said antigen and a co-stimulatory molecule component comprising B7-2.

187. A method according to claim 186 wherein said condition is an autoimmune disease.

20 188. A method according to claim 187 wherein said autoimmune disease is selected from the group consisting of type I diabetes mellitus, multiple sclerosis, rheumatoid arthritis, dermatomyositis, juvenile rheumatoid arthritis and uveitis.

189. A method of treating a condition in a subject which would be benefited by
25 increasing Th-1 response and/or decreasing Th-2 response comprising:
(a) isolating T cells in accordance with the method of claim 163 which are specific for an antigen capable of triggering a Th-2 response upon recognition of said antigen by said subject's T cells; and

- (b) combining said isolated T cells with an artificial antigen presenting cell having an MHC component capable of binding said antigen and a co-stimulatory molecule component B7-1.

5 190. A method according to claim 189 wherein said condition is an allergy.

191. A method according to claim 190 wherein said allergy is to allergen selected from the group consisting of dust, animal skin bypass products, vegetables, fruits, pollen and chemicals.

10

192. A method according to claim 189 wherein said condition is a cancer.

193. A method according to claim 189 wherein said condition is a viral infection.

15 194. A method according to claim 189 wherein said condition is a bacterial infection.

195. A method of identifying antigen-specific T cells specific for epitopes on a graft donor's tissue likely to elicit graft vs. host rejection response comprising:

20

- (a) predicting epitopes of a donor's MHC likely to be antigenic by computer modeling; and
- (b) testing the predicted epitopes with a recipient's T cells to identify T cells specific for said epitopes according to claim 162.

25

196. A method of treating a recipient mammal to reduce rejection of allografts in a transplantation therapy regimen comprising:

30

- (a) predicting epitopes of a donor's MHC likely to be antigenic by computer modeling;
- (b) testing the predicted epitopes with a recipient's T cells to identify T cells specific for said epitopes according to claim 162;
- (c) using the epitopes as antigen in an artificial APC;

- (d) contacting said artificial APC of (c) with a biological sample from said recipient to form an artificial APC:epitope specific T cell complex, said sample further comprising T cells specific for said epitope;
 - (e) removing said complex formed in (d) from said biological sample so as to
- 5 deplete a recipient's T cell population of T cells specific for said epitope.

197. A kit for isolation and/or modulation of T cells specific for an antigen of interest comprising components selected from the group consisting of

- (a) artificial APCs;
- 10 (b) solid supports;
- (c) reagents; and
- (d) an immunomodulatory column device.

198. A kit according to claim 197 wherein said artificial APCs have components in any

15 combination, said components selected from the group consisting of lipids, neutral phospholipids, phosphatidylcholine, cholesterol, solid supports, full length MHC components or portions thereof sufficient to bind an antigen, said MHC components specific for an antigen, antigens, accessory molecules, co-stimulatory molecules, adhesion molecules, modulation molecules, irrelevant molecules, and labels.

20 199. A kit according to claim 198 wherein said solid supports are selected from the group consisting of a glass bead from 25 to 300 μm diameter, and a magnetic bead from 25 to 300 μm .

25 200. A kit according to claim 198 wherein said MHC components is selected from the group consisting of a natural MHC, a recombinant MHC having sufficient composition for binding an antigen, an $\alpha 1$ and $\alpha 2$ subunit set of a Class I MHC, an $\alpha 1$ and $\beta 2$ subunit set of a Class II MHC, a peptide derived from said α and β subunits, and a portion of a natural MHC having sufficient composition for binding an antigen.

201. A kit according to claim 198 wherein said accessory molecule is LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4), and antibodies to the ligands of the foregoing molecules.

5

202. A kit according to claim 198 wherein said co-stimulatory molecule component is selected from the group consisting of B7-1, B7-2, CD5, CD9, CD2, CD40 and antibodies to their ligands.

10 203. A kit according to claim 198 wherein said T cell modulation molecule component is selected from the group consisting of a cytokine, a chemokine, CD72, CD22, CD58, anti-CD22, anti-CD58, anti-CD72, anti-cytokine receptor, and anti-chemokine receptor.

15 204. A kit according to claim 198 wherein said adhesion molecule component is selected from the group consisting of ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1, anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L, anti-selectin E, and anti-selectin P.

20 205. A kit according to claim 198 wherein said antigen is presented by an MHC components for contact with and recognition by a T cell receptor, said antigen selected from the group consisting of a peptide, a peptide derived from the recipient for graft versus host diseases, a cancer cell-derived peptide, a peptide derived from an allergen, a donor-derived peptide, a pathogen-derived molecule, a peptide derived by epitope mapping, a self-derived molecule, a self-derived molecule that has sequence identity
25 with said pathogen-derived antigen, said sequence identity having a range selected from the group consisting of between 5 and 100%, 15 and 100%, 35 and 100%, and 50 and 100%.

206. A kit according to claim 198 wherein said antigen has a label.

207. A kit according to claim 198 wherein said irrelevant molecule components, has a moiety for binding a solid support either directly or through an intermediate molecule, or for binding a label, said solid support further selected from the group consisting of a glass bead from 25 to 300 μm diameter, and a magnetic bead from 25 to 300 μm diameter.

208. A kit according to claim 207 wherein said irrelevant molecule has a label.

209. A kit according to claim 198 wherein a lipid of said liposome has a label.

210. A kit according to claim 198 wherein said label is associated with a lipid layer of said liposome.

211. A kit according to claim 197 wherein said solid supports are selected from the group consisting of a glass bead from 25 to 300 μm diameter, and a magnetic bead from 25 to 300 μm diameter, a solid support coated with a capture molecule capable of binding to an irrelevant molecule, and a solid support coated with a lipid layer and a capture molecule capable of binding to an irrelevant molecule.

212. A kit according to claim 197 wherein said reagents comprise components in any combination, said components selected from the group consisting of (1) buffers for carrying out T cell identification, isolation, and modification, (2) media for expanding T cells, (3) co-stimulatory molecules, (4) adhesion molecules, (5) modulation molecules, (6) labels, (7) soluble factors for activating T cells, and (8) soluble factors for modulating T cells.

213. A kit according to claim 212 wherein said label is selected from the group consisting of biotin, vancomycin, a fluorochrome, FITC, and a radiolabel.

214. A kit according to claim 197 wherein said immunomodulatory column is designed according to claim 215.

5 215. An immunomodulatory column comprising:

a multiplicity of compartments positioned in relation to one another in series, said compartments having a channels interconnecting adjacent compartments, said channels further having a means to isolate said compartments from one another, said compartments further having at least one entrance and at least one exit ports for receiving or expelling,
10 respectively, a flowable medium, said ports further having a means to close said ports to impede said flowable medium, said compartments further optionally comprising components selected from the group consisting of solid supports, and artificial APCs.

15 216. A method for identifying a gene which is expressed by a T cell specific for an antigen of interest comprising:

- (g) obtaining a biological sample containing T cells which are specific for an antigen of interest;
- (h) labeling, with a first label, at least the intracellular gene product of interest produced by T cells in said biological sample;
- 20 (i) preparing a liposome:MHC:antigen complex, wherein the antigen in said liposome:MHC:antigen complex is said antigen of interest;
- (j) contacting the biological sample obtained in step (a), as labeled in accordance with step (b), with the liposome:MHC: antigen complex obtained in step (c) to form a liposome:MHC:antigen:T cell complex;
- 25 (k) labeling, with a second label, said liposome:MHC:antigen:T cell complex obtained in step (d); and
- (l) discriminating, according to antigen specificity, cells producing said intracellular gene product of interest, which cells have both the first label and the second label.

217. A method according to claim 216 wherein said first label and said second label are selected from the group consisting of biotin, a flurochrome, FITC, and a radioactive label; provided that said first label and said second label are not the same label.

5 218. A method of obtaining a monoclonal population of T cells specific for an antigen of interest comprising:

(c) isolating T cells specific for an antigen of interest in accordance with the method of claim 163; and

10 (d) culturing said T cells in an individual well with said antigen of interest and an artificial APC.

219. A method of monitoring an immunological outcome of intervention on antigen-specific and bystander T cells comprising:



15 (a) identifying antigen-specific T cells that are specific for an antigen of interest from a patient;



(b) identifying a functional phenotype of said antigen-specific T cells identified in (a); and

(c) correlating said functional phenotype with a clinical outcome of said patient.

ABSTRACT

The present invention is directed to artificial antigen presenting cells and methods of making artificial antigen presenting cells. Such artificial antigen presenting cells may be used in certain methods of isolating and expanding T cell populations as well as
5 modulating T cell responses. Additionally, the present invention provides novel methods for the identification and isolation of antigen-specific T cells. The methods provide for the construction of liposomes containing MHC:peptide complexes, accessory molecules, co-stimulatory molecules, adhesion molecules, and other molecules irrelevant to T cell binding or modulation that are used in the binding of artificial antigen presenting cells to
10 solid support systems that may be used in the retrieval and identification of antigen-specific T cells. Additionally, the present invention is directed to devices and methods for treating conditions which would benefit from modulation of T cell response, for example, autoimmune disorders, allergies, cancers, viral infections, and graft rejection.

**FIG. 1****FIG. 2**

**FIG. 3****FIG. 4**




FIG. 5




FIG. 6




FIG. 7A




FIG. 7B





FIG. 8

07/24

AG111.207 T-T HYBRIDOMA
I-A^s/OVA³²³⁻³³⁶ SPECIFIC



HT.01
B CELL
HYBRIDOMA

FIG. 9A

8D051.15 T-T HYBRIDOMA
I-A^d/OVA³²³⁻³³⁶ SPECIFIC




FIG. 9B




FIG. 10A




FIG. 10B




FIG. 10C





FIG. 11

I α 52 SUPPLEMENTED FTOC
Hi15 EXPANDED LINE






FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 13E




FIG. 14A




FIG. 14B




FIG. 14C





FIG. 14D

**FIG. 15**

14/24

FIG. 16A.




FIG. 16B.



FIG. 16C.




FIG. 16D.

15/24

FIG. 17A.



FIG. 17B.




FIG. 17C.




FIG. 17D.

16/24

FIG. 18A.




FIG. 18B.





FIG. 18C.




FIG. 18D.




FIG. 19B. 200 20 2 0.1x 200 20 2 0.1x




FIG. 19D. 70 10 1x 70 10 1x




FIG. 20












FIG. 21

**FIG. 22**

*FIG. 23A**FIG. 23B**FIG. 23C**FIG. 23D**FIG. 23E**FIG. 23F*

**FIG. 24**




FIG. 25A




FIG. 25B




FIG. 26




FIG. 27A




FIG. 27B




FIG. 27C

**DECLARATION
AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **METHODS FOR ISOLATION, QUANTIFICATION, CHARACTERIZATION AND MODULATION OF ANTIGEN-SPECIFIC T CELLS** the specification of which

(Check One) ☒ is attached hereto OR
☐ was filed on _____ as United States Application Serial No. To Be Assigned
or
PCT International Application No.
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date
60/105,018	October 20, 1998

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned

POWER OF ATTORNEY: As a named inventor, I hereby appoint as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Roland N. Smoot, Reg. No. 18,718; Conrad R. Solum, Jr. Reg. No. 20,467; James W. Geriak, Reg. No. 20,233; Robert M. Taylor, Jr., Reg. No. 19,848; Samuel B. Stone, Reg. No. 19,297; Douglas E. Olson, Reg. No. 22,798; Robert E. Lyon, Reg. No. 24,171; Robert C. Weiss, Reg. No. 24,939; Richard E. Lyon, Jr., Reg. No. 26,300; John D. McConaghy, Reg. No. 26,773; William C. Steffin, Reg. No. 26,811; Coe A. Bloomberg, Reg. No. 26,605; J. Donald McCarthy, Reg. No. 25,119; John M. Benassi, Reg. No. 27,483; James H. Shalek, Reg. No. 29,749; Allan W. Jansen, Reg. No. 29,035; Robert W. Dickerson, Reg. No. 29,914; Roy L. Anderson, Reg. No. 30,240; David B. Murphy, Reg. No. 31,125; James C. Brooks, Reg. No. 29,898; Jeffrey M. Olson, Reg. No. 30,790; Steven D. Hemminger, Reg. No. 30,755; Jerrold B. Reilly, Reg. No. 32,293; Paul H. Meier, Reg. No. 32,274; John A. Rafter, Jr., Reg. No. 31,653; Kenneth H. Ohriner, Reg. No. 31,646; Mary S. Consalvi, Reg. No. 32,212; Lois M. Kwasigroch, Reg. No. 35,579; Lawrence R. LaPorte, Reg. No. 38,948; Robert C. Laurenson, Reg. No. 34,206; Bradford J. Duft, Reg. No. 32,219; Suzanne L. Biggs, Reg. No. 30,158; Richard J. Warburg, Reg. No. 32,327; John M. Johnson, Reg. No. 33,334; Daniel M. Chambers, Reg. No. 34,561; Troy M. Schmelzer, Reg. No. 36,667; Jessica R. Wolff, Reg. No. 37,261; Howard N. Wisnia, Reg. No. 37,502; Douglas C. Murdock, Reg. No. 37,549; Jeffrey W. Guise, Reg. No. 34,613; F.T. Alexandra Mahaney, Reg. No. 37,668; Charles S. Berkman, Reg. No. 38,077; Edward M. Jordan, Reg. No. 40,666; John C. Kappos, Reg. No. 37,861; Keith Kind, Reg. No. 42,735; Stephen S. Korniczky, Reg. No. 34,853; Jonathan T. Losk, Reg. No. 39,755; Theodore S. Maceiko, Reg. No. 35,593; Hope E. Melville, Reg. No. 34,874; Jeffrey A. Miller, Reg. No. 35,874; Kurt T. Mulville, Reg. No. 37,194; Clarke W. Neumann, Reg. No. 39,789; Vicki Norton, Reg. No. 40,745; Kenneth S. Roberts, Reg. No. 38,283; Thomas R. Rouse, Reg. No. 40,793; James K. Sakaguchi, Reg. No. 41,285; Stephen C. Beuerle, Reg. No. 38,380; Carol A. Schneider, Reg. No. 34,923; Sheryl R. Silverstein, Reg. No. 40,812; Brent D. Sokol, Reg. No. 38,621; Jeffrey D. Tekanic, Reg. No. 36,031; Christopher A. Vanderlaan, Reg. No. 37,747; David E. Wang, Reg. No. 38,358; Lisa Ward Karmelich, Reg. No. 41,421; Michael J. Wise, Reg. No. 34,047; Wesley B. Ames, Reg. No. 40,893; Charles Balgenorth, Reg. No. 37,586; Thomas J. Brindisi, Reg. No. 40,348; James P. Brogan, Reg. No. 35,833; David T. Burse, Reg. No. 37,104; Bruce G. Chapman, Reg. No. 33,846; Farshad Farjami, Reg. No. 41,014; Charles C. Fowler, Reg. No. 39,675; and Corrine M. Freeman, Reg. No. 37,625.; of LYON & LYON, 633 West Fifth Street, Suite 4700, Los Angeles, California 90071-2066 telephone (619) 552-8400

Douglas C. Murdock

Reg. No.: 37,549

Send Correspondence to: Douglas C. Murdock	LYON & LYON LLP 633 W Fifth St., Suite 4700 Los Angeles, CA 90071	Direct Telephone calls to: (619) 552-8400, Extension 5545
---	---	--

Residence, post office address, citizenship and signature of inventor(s) set forth beginning on next page.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

	FULL NAME OF INVENTOR	FIRST Name Salvatore	MIDDLE Initial	LAST Name Albani	
INVENTOR'S SIGNATURE _____				DATE _____	
201	RESIDENCE & CITIZENSHIP	City 629 4 th Street, Encinitas	State or Foreign Country California	Country of Citizenship	
	POST OFFICE ADDRESS	c/o Cevis 4186 M Sorrento Valley Blvd.	City San Diego	State or Country California	Zip Code 92121
	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
INVENTOR'S SIGNATURE _____				DATE _____	
202	RESIDENCE & CITIZENSHIP	City	State or Foreign Country	Country of Citizenship	
	POST OFFICE ADDRESS		City	State or Country	Zip Code
	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
INVENTOR'S SIGNATURE _____				DATE _____	
203	RESIDENCE & CITIZENSHIP	City	State or Foreign Country	Country of Citizenship	
	POST OFFICE ADDRESS		City	State or Country	Zip Code
	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
INVENTOR'S SIGNATURE _____				DATE _____	
204	RESIDENCE & CITIZENSHIP	City	State or Foreign Country	Country of Citizenship	
	POST OFFICE ADDRESS		City	State or Country	Zip Code
	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
INVENTOR'S SIGNATURE _____				DATE _____	
205	RESIDENCE & CITIZENSHIP	City	State or Foreign Country	Country of Citizenship	
	POST OFFICE ADDRESS		City	State or Country	Zip Code
	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
INVENTOR'S SIGNATURE _____				DATE _____	
206	RESIDENCE & CITIZENSHIP	City	State or Foreign Country	Country of Citizenship	
	POST OFFICE ADDRESS		City	State or Country	Zip Code

(Signatures should conform to names as presented at 201 et seq. above.)

SEQUENCE LISTING

<110> ALBANI, SALVATORE

<120> METHODS FOR ISOLATION, QUANTIFICATION, CHARACTERIZATION
AND MODULATION OF ANTIGEN-SPECIFIC T CELLS

<130> 246/285

<140> To Be Assigned

<141> Filed Herewith

<150> 60/105,018

<151> 1998-10-20

<160> 14

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide derived from third hyper V
region of IE molecule Mus musculus

<400> 1

Ala	Ser	Phe	Glu	Ala	Gln	Gly	Ala	Leu	Ala	Asn	Ile	Ala	Val	Asp	Lys
1				5				10						15	

Ala

<210> 2

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide derived from the bole I protein
of Epstein Barr virus

<400> 2

Thr	Arg	Asp	Asp	Ala	Glu	Tyr	Leu	Leu	Gly	Arg	Glu	Ser	Val	Leu
1				5					10					15

<210> 3

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide derived from the hemophilus influenza virus

<400> 3

Thr	Ser	Phe	Pro	Met	Arg	Gly	Asp	Leu	Ala	Lys	Arg	Glu	Pro	Asp	Lys
1				5					10					15	

<210> 4

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide derived from the TCR receptor gene of Mus musculus

<400> 4

Leu	His	Ile	Ser	Ala	Val	Asp	Pro	Glu	Asp	Ser	Ala	Val	Tyr	Phe	Cys
1				5					10					15	

Ala	Ser	Ser	Gln	Glu	Phe	Phe	Ser	Ser	Tyr	Glu	Gln	Tyr	Phe	Gly	Pro
			20					25					30		

Gly	Thr	Arg	Leu
			35

<210> 5

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide derived from the influenza virus

<400> 5

Gly	Ile	Leu	Gly	Phe	Val	Phe	Thr	Leu
1				5				

<210> 6
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide derived from the influenza virus
 <400> 6

Val Lys Leu Gly Glu Phe Tyr Asn Gln
 1 5

<210> 7
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide totally artificial
 <220>
 <223> Xaa in position 2 stands for cyclohexylalanine.
 <400> 7

Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala
 1 5 10

<210> 8
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide derived from the influenza virus
 <400> 8

Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr
 1 5 10

<210> 9
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Synthesized peptide derived from the ovalbumin
of Mus musculus

<400> 9

Ile	Ser	Gln	Ala	Val	His	Ala	Ala	His	Ala	Glu	Ile	Asn	Glu	Ala	Gly
1				5				10						15	

Arg

<210> 10

<211> 15

<212> PRT

<213> E. coli

<220>

<223> dnaJp1 heat shock protein

<400> 10

Gln	Lys	Arg	Ala	Ala	Tyr	Asp	Gln	Tyr	Gly	His	Ala	Ala	Phe	Glu
1				5				10					15	

<210> 11

<211> 15

<212> PRT

<213> Homo sapiens

<400> 11

Gln	Lys	Arg	Ala	Ala	Val	Asp	Thr	Tyr	Cys	Arg	His	Asn	Tyr	Gly
1				5				10					15	

<210> 12

<211> 9

<212> PRT

<213> Homo sapiens

<400> 12

Gly	Ile	Leu	Gly	Phe	Val	Phe	Thr	Leu
1				5				

<210> 13

<211> 9

<212> PRT

<213> Homo sapiens

<400> 13

Val Lys Leu Gly Glu Phe Tyr Asn Gln
1 5

<210> 14

<211> 13

<212> PRT

<213> Homo sapiens

<400> 14

Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr
1 5 10